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Selenium and Biology have a unique relationship. Selenium is an element which exists in several 
amino acids, including selenocysteine and selenomethionine. It plays several vital roles in the human 
body and is essential for several physiological processes. 
The last few years have witnessed the development of a new generation of biologically active and 
pharmaceutically relevant organo-selenium compounds, ranging from effective anticancer agents to 
novel ligands for serotonin 5-HT6 receptors and ABCB1 efflux pump modulators.  
This study describes the role of phenylselenoether-hydantoin hybrids as ABCB1 efflux pump 
modulating agents. Moreover, this work aims to synthesize novel and highly (re)active agents 
employing triazine-methyl piperazine hybrids for therapeutic applications in the treatment of current 
civilization central nervous system disorder.  
In summary, a library of 50 active novel compounds has been prepared to serve as efflux pump 
modulators or 5-HT6 ligands.  
Melting point, mass spectroscopy (MS), and nuclear magnetic resonance spectroscopy (NMR) 
evaluation have been employed to establish and confirm the structure of the compounds. The 
biological assays have been performed to evaluate their affinity towards 5HT6 receptor or efflux pump 
modulating ability. Finally, structure-activity relationship analysis has been performed to review and 






Selen ist ein Element, das in mehreren Aminosäuren, einschließlich Selenocystein und 
Selenomethionin, vorkommt. Es spielt verschiedene lebenswichtige Rollen im menschlichen Körper 
und ist für zahlreiche physiologische Prozesse unerlässlich. 
In den letzten Jahren wurde eine neue Generation biologisch aktiver und pharmazeutisch relevanter 
Organo-Selen-Verbindungen entwickelt, die von wirksamen Krebsbekämpfungsmitteln bis hin zu 
neuartigen Liganden für Serotonin-5-HT6-Rezeptoren und ABCB1-Effluxpumpenmodulatoren 
reichen. 
Diese Studie beschreibt die Rolle von Phenylselenoether-Hydantoin-Hybriden als ABCB1-
Effluxpumpenmodulatoren sowie die Synthese von neuartigen und hoch (re)aktiven Wirkstoffen 
unter Verwendung von Triazin-Methylpiperazin-Hybriden für therapeutische Anwendungen bei der 
Behandlung von Störungen des Zentralnervensystems der modernen Gesellschaft Zivilisation. 
Zusammenfassend lässt sich sagen, dass eine Bibliothek von 50 aktiven neuartigen Verbindungen 
vorbereitet wurde, die als Effluxpumpenmodulatoren oder 5-HT6-Liganden dienen sollen. 
Die Verbindungen wurden durch Schmelzpunkt-, Massenspektroskopie- (MS) und 
Kernresonanzspektroskopie- (NMR) charakterisiert. Biologische Assays wurden durchgeführt, um 
die Fähigkeit der synthetisierten Verbindungen zur Modulierung des 5HT6-Rezeptors oder der 
Effluxpumpe zu bestimmen. Schließlich wurde eine Struktur-Aktivitäts Beziehungsanalyse 





Mol ganz korz 
 
Selen iss e Element unn kommt in a paar Aminosäure vor, inklusive Selenocystein unn 
Selenomethionin. Es hat verschiedene lebenswichtige Rolle im menschliche Kerper unn is vor 
zahlreiche physiologische Prozesse notwennig. 
In de ledschde Johre is e neijie Generation vun biologisch aktive unn pharmazeutisch relevante 
Organ-Selen-Verbindunge entwickelt wor, die vun wirksame Mittel vor die Bekämpfung vun Krebs 
bis hin zu neijartiche Ligande vor die Serotonin-5-HT6-Rezeptore und Modulatore vun de ABCB1-
Effluxpumpe reiche. 
Die do Studie beschreibt die Roll vun Phenylselenoether-Hydantoin-Hybride als Modulatore vun de 
ABCB1-Effluxpumpenmodulatoren unn die Synthese vun neijartiche unn hoch(re)aktive Wirkstoffe. 
Das Zeich soll dann bei de Behannlung vun Sterunge vum Zentralnervesystem angewend werre. 
Dodebei werre Triazin-Methylpiperazin-Hybride verwennd. 
Zusamme genomm lässt sich sahn, dass e Haufe vun 50 aktive neijartiche Verbindunge hergestellt 
wor is, die als Modulatore vun Effluxpumpe odder als 5-HT6-Ligande ehr Ding mache solle. 
Die Verbindunge sinn dorch Schmelzpunkt-, Massespektroskopie (MS) unn 
Kernresonanzspektroskopie- (NMR) beschrieb wor. Biologische Knebb sinn dorchgefiehrt wor, um 
die Affinität vun de synthetische Verbindunge als Modulatore vor die 5HT6-Rezeptore oder vor die 
Effluxpumpe se bestimme. Unn dann sinn noch a paar Analyse vor die Beziehunge zwische de 
Struktur unn de Aktivität gemacht wor, um sich dodemedd die pharmakophore Eigenschafte 






Le sélénium est un élément qui existe dans plusieurs acides aminés, dont la sélénocystéine et la 
sélénométhionine. Il joue plusieurs rôles vitaux dans le corps humain et est essentiel à plusieurs 
processus physiologiques. 
Ces dernières années ont vu le développement d'une nouvelle génération de composés organo-
séléniés biologiquement actifs et pharmaceutiquement pertinents, allant d'agents anticancéreux 
efficaces à de nouveaux ligands pour les récepteurs de la sérotonine 5-HT6 et les modulateurs de la 
pompe à efflux ABCB1.  
Cette étude décrit le rôle des hybrides de phénylsélénoéther-hydantoïne en tant qu'agents modulateurs 
de la pompe à efflux ABCB1. En outre, ces travaux visent à synthétiser de nouveaux agents hautement 
(ré)actifs utilisant des hybrides de triazine-méthyl-pipérazine pour des applications thérapeutiques 
dans le traitement des troubles du système nerveux central de la civilisation actuelle.  
En résumé, une bibliothèque de 50 nouveaux composés actifs a été préparée pour servir de 
modulateurs de la pompe à efflux ou de ligands 5-HT6.  
Le point de fusion, la spectroscopie de masse (MS) et l'évaluation par spectroscopie par résonance 
magnétique nucléaire (RMN) ont été utilisés pour établir et confirmer la structure des composés. Les 
essais biologiques ont été réalisés pour évaluer leur affinité avec le récepteur 5-HT6 ou la capacité de 
modulation de la pompe à efflux. Enfin, une analyse de la relation structure-activité a été réalisée 
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Europe’s population is getting older as life expectancy, and the percentage of the European population 
that is surviving at older ages has increased dramatically over the last century. In 2018, the share of 
the population aged 65 years or overreached 18.2% of the European Union (EU) population, and this 
percentage is predicted to increase to 30% by 2050 (1). Globally, the elderly people aged 60 years or 
older represent approximately 10% of the world population, and this percentage is also expected to 
double by 2050 (2).  
Population aging will be accompanied by more illness, disability, and dependency. People of all age 
groups, regions, and countries are affected by noncommunicable diseases (NCDs), also known as 
chronic diseases, such as atherosclerosis and cardiovascular disease, cancer, osteoarthritis and 
osteoporosis, cataracts, type 2 diabetes, hypertension, and Alzheimer's disease. However, these 
conditions are often associated with older age groups. Elderly people are also prone to develop 
"comorbidities" (i.e., more than one disease/condition or multiple inter-related health problems), 
which severely impact their health and quality of life.  
The mortality rates of age-related diseases (ARDs) increase with age (3). According to the World 
Health Organization (WHO), NCDs kill 41 million people each year, equivalent to 71% of all deaths 
(56.9 million) globally. Of these, an estimated 1.7 million (4% of NCD deaths) occurred in people 
younger than 30 years of age, 15.2 million (38%) in people aged between 30 years and 70 years, and 
23.6 million (58%) in people aged 70 years and older (4).  
NCDs are estimated to account for 91% of all deaths in Germany (5). Therefore, the prevalence of 
the major NCDs (diabetes, cardiovascular diseases, cancer, chronic respiratory diseases, and mental 
disorders) is expected to rise worldwide and particularly in the developed countries, such as the 
United States of America (USA) and Western Europe, at least in part due to their growing populations 
of elderly. However, the highest risk of dying from NCDs is currently observed in low-income and 
middle-income countries, especially in sub-Saharan Africa, the Middle East, and, for men, in central 
Asia and Eastern Europe.  
We can summarize the most common functions change and corresponding age-related diseases in the 





Table 1: The most common functions change and corresponding age-related diseases.  
 Type of function Disease 
Sensory Changes related diseases ❖ Hearing Loss 
❖ Visual Acuity 
❖ Dizziness 
Immunosenescence ❖ Inflammatory diseases 
❖ Viral infections 
Urologic changes ❖ antimicrobial resistance. 




❖ Diabetes Mellitus 
❖ Osteoporosis 
❖ Multiple Chronic Conditions 
Psychological and cognitive ❖ Cognitive Aging 
❖ Dementia 
❖ Depression 
Among all of them, somatic disease and multiple chronic conditions, psychological and 
cognitive attract more attention in the last few years in the attempt to prepare an effective and 
selective treatment. 
 
Population aging is a powerful and transforming demographic force that will inevitably affect health 
care and social costs.  The remarkable increases in life expectancy and projected growth of the older 
population will impact the society and pose new and additional special needs and services, such as 
the need for services at home, interactions with health care providers, assistance with the daily life 
duties, specialized care in clinics and hospitals, and advance care planning (7).  
According to Statistisches Bundesamt (Destatis), of 954.874 death cases, the percentage of fatalities 
by chapters of the International Statistical Classification of Diseases and Related Health Problems 
2018 were: 24.9% by neoplasms, 6% due to mental and behavioural disorders, and 3.6% by diseases 
of the nervous system (8).  
Among several psychological and cognitive diseases, depression and anxiety are common within the 
aged population. In general, older adults present higher vulnerability towards risk factors and worse 
symptoms of depression or anxiety than younger adults (9-11). In Germany, the mean health care 
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costs were estimated to be around 5,243 € per six months for people with posttraumatic stress disorder 
(PTSD). The  health-related quality of life was also observed to be lower due to anxiety/depression 
(12).  
In this context, the 5-hydroxytryptamine (5-HT: serotonin) subtype 6 receptor (5-HT6R), one of the 
latest cloned receptors among the known 5-HT receptors, has gained considerable attention as an 
attractive target for drug development against psychological and cognitive diseases. The expression 
profile of 5-HT6R in the central nervous system (CNS), especially in the striatum, hippocampus, and 
cortex (13), and its high affinity for antipsychotic and antidepressant drugs have suggested significant 
implications for 5-HT6R modulators in a broad spectrum of CNS disorders, including depression, 
cognitive dysfunction associated with Alzheimer's disease, anxiety, and schizophrenia (14, 15).  
Cancer can be considered an age-related disease because the incidence and prevalence of most 
cancers increase with age, peaking in men and women in their 80s. Almost 70% of all cancer cases 
and cancer-related deaths were reported in patients aged 65 years or older (16). Older people exhibit 
worse prognosis of cancer because of delayed diagnosis. Different methods are required for the 
diagnosis and treatment of cancer in older people, such as new chemotherapy agents (17).  
The emergence of multidrug resistance (MDR) in cancer cells is one of the biggest challenges face 
by physicians and scientists across the globe. One of the essential mechanisms in MDR action 
involves adenosine triphosphate-binding cassette (ABC) transporters, such as the P-glycoprotein 
(Pgp, ABCB1), which are involved in crucial processes in cancer cells’ defense. Designing 
compounds which target these transporter proteins provides an interesting strategy to overcome drug 
resistance (18). 
1.1. 5-HT6 receptor 
 Serotonin mediates diverse behavioral and physiological actions in both the peripheral and central 
nervous systems. Based on structural, biochemical, and pharmacological differences, 5-HT receptors 
(5-HTRs) are classified into seven distinct receptor families: 5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HT5, 5-
HT6, and 5-HT7 receptors. Except for the 5-HT3 receptors, which are ligand-gated ion channels, all 
5-HT receptors are G-protein-coupled receptors (GPCR), transmitting their signals via G-proteins 
(19).  





Table 2: 5-HT distributions and functions in the CNS, which could be imperative for selective and more 
effective drug design. 





Addiction, aggression, anxiety, appetite, 
autoreceptor, blood pressure, cardiovascular 
function, emesis, heart rate, impulsivity, memory, 
mood, nausea, nociception, penile erection, pupil 
dilation, respiration, sexual behavior, sleep, 
sociability, thermoregulation, vasoconstriction, 






Peripheral nervous system 
Smooth Muscle 
Addiction, anxiety, appetite, cognition, 
imagination, learning, memory, mood, perception, 
sexual behavior, sleep, thermoregulation, 
vasoconstriction, cardiovascular function, GI 




Peripheral nervous system 





Peripheral nervous system 
Anxiety, appetite, GI motility, learning, memory, 
mood, respiration 
5-HT5 CNS Autoreceptor, locomotion, sleep 





Anxiety, autoreceptor, memory, mood, respiration, 
sleep, thermoregulation, vasoconstriction 
Gastrointestinal tract (GI tract).  
 
The 5-hydroxytryptamine (5-HT: serotonin) subtype 6 receptor (5-HT6R) is one of the most recent 
additions to the family of mammalian 5-HT receptors. It belongs to (GPCRs) which transmit their 
signals via G-proteins (23). 5-HT6R was first identified by Kohen et al. in 1996 (24) and since then 
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has gained considerable interest as an attractive target for designing novel drugs targeting 
Alzheimer’s’ disease, schizophrenia, depression, and Parkinson’s disease (25).  
The growing interest of this receptor stem, at least in part, from its predominant expression in the 
central nervous system (CNS). Therefore, the potential therapeutic indications of the 5-HT6R ligands 
encompass a spectrum of diseases, including depression (26), cognitive dysfunction associated with 
Alzheimer's disease (27), anxiety, dementia (28), schizophrenia, and reducing food intake and body 
weight (29). Moreover, due to the 5-HT6 receptor unique distribution, predictions have been made 
that these new agents will have quite a few side-effects (30).  
 The results of preclinical studies are rather confusing since they reveal that activation and inhibition 
of 5-HT6 receptor evoke the same pharmacological responses, e.g., in the animal behavioral model 
of depression, both agonists and antagonists presented antidepressant- or anti-anxiety-like effects 
(23). Nevertheless, despite the abundance (>20) of selective 5-HT6R antagonists (i.e., Ro 04-6790 1, 
Ro 63-0563 2 (31), SB-258585 3, the novel and highly selective pyrazole-conjugated aryl 
sulfonamides 4 and 1-sulfonyl-6-piperazinyl-7-azaindoles 5), there are only a limited number of 5-
HT6R agonists that have exhibited high selectivity and have reached Phase I clinical trials such as 
Wyeth agonist WAY-181187 6 (25, 30) (Figure 1). 
Within 20 years, from 1995 to 2015, more than 3000 active 5-HT6R ligands have been successfully 
prepared and studied. Still, their structural diversity is limited, with 80% of sulfone-containing 
structures and more than 40% of indole-containing ones (32, 33).  
Recently, a new group of non-indole and non-sulfone hydantoin-triazine 5-HT6R ligands were 
synthesized by Lubelska et al. and evaluated for their pro-cognitive and antiobesity activities. The 
compounds presented significant anxiolytic, precognitive, and some antiobesity properties in in vivo 
models. Moreover, these compounds also met the criteria established for “drug-likeness” (33). 
Nevertheless, no 5-HT6R agent has reached the pharmaceutical market. The most innovative 5-HT6R 
agents, such as Idalopirdine 7 and Intepirdine 8, failed at phase III of clinical trials, while SUVN-502 
9 (34) still provides an exceptional hope since it has been successfully accepted in phase II trials. 
Most of these ligands exhibit an insufficient “drug-ability” profiles, such as “ADMET (absorption, 
distribution, metabolism, elimination, toxicity). Moreover, most of these ligands are unable to cross 
the blood-brain barrier (23, 33).  
To sum up, the serotonin 5-HT6 receptor is an interesting target for drug developers because of:  
❖ Unique distribution, exclusive to CNS  
❖ Multiple cellular signaling pathways activated by the receptor in CNS  






Figure 1: Some 5-HT6R agonist and antagonist 
 
1.2. Designing novel 5-HT6 receptor Ligands 
Lines of evidence have indicated several families of chemical compounds that display significant 
affinities for the serotonin receptors 5-HT6. The most active compounds with affinities in nano- or 
sub-nanomolar ranges belong to the families of amine derivatives, including nitrogen heterocycles of 
pyridino-sulfonamide, indole, benzothiophene, benzimidazole, or aza-analogs of ergoline (33).  
In 2005, Rodríguez et al. suggested a pharmacophore model for the 5-HT6R antagonists. The 
pharmacophore model comprises four distinct features: large hydrophobic area (HYD), positive 
ionizable nitrogen (PI),  a hydrogen bond acceptor (HBA), and a central aromatic fragment (35).  
The HYD is commonly personified by fused aromatic rings of naphthalene or halogen-substituted 
benzene, an indole, or a benzothiophene. The nitrogen heterocycle, (un)substituted piperazine is a 
suitable moiety containing the PI. The HBA frequently occurs in several sulfonyl ligands and the 
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carbonyl moieties. Interestingly, the HYD linked to aromatic heterocyclic groups, such as pyridine,  
benzimidazole,  quinolone, or triazine, provides an aromatic feature (36). 
In 2017, D. Łażewska et al. demonstrated the roles of piperazine linked to 1,3,5-triazine (compounds 
10-12) for the 5-HT6R affinity. The HYD is fragment determined by both a kind of aromatic moieties 
linked by the methylene group to the 1,3,5-triazine ring and substituents at the aromatic moieties. It 
is confirmed that more hydrophobic substituents are more favorable.  
For HBA, the results proved that the sulfonyl group is not required for a strong affinity to the 5-HT6R. 
Instead, a one-atom spacer which can be embodied by the sulfonyl, methylene group, or an ether-
chalcogen atom, such as oxygen or sulfur, seems to be crucial, and lack of this motif caused an 
enormous decrease of the affinity (Figure 2) (36). 
 
 
Figure 2: Examples of some of the 1st generation of 5-HT6R triazine-piperazine agents 
 
1.3. Selenium and CNS  
Selenium-containing organic molecules exhibit promising pharmacological properties. The oxidative 
stress is proposed as a mechanism in neurodegenerative diseases. Selenium and selenium-dependent 
enzymes, such as glutathione peroxidases (GPx), thioredoxin reductases (TrxR), and methionine-
sulfoxide-reductase (Msrs), are involved in antioxidant defense, intracellular redox regulation, and 
modulation and thereby exhibit neuroprotective actions. Selenium-dependent enzymes have a 
significant influence on proper brain function (37, 38). The brain receives a priority supply of 
selenium uptakes (39-41). Selenoenzyme GPx4 controls the interneuron function. Cerebral selenium 
deficiency may cause reduced GPx4 expression and, consequently, increased/reduced interneuron 
development (42). 
Elemental selenium intakes have important roles for cell death, prevention of lipid peroxidation, and 
plasma membrane protection (43). A few examples of compounds which have central nervous system 
pharmacological properties are presented in Figure 3.  
Organoselenium compounds, such as compound 13 (methyl phenyl selenide, CH3SePh) exhibited an 
antidepressant- action in the mouse models, reduced the immobility time in the mouse forced 
swimming test FST and the tail suspension test TST (44). Compound 14 (m-trifluoromethyl-diphenyl 
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diselenide (m–CF3–PhSe)2) displayed antioxidant, anxiolytic activities and presented antidepressant 
effect in the mouse FST (45).  
3-(4-fluorophenylselenyl)-2,5-diphenylselenophene (F-DPS) 15 blocked behavioural changes 
induced by neuropathic pain. In addition, sub-chronic treatment inverted depression-like behavior 
(FST) test and (TST) test and formed a noteworthy anxiolytic-like action in mice (46, 47).  
Compound 16 ((Z)-2,3-Bis(4-chlorophenylselanyl)prop-2-en-1-ol, also exhibited anti-depressant 
effect in the mouse TST and FST (48). Moreover compound 17 (4-phenyl-1-(phenylselanylmethyl)-
1,2,3-triazole) was identified as an antidepressant agent (49). 
Diphenyl diselenide (PhSe)2 18 exhibited a neuroprotective activity by reducing neuropathic and 
acute thermal hyperalgesia in mice (50). Moreover, compound 18 exhibited antidepressant-like and 
anxiolytic-like activity in mice (51, 52). Compound 18 also provided a neuroprotective effect against 
the toxic impact of MeHg on mitochondrial activities in mice. Compound 18 reduced oxidative stress 
and MeHg deposition in the brain (53).  
The elemental selenium proved to play several imperative roles in CNS. Oral supplementation of 
dietary selenium may considerably slow down the process of neurodegeneration. Selenium exhibits 
a protective effect against the neurotoxicity caused by the multiple-dose administration of 
methamphetamine. Se uptakes significantly increase the glutathione peroxidase (GPx) activity and 
modulates the oxidative damages mediated by increased production of hydrogen peroxide or other 
reactive oxygen species (ROS) in the dopaminergic system (54, 55).  
Inadequate uptake of selenium may also contribute to Alzheimer’s disease pathophysiology. 
Selenium supplementation resulted in reduced intractable epileptic seizures in children. Moreover, 
low plasma selenium concentrations in the elderly were linked to faster cognitive failure. In contrast, 
high dietary selenium uptake significantly improved mood, reduced anxiety, depression, and tiredness 
compared to people with lower selenium intake (39).  
Sodium selenate (19) supplementation at a high dose encouraged an increase in selenium uptake into 
the CNS, which increased the expression and incorporation of selenium into biomolecules (56). 
Sodium selenite 20 administered to mice reduced the immobility time in the FST, exerting 










Figure 3: Selenium containing compounds with CNS pharmacological properties 
 
1.4. Selenium and nitrogen heterocycles 
The chemistry of selenium and nitrogen heterocycles is attracting considerable attention in the attempt 
to obtain organoselenium compounds with high GPx like activity. Several pyridyl and pyrimidinyl 
based diselenide compounds, such as 21, 22, have been prepared, which presented good antioxidant 
activity (58). 
A series of compounds comprising selenium analogues of captopril (23) was also synthesized, which 
inhibited the angiotensin-converting enzyme (ACE) (59). Moreover, dipeptide-based selenium 
compounds (24, 25) were also prepared by Bhaskar et al. and evaluated for ACE inhibition. 
Intriguingly, selenocysteine containing peptides demonstrated better antioxidant activity than 
cysteine-containing peptides (60). Furthermore, selenium-containing naphthylamide (26, 27) and 3-
allyl seleno-6-alkyl thiopyridazine (28) exhibited moderate to good anticancer activities (61, 62).  
Recently, the click chemistry provides the advantage of preparing multifunctional compounds 
containing selenium and triazole moiety (29). The synthesis and antitumor activity of selenium-
containing triazoles combined with diphenyl diselenide and a-Lapachone motifs have been reported. 
The compounds presented excellent antitumor activity against several cancer cell lines (63).  
Organoselenium compounds containing nitrogen heterocycles were also employed as antiviral agents. 
Selenoacyclovir (30) exhibited promising anti-herpes simplex virus-1 and -2 activities whilst 
selenoganciclovir (31) revealed moderate anti-human cytomegalovirus activity (64). 
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Another class of selenium-nitrogen heterocycle includes nucleic acids. The replacement of oxygen 
by selenium in nucleobases opens the window for a new application of the selenium in DNA and 




Figure 4: Selenium and nitrogen heterocycles compounds 
 
1.5. Multidrug resistance and cancer 
The emergence of multidrug resistance (MDR) in cancer cells is a critical problem requiring special 
attention for more efficient cancer therapy. MDR are mechanisms that cancer cells developed to 
confront the cytotoxic effect of anticancer drugs (67).  
MDR is responsible for increased death rate to over 90% in cancer patients receiving traditional 
chemotherapeutics or new drugs. Different mechanisms of resistance in cancer cells are summarized 





Table 3: Different mechanisms of resistance in cancer cells 
Mechanisms Types of action 
Upregulation actions 
• Increasing drug efflux 
• Improving cell growth, and in the 
term, survival signaling. 
• An increase in DNA repairing and 
overexpression of plasma membranes. 
Down-regulation 
• Downregulation of apoptosis signals 
• Decrease drug uptakes 
 
P-glycoprotein (Pgp) transporters play an important role in the MDR mechanism, namely by 
increasing drug efflux. They are expressed widely in cancer cells, recognize and catalyse the efflux 
of various anticancer drugs from cells (68-71).  
1.6. ABC transporters 
Cells contain transporters to sustain an equilibrium condition. There are two kinds of transporters, 
namely primary transporters and secondary ones. These transporters play a central role in the 
transportation of organic and inorganic molecules across cellular membranes. The primary 
transporters work against gradients employing adenosine triphosphate (ATP) hydrolysis as a source 
of energy. Whilst in secondary transporters, the energy is consequent from the electrochemical 
gradient generated by active transport (72).  
ABC belongs to the ATP Binding Cassette transporters. ABC proteins are present in the cytoplasmic 
(inner) membrane of bacteria, and both the plasma membrane and organelle membranes in 
eukaryotes. ABC are found in bacteria and eukaryotes (73, 74). They are characterized by two pairs 
of domains: two nucleotide-binding domains (NBD), which comprise of a phosphate-binding loop, 
and two transmembrane domains (TMDs). ATP hydrolysis at NBD leads to change of TMDs and 
activate the transportation across the membrane (72).  
In bacteria, NBD and TMSs exist as two or four separate polypeptides, whereas in eukaryotes, the 
four domains are often fused into a single abundant protein with an internal duplication (75). Most 
ABC transporters on eukaryotes are exporting while serving as an exporting and importing in Bacteria 
(75). There are 48 ABC transporters in humans, which are subdivided into seven sub-families: A-G. 
Many of these sub-families are involved in diseases, including cystic fibrosis (76), Tangier disease 
(77), adrenoleukodystrophy, and cancer (78-80).  
12 
 
ABC transports a range of inorganic and organic molecules, such as metal ions, amino acids, vitamins,  
sugars, peptides, lipids, oligonucleotides, and polysaccharides across the membrane. (75).  
ABC transporters are present in the liver, placenta, and blood-brain barrier in humans. They serve as 
an intermediate in the detoxification of hydrophobic organic molecules and, therefore, result in the 
multidrug resistance of some anticancer drugs (81). 
1.7. ABC and multidrug resistance 
Three sub-families are belonging to the ABC superfamily, which serves as a multidrug efflux pump 
and hence are responsible for drug resistance. These families include P-glycoprotein (ABCB1), 
MRP1 (ABCC1), and breast cancer resistance protein (ABCG2) and are located in the plasma 
membrane. These proteins are also overexpressed in tumor cells, resulting in increased expulsion of 
the toxic materials (82). Efflux pump modulators have recently received considerable attention in 
cancer therapy (83).  
Pgp and ABCG2 export unmodified drugs whilst MRP1  export both conjugated drugs with 
glutathione and unconjugated ones together with free glutathione (75, 83).  
Pgp (ABCB1) is the first human ABC transporter cloned and characterized for its ability to confer 
multidrug resistance on cancer cells. ABCB1 transports a wide range of amphipathic molecules, 
including anticancer drugs, HIV protease inhibitors, analgesics, antihistamines, H2-receptor 
antagonists, immunosuppressive agents, cardiac glycosides, calcium channel blockers, calmodulin 
antagonists, anti-emetics, anthelminthic, antibiotics, and steroids (83). Pgp is abundantly found in the 
apical membranes of epithelial cells lining the colon, small intestine, pancreatic, bile ductulus, 
proximal kidney tubule (84), endothelial cells lining capillaries in the brain, testis, and inner ear Since 
Pgp is also found in pregnant endometrium, the placenta, and the adrenal gland (85), it protects the 
fetus and sensitive organs from toxic substances (86-88). 
Moreover, Pgp is also highly expressed in the mitochondrial membrane and cell nucleus. It pumps 
out anticancer drugs from mitochondria or nuclei into the cytosol, thereby causing multidrug 
resistance in the cancer cells (89, 90). A recent study proved that ABCB1 is involved in the uptake 
of the antidepressant vortioxetine into mice's brains (91). 
ABCB4 is closely related to Pgp, with 78% genetic sequence homology. It is found in the intestine, 
kidney, placenta, brain endothelial cells, and hematopoietic stem cells. It transports both positively 
and negatively charged drugs, such as sulfate conjugates. It exports phosphatidylcholine (PC) from 
the liver canalicular cells into the bile (92). Moreover, ABCB4 plays an essential physiological role 
by secreting riboflavin (vitamin B2) into milk (93). 
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ABC multidrug transporters play several other physiological roles. They can change the absorption 
and deposition of many drugs. Pgp and ABCG2, for instance, can reduce the uptake of drugs in the 
intestine and hence reduce or their therapeutic activity. On the other hand, they can also limit the 
accumulation of drugs in the brain by pumping them back to the blood (94, 95). 
MRP1 is expressed at the basolateral membrane of polarized epithelial cells and protects tissues such 
as the bone marrow, kidney collecting tubules, and oropharyngeal and intestinal mucosa from 
xenobiotics. It is also involved in drug clearance from the cerebrospinal fluid, testicular tubules, and 
peritoneum. MRP1 provides resistance against a variety of anticancer agents. It prefers anionic 
substrates, and as mentioned before, drugs are either exported as anionic glutathione, glucuronate, or 
sulfate conjugates or co-transported with free glutathione. MRP1 also transports heavy metal 
oxyanions, such as arsenite and trivalent antimonite (83, 95).  
1.8. MDR modulators 
MDR modulators have received growing interest in the last few decades due to their ability to 
reversibly block the efflux pump-action and hence recover the effects exerted by the anticancer drugs  
(96). Such agents may either disrupt the hydrolysis of ATP or compete with the substrates for the 
drug-binding pocket of the transporter. In this way, the modulators will help to sustain an active 
concentration of drug inside the cell or lowering the cytotoxic concertation of the drug (83). 
Even though the fact that numerous Pgp modulators have been prepared and investigated (96), fewer 
numbers of MRP1 and ANCG2 modulators have been designed. Recently, some multifunctional, 
such as Elacridar (GF120918) 32, agents have been developed, which inhibited Pgp and ABCG2. 
Some other agents like Biricodar (VX710) 33 inhibited the activity of Pgp, MRP1, and ABCG2 at 
low doses (97, 98). 
Verapamil 34, cyclosporine A 35, tamoxifen 36, and vincristine 37 represent the first generation of 
modulators. These agents were already employed in clinical uses to treat other medical conditions, 
such as blood pressure, immunosuppression, and estrogen receptor modulator. These agents, 
however, presented low efficacy at tolerable doses. Furthermore, these compounds caused severe side 
effects on patients. The second-generation agents, such as valspodar and VX-710, presented better 
efficiency at low doses, but these agents provided poor pharmacokinetics. The third-generation 
modulators include zosuquidar 38 and tariquidar 39, which exhibited low toxicity and high selectivity 
and potency against Pgp (83). 
It is essential to understand that MDR modulators may interact with some of the functions of ABC 
receptors and cause positive or negative consequences (94, 99). Since all of the inhibitors, including 
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the third-generation agents, failed to reach the market,  there is an urgent need for new, effective, and 
nontoxic inhibitors (100). 
 




1.9. Recent advance in cancer therapy 
ABCB1 (Pgp) is the most studied member of the ATP-binding cassette (ABC) transport proteins. It 
is encoded by the MDR1 gene and export various cytotoxic agents out of cells by depending on energy 
mechanism, (ATP) hydrolysis. This action reduces the concentrations inside the cell. Up to date, no 
ABCB1 modulator has reached the market due to a lack of clinical efficacy, pharmacokinetic 
interaction, or other side effects related to toxicity. As a result, there is an urgent need to develop 
novel, selective, and effective ABCB1 inhibitors to reverse drug resistance (101). 
Multifunctional compounds serve as the source of lead structures in designing efficient molecules 
that could act as anticancer and efflux pump modulators. Moreover, combining two or more 
multifunctional motifs in one molecule provides an interesting strategy from the perspective of drug 
design. Nitrogen heterocycles and chalcogens (in general and selenium in particular) attract 
considerable attention due to their diverse biological activities.  
The literature reveals that the presence of an aromatic ring is vital for the MDR modulation effect. 
The addition of another aromatic ring, mostly a benzene or nitrogen heterocycle, increases the 
modulation effect. The presence of a positive ionizable centre and hydrogen bond acceptor is also 
beneficial but not essential for the efflux pump modulation activity (102).  
Triazole-N-ethyl-tetrahydroisoquinoline based compounds, for instance, compound 40, presented 
more potency than the classical Pgp inhibitor verapamil (103). Moreover, 1,2,3-triazole-pyrimidine 
sulfide hybrid compound 41 was reported to act as a potential reversal agent against ABCB1-
mediated multidrug resistance. Compound 41 exhibited good ABCB1 inhibition activity and was 
suggested as a lead structure for further synthesis of ABCB1 modulators agents (101). Aryl piperazine 
derivatives of hydantoin (42) and aryl-piperazine derivatives of hydantoin-3-acetate (43) significantly 
inhibited the ABCB1 (102, 104). 
Intriguingly, an indole derivative (44) served as an adjuvant and inhibited ABCB1 and ANCG2. This 
adjuvant activity enhanced the chemotherapeutic activity and increased the intracellular concentration 
of doxorubicin and mitoxantrone in MDR cells(105).  
It is possible to design novel agents based on suitable pharmacophore moiety, which exerts the 
biological activities via multiple biochemical pathways. Nitrogen heterocycles, such as piperazine, 
could be considered good candidate for building up such novel compounds. Piperazine derivatives 
presented excellent cytotoxic and antiproliferative activities. They act via different biochemical 



















2.  Aims of the thesis 
Following the study of Rodríguez et al. and D. Łażewska et al. (36), the main goal of the work is to 
obtain a new and active chemical group of ligands for the 5-HT6 receptors. This study will give a 
proper perspective for future therapeutic usage in treating current civilization CNS diseases, i.e., a 
group of compounds with an antidepressant, pro-cognitive, anxiolytic, or antiobesity action. Also, 
following the study of Żesławska et al. (102), the second part of this work will discuss the design, 
synthesis, and biological evaluation of novel ABCB1 modulators.  
There is a real need for more active compounds with satisfying “drug-ability” properties, which can 
be a good source of new drug candidates. The work may also give indications for further 
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PL 31-343 Cracow, Poland; kurczab@if-pan.krakow.pl (R.K.); satala@if-pan.krakow.pl (G.S.)
2 Department of Technology and Biotechnology of Drugs, Jagiellonian University, Medical College, Medyczna 9,
PL 30-688 Cracow, Poland; s8wealii@stud.uni-saarland.de (W.A.); dlazewska@cm-uj.krakow.pl (D.Ł.);
mwiecek@cm-uj.krakow.pl (M.W.); annamaria.lubelska@doctoral.uj.edu.pl (A.L.);
glatacz@cm-uj.krakow.pl (G.L.); mfkonono@cyf-kr.edu.pl (K.K.-K.)
3 Division of Bioorganic Chemistry, School of Pharmacy, University of Saarland, Campus B2 1,
D-66123 Saarbruecken, D-66123 Saarland, Germany; c.jacob@mx.uni-saarland.de
4 Department of Pharmacodynamics, Jagiellonian University, Medical College, Medyczna 9,
PL 30-688 Cracow, Poland; magda.dudek@uj.edu.pl
5 Department of Clinical Pharmacy, Jagiellonian University, Medical College, Medyczna 9,
PL 30-688 Cracow, Poland; mj.wiesek@gmail.com (M.J.-W.); annairena.partyka@uj.edu.pl (A.P.);
awesolowska@cm-uj.krakow.pl (A.W.)
6 Department of Inorganic Chemistry, Jagiellonian University, Medical College, Medyczna 9,
PL 30-688 Cracow, Poland; m.starek@uj.edu.pl (M.S.); monika.1.dabrowska@uj.edu.pl (M.D.)
* Correspondence: j.handzlik@uj.edu.pl; Tel.: +48-12-620-55-84
† These authors contributed equally to this work.
Received: 1 September 2018; Accepted: 24 September 2018; Published: 3 October 2018


Abstract: This study focuses on the design, synthesis, biological evaluation, and computer-aided
structure-activity relationship (SAR) analysis for a novel group of aromatic triazine-methylpiperazines, with
an hydantoin spacer between 1,3,5-traizine and the aromatic fragment. New compounds were synthesized
and their affinities for serotonin 5-HT6, 5-HT1A, 5-HT2A, 5-HT7, and dopamine D2 receptors were evaluated.
The induced-fit docking (IFD) procedure was performed to explore the 5-HT6 receptor conformation
space employing two lead structures. It resulted in a consistent binding mode with the activity data.
For the most active compounds found in each modification line, anti-obesity and anti-depressive-like
activity in vivo, as well as “druglikeness” in vitro, were examined. Two 2-naphthyl compounds (18
and 26) were identified as the most active 5-HT6R agents within each lead modification line, respectively.
The 5-(2-naphthyl)hydantoin derivative 26, the most active one in the series (5-HT6R: Ki = 87 nM), displayed
also significant selectivity towards competitive G-protein coupled receptors (6–197-fold). Docking studies
indicated that the hydantoin ring is stabilized by hydrogen bonding, but due to its different orientation,
the hydrogen bonds form with S5.44 and N6.55 or Q6.58 for 18 and 26, respectively. Compound 26 exerted
anxiolytic-like and antidepressant-like activities. Importantly, it demonstrated anti-obesity properties in
animals fed palatable feed, and did not show toxic effects in vitro.
Keywords: serotonin receptors; 5-HT6 ligands; 1,3,5-triazine; hydantoin; docking; obesity;
antidepressive; ADMET in vitro
Molecules 2018, 23, 2529; doi:10.3390/molecules23102529 www.mdpi.com/journal/molecules
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1. Introduction
The serotonin receptor 5-HT6 is one of the recently discovered members of the 5-HTRs family [1].
It is quite unique, since it includes a short third cytoplasmatic loop in parallel, with a long C-terminal
tail, and one introne located in the middle of the third cytoplasmatic loop [2,3]. The localization
of 5-HT6R is limited to the central nervous system, especially as it is located in the brain areas
involved in learning and memory processes. Relatively limited, but intensive, research efforts in this
area led to several families of potent 5-HT6R ligands [4,5], which have been proposed for potential
treatment in the cognitive dysfunction associated with Alzheimer’s disease, anxiety or depression [5–7].
Over 20 compounds have qualified for clinical trials, most of which in studies following a cure for
Alzheimer’s disease [5]. Nonetheless, none has reached the pharmaceutical market yet. Recent lines
of evidence also point towards promising properties of some 5-HT6R ligands in the battle against
obesity [8,9]. Therefore, the search for new ligands for the 5-HT6R, in particular, those with an action
directed against obesity, seems to be a challenge for current medicinal chemistry.
Lines of evidence have identified several groups of chemical compounds, which displayed
significant affinities for the serotonin receptors 5-HT6 [4,10,11]. The structure-activity relationship
(SAR) analysis performed for the 5-HT6 ligands obtained previously enabled to identify
pharmacophore features, including a triangle topology with tops of: A bulky hydrophobic area
(HYD), positive ionizable nitrogen (PI), and hydrogen bond acceptor (HBA), as well as a central
aromatic fragment (AR) (Figure 1) [12].
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Figure 1. Modified pharmacophore model based of the 1,3,5-triazine with mapped compound 2, 
including four key pharmacophore features, namely: A positive ionizable group (PI, red), an 
aromatic ring (AR, orange), a hydrogen bond acceptor group (HBA, green) and hydrophobic group 
(HYD, blue) (A). The lead compound 2 mapped onto the binding site of 5-HT6R (B). Examples of the 
most active 1,3,5-traizne 5-HT6 ligands found recently 1–3 (C). 
Taking into consideration the pharmacophore features, our previous studies have successfully 
found a new group of potent 5-HT6R agents among methylpiperazine derivatives of benzyl 
Figure 1. Modified pharmacophore l f t e 1,3,5-triazine with mapped compound 2,
including four key pharmacophore features, namely: A positive ionizable group (PI, red), an aromatic
ring (AR, orange), a hydrogen bond acceptor group (HBA, green) and hydrophobic group (HYD, blue)
(A). The lead compound 2 mapped onto the binding site of 5-HT6R (B). Examples of the most active
1,3,5-traizne 5-HT6 ligands found recently 1–3 (C).
Taking into consideration the pharmacophore features, our previous studies have successfully
found a new group of potent 5-HT6R agents among methylpiperazine derivatives of benzyl
2-amino-1,3,5-triazines which fit 3 out of 4 pharmacophore features. Two closed HBAs were the missing
feature [13]. The computer-aided SAR analysis allowed us to modify the previous pharmacophore
features and it has underlined the notable importance of aromatic substituents separated by a short
linker from the 1,3,5-triazine. Thus, a bulky aromatic moiety, represented by the naphthyl (1) or
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m-chloro- (2) or m-methyl- (3) substituted phenyl ring (Figure 1) was beneficial for the kind of 5-HT6R
affinity evaluated experimentally [13].
Taking into account both, the need to search for the 5-HT6R agents with new pharmacological
possibilities and the results of previous SAR studies, we decided to explore a novel group of
triazine-methylpiperazine derivatives (Figure 2), in which the spacer between 1,3,5-traizine and
aromatic fragment is represented by a differently positioned hydantoin system containing both,
two closed HBAs and HYD/AR features. In the first step, five pilot compounds (4–8) were synthesized
and evaluated with regard to their affinity for the 5-HT6R. These initial studies resulted in two parallel
lead structures 5 and 7 (Figure 2). Chemical modifications of the lead structures subsequently provided
a series of compounds 9–27 (Table 1). Therefore, these studies are focused on the design, synthesis and
biological evaluation, including affinity and selectivity for the 5-HT6R, as well as computer-aided SAR
discussion for an entire series of hydantoin-triazines (4–27). For representative compounds, anti-obesity
and anti-depressive activity in vivo, as well as their “drugability” properties, were also examined.
2. Results
2.1. Identification of Lead Structures
In the first step, a nonaromatic 5,5-dimethylhydantoin 1,3,5-triazine derivative 4 was found as a
moderate 5-HT6R ligand after the radioligand binding assay and was therefore selected as an initial
lead structure (Figure 2). Then, four different hydantoin moieties were taken into consideration as lead
modifications, including: two N-substituted p-chlorobenzyl derivatives 5 and 6, with respect to position
3-N (5) and 1-N (6), the 5-(4-chlorophenyl)-5-methyl derivative 7 and 5,5-bis(4-chlorophenyl)hydantoin
8 (Figure 2).
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Table 1. Structures and affinities for serotonin/dopamine receptors of hydantoin-triazine compounds 4–26.
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4 B Methyl 427 22,330 9.99 × 106 nt 35,790 
5 - - 4275 5007 15,430 nt 1620 
6 A 4-Chlorophenyl 127 4098 23,300 nt 3711 
7 B 4-Chlorophenyl 176 31,240 28,070 nt 938 
8 - - 1058 6855 3052 nt 594 
9 A Phenyl 592 8783 42,630 1596 350 
10 A 3-Chlorophenyl 271 4631 13,570 328 159 
11 A 2,5-dichlorophenyl 597 2867 4155 809 279 
12 A 2,4-dichlorophenyl 205 681 7693 3589 1116 
13 A 4-Fluorophenyl 663 6557 48,360 3548 953 
14 A 3-Fluorophenyl 447 6577 37,090 239 88 
15 A 3-Bromophenyl 570 6677 12,930 1327 571 
16 A 3-Methoxyphenyl 692 15,490 23,910 2036 3587 
17 A 3-Methylphenyl 895 5207 16,990 817 420 
18 A 2-Naphthyl 182 888 5718 1907 1525 
19 B Phenyl 726 41,040 31,620 12,150 1096 
20 B 3-Chlorophenyl 418 16,780 4101 7396 791 
21 B 2,5-dichlorophenyl 403 11,550 26,190 11,050 1565 
22 B 2,4-dichlorophenyl 457 15,090 13,980 10,770 10,130 
23 B 2,3,4-trichlorophenyl 195 4738 6028 3433 8905 
24 B 4-Methylphenyl 667 23,300 22,320 24,410 564 
25 B 1-Naphthyl 121 7811 7146 8080 3367 
26 B 2-Naphthyl 87 4247 14,160 17,170 514 
Ref.   7 b 9 b 20 c - 18 d 
a Tested experimentally in the radioligand binding assay, binding affinity, Ki, expressed as the 
average of at least two independent experiments; nt—not tested. b–d Reference ligands for GPCRs 
investigated, b olanzapine, c buspirone, d clozapine. 
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5-HT6 [3H]-LSD D2 [3H]-Raclopride 5-HT1A [3H]-8-OH-DPAT 5-HT2A [3H]-Ketanserin 5-HT7 [3H]-5-CT
4 B Methyl 427 22,330 9.99 × 106 nt 35,790
5 - - 4275 5007 15,430 nt 1620
6 A 4-Chlorophenyl 127 4098 23,300 nt 3711
7 B 4-Chlorophenyl 176 31,240 28,070 nt 938
8 - - 1058 6855 3052 nt 594
9 A Phenyl 592 8783 42,630 1596 350
10 A 3-Chlorophenyl 271 4631 13,570 328 159
11 A 2,5-dichlorophenyl 597 2867 4155 809 279
12 A 2,4-dichlorophenyl 205 681 7693 3589 1116
13 A 4-Fluorophenyl 663 6557 48,360 3548 953
14 A 3-Fluorophenyl 447 6577 37,090 239 88
15 A 3-Bromophenyl 570 6677 12,930 1327 571
16 A 3-Methoxyphenyl 692 15,490 23,910 2036 3587
17 A 3-Methylphenyl 895 5207 16,990 817 420
18 A 2-Naphthyl 182 888 5718 1907 1525
19 B Phenyl 726 41,040 31,620 12,150 1096
20 B 3-Chlorophenyl 418 16,780 4101 7396 791
21 B 2,5-dichlorophenyl 403 11,550 26,190 11,050 1565
22 B 2,4-dichlorophenyl 457 15,090 13,980 10,770 10,130
23 B 2,3,4-trichlorophenyl 195 4738 6028 3433 8905
24 B 4-Methylphenyl 667 23,300 22,320 24,410 564
25 B 1-Naphthyl 121 7811 7146 8080 3367
26 B 2-Naphthyl 87 4247 14,160 17,170 514
Ref. 7 b 9 b 20 c - 18 d
a Tested experimentally in the radioligand binding assay, binding affinity, Ki, expressed as the average of at least two
independent experiments; nt—not tested. b–d Reference ligands for GPCRs investigated, b olanzapine, c buspirone,
d clozapine.
Compounds 5–8 were synthesized and their affinity for the 5-HT6R was evaluated in the
radioligand binding assays. Results displayed an increase of the 5-HT6R affinity in the case
of compounds 6 and 7, whereas both 5 and 8 were much less active than the initial lead 4.
Interestingly, the structure-activity relationship indicated a crucial role for the position of the
1,3,5-triazine substitution at hydantoin ring. Thus, 1,3,5-triazine linked by a methylene group
at position 3 of hydantoin seems to be profitable (6), whilst that fragment situated at position
1 of hydantoin caused a huge decrease in activ ty (5). Taking into account these r sults, both
1-(4-chlorobenzyl)-3-((4-amino-6-(4-methylpiper zin-1-yl)-1,3,5-triazin-2-yl)methyl)-5,5-hydantoin
(6), and the 3-((4-amino-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)methyl)-5-(4-chlorophenyl)-5
-methylhydantoin (7) were selected in parallel as two particularly promising lead structures (Lead
1 and Lead 2, Figure 2). These two leads were subsequently modified within their aromatic area to
generate a library of two distinct series of derivatives, i.e., compounds 9–18 and compounds 19–26,
respectively (Table 1).
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2.2. Chemical Synthesis of Compounds 5–26
The final compounds 5–26 were obtained using four different synthesis pathways (Scheme 1a–d).
The synthesis of 5,5-dimethylhydantoin triazine derivative 4 was described earlier [14]. As for
the syntheses of the 3-benzyl derivative (5) and the 1-arylmethyl ones (6, 9–18), the commercial
5,5-dimethylhydantoin (DMH) was a starting material, which was substituted with an appropriate
arylmethyl halide and methyl bromoacetate in a different order, respectively (a and b, Scheme 1).
The reactions were performed as basic two-phase alkylations in acetone in the presence of a catalytic
amount of benzyltriethylammonium chloride (TEBA). In case of 5, an alkylation with 4-chlorobenzyl
at position 3 was the first step (27) [15], followed by the introduction of the methyl acetate fragment at
position 1 (28, Scheme 1a). In contrast, the methyl ester 29a for the synthesis of 6 and the ethyl ester
29b, i.e., the common first intermediate for the synthesis of 9–18, were obtained by an alkylation of
5,5-dimethylhydantoin with a suitable alkyl bromoacetate at position 3. The ester 29 was substituted
using commercial arylmethyl halides to give compounds 30–40. Although a variety of purification
methods was applied, including extraction, crystallization with charcoal and chromatography, only
compounds 33, 34 and 40 gave precipitates (purity > 90%). Compounds 30–32 and 35–39 were obtained
as glue-like residues with varying contents of the target product (44–81%) and were used for final
cyclization in the crude form. In the case of 5-aryl-5-methylhydantoin derivatives (7, 19–26), standard
Bucherer-Bergs cyclic condensation of suitable commercial ketones (41–49) was the first synthetic step
providing 5-aryl-5-methylhydantoins 50–58. Next, esters 59–67 were synthesized via N-alkylation of
50–58 in the hydantoin position 3 with methyl bromoacetate, under similar conditions to those for 29
and purification methods as those for 30–40 (Scheme 1c). Among the esters (59–67), compounds 60
and 66 were obtained in glue forms (purity 76–85%) with the remaining compounds (59, 61–65 and
67) yielding white crystals (purity 95–100%). The ester intermediate for compound 8 was obtained
within a 3-step synthesis, starting from the acyloin condensation of commercial 4-chlorobenzaldehyde
(68), followed by oxidation to benzyl compound 69. The benzyl intermediate was used to perform
a cyclic condensation with urea providing 5,5-bis(4-chlorophenyl)hydantoin (70), followed by an
alkylation with methyl bromoacetate in position 3 of the hydantoin, in the aforementioned conditions
of two-phase alkylation, to produce ester 71 (Scheme 1d). All ester hydantoin intermediates (28, 30–40,
59–67, and 71) were converted into the 1,3,5-triazine final products (5–26) via cyclic condensation with
1-(imino(4-methylpiperazin-1-yl)methyl)guanidine, which proceeded in sodium methanolate under
the conditions corresponding to those for a series of benzyl-1,3,5-triazines described previously [13,14].
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36, 14  R: 3-F-Ph
37, 15  R: 3-Br-Ph
38, 16  R: 3-MeO-Ph
39, 17  R: 3-Me-Ph
40, 18  R: 2-Naphthyl
30, 6    R: 4-Cl-Ph
31, 9    R: Ph
32, 10  R: 3-Cl-Ph 
33, 11  R: 2,5-diCl-Ph
34, 12  R: 2,4-diCl-Ph





































 7, 41, 50, 59    R: 4-Cl-Ph
19, 42, 51, 60   R: Ph
20, 43, 52, 61   R: 3-Cl-Ph 
21, 44, 53, 62   R: 2,5-diCl-Ph
22, 45, 54, 63   R: 2,4-diCl-Ph
23, 46, 55, 64   R: 2,3,4-triCl-Ph
24, 47, 56, 65   R: 4-Me-Ph
25, 48, 57, 66   R: 1-Naphthyl





68 69 70 71
29a, 30  R1: CH3
29b, 31-40  R1: C2H5
 
Scheme 1. Synthesis of compounds 5–26 (Table 1); (a) 3-arylmethylhydantoin product 5; (b) 
1-arylmethylhydantoin derivatives (6, 9–18); (c) 5-aryl-5-methylhydantoin derivatives (7, 19–26); (d) 
5,5-diarylhydantoin derivative and triazines (8). Reagents and conditions: (i) RCH2Cl, K2CO3, TEBA, 
acetone, 3–5 h reflux; (ii) BrCH2COOMe, K2CO3, TEBA, acetone, 5–7 h reflux; (iii) 
1-(imino(4-methylpiperazin-1-yl)methyl)guanidine hydrochloride, MeONa, reflux for 3–5 h, then rt, 
10–20 h; (iv) KCN, (NH4)2CO3, 50% EtOH, 55 °C; (v) KCN, EtOH, 1 h reflux; (vi) HNO3 conc., 3 h 
reflux; (vii) EtONa, urea, 2 h reflux, HCl. 
2.3. Molecular Modeling 
Molecular docking was performed to gain an insight into the binding mode of the library of 
compounds synthetized (5–26) to the recently developed 5-HT6R homology models [13] built on the 
β2 adrenergic receptor template and optimized for the structures of Lead 1 and 2. The molecular 
docking indicated that newly synthesized compounds, generally, exhibited a very consistent 
binding mode with recently reported 5-HT6 ligands [16–18]. An influence of the topology of aromatic 
substituents and the position of the 1,3,5-triazine substitution at the hydantoin ring on the binding 
Schem 1. Synthesis of compounds 5–26 (Table 1); ( ) 3-arylmethylhydantoin product 5;
(b) 1-arylmethylhydantoin derivatives (6, 9–18); (c) 5-aryl-5-methylhydantoin derivatives (7, 19–26);
(d) 5,5-diarylhydantoin derivative and triazines (8). Reagents a conditions: (i) RCH2Cl, K2CO3,
TEBA, acetone, 3–5 h reflux; (ii) BrCH2COOMe, K2CO3, TEBA, acetone, 5–7 h reflux; (iii)
1-(imino(4-methylpiperazin-1-yl)methyl)guanidine hydrochloride, MeONa, reflux for 3–5 h, then rt, 10–20 h;
(iv) KCN, (NH4)2CO3, 50% EtOH, 55 ◦C; (v) KCN, EtOH, 1 h reflux; (vi) HNO3 conc., 3 h reflux; (vii)
EtONa, urea, 2 h reflux, HCl.
2.3. Molecular Modeling
Molecular docking was performed to gain an insight into the binding mode of the library of
compounds synthetized (5–26) to the recently developed 5-HT6R homology models [13] built on the β2
adrenergic receptor template and optimized for the structures of Lead 1 and 2. The molecular docking
indicated that newly synthesized compounds, generally, exhibited a very consistent binding mode with
recently reported 5-HT6 ligands [16–18]. An influence of the topology of aromatic substituents and
the position of the 1,3,5-triazine substitution at the hydantoin ring on the binding has been observed
(Figure 2) and was in good agreement with results of the radioligand binding assay (see below).
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2.4. Pharmacology
2.4.1. Radioligand Binding Assay
Compounds 5–26 were evaluated with respect to their affinity and selectivity for the target
5-HT6R in radioligand binding assays based on the human serotonin receptors 5-HT6, 5-HT1A, 5-HT2A,
5-HT7bR and dopaminergic D2LR, all of whom were expressed stably in HEK-293 cells. Five selective
radioligands were employed (Table 1). Results expressed as Ki indicate that all derivatives of both leads
displayed submicromolar affinities for the target 5-HT6R. More active agents (6, 7, 18, 23, 25 and 26)
exerted Ki(5-HT6R) values lower than 200 nM. Compound 26 was the most active one (Ki = 87 nM) and
also highly selective over 5-HT1AR, 5-HT2AR, and D2LR, with some selectivity over 5-HT7R (6-fold).
Furthermore, a slightly less active 5-HT6R agent, compound 25, was highly selective with respect to
all competitive GPCRs tested (Table 1). Most of the compounds displayed much weaker affinities for
5-HT1A, 5-HT2A and D2LR receptors than for 5-HT6R. Notably, compounds 8–11, 14, 17 and 24 were
more potent for 5-HT7R than for the target 5-HT6R, in particular, compound 14 (5-HT7R; Ki = 88 nM),
which was also selective toward 5-HT7R (Table 1).
2.4.2. Behavioral Tests In Vivo
The most potent 5-HT6R agent identified in the radioligand binding assays, i.e., compound 26,
was selected for behavioral assays to determine its antidepressant- and anxiolytic-like properties
in vivo in male Wistar rats.
Antidepressant-Like Activity of Compound 26
In the forced swim test (FST), compound 26 significantly decreased immobility time about 20%
(ANOVA: F(3,28) = 3.7674, p < 0.05) vs. vehicle treated group. A U-shaped dose-response in the FST
test for compound 26 was observed (Figure 3).
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The data are presented as the mean ± SEM of 6–8 rats. The data were statistically evaluated by 
one-way ANOVA followed by Bonferroni’s post-hoc test, * p < 0.05 vs. vehicle group. 
This effect seems to be typical for some antidepressants with different mechanisms of action 
also producing U-shaped dose-response curves in some animal models and evaluated for 
antidepressant-like activity [19,20]. Moreover, this effect was also observed for other 5-HT6 ligands 
(i.e., SB258585) [21]. 
Anxiolytic-Like Activity of Compound 26 
Anxiolytic-like activity was assessed using a Vogel conflict drinking test. As demonstrated in 
Figure 4, compound 26, administered at a dose of just 3 mg/kg, has significantly increased (by 76%) 
Figure 3. Influence of compound 26 on the immobility time of rats in the forced swim test.
Compound 26 was admi istered i.p. 60 min before the test. The animals were observed for 5 min.
The data are presented as the mean± SEM of 6–8 rats. The data were statistically evaluated by one-way
ANOVA followed by Bonferroni’s post-hoc test, * p < 0.05 vs. vehicle group.
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This effect seems to be typical for some antidepressants with different mechanisms of
action also producing U-shaped dose-response curves in some animal models and evaluated for
antidepressant-like activity [19,20]. Moreover, this effect was also observed for other 5-HT6 ligands
(i.e., SB258585) [21].
Anxiolytic-Like Activity of Compound 26
Anxiolytic-like activity was assessed using a Vogel conflict drinking test. As demonstrated in
Figure 4, compound 26, administered at a dose of just 3 mg/kg, has significantly increased (by 76%) the
number of accepted shocks (ANOVA: F(3,22) = 3.4967, p < 0.05) during the 5 min experimental session.
Thus, compound 26 (at a dose of 3 mg/kg) exerted anxiolytic-like activity in this behavioral test.
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Figure 4. Compound 26 increases the number of shocks accepted in the Vogel conflict test in rats.
C mpound 26 was administered i.p. 60 min be ore the te t. The animals were monit red for 5 min.
The data are presented as the mean± SEM of 6–8 rats. The data were statistically evaluated by one-way
ANOVA followed by Bonferroni’s post-hoc test, * p < 0.05 vs. vehicle group.
2.4.3. Metabolic Assays In Vivo
Compounds 6 and 26, representing the most potent 5-HT6R agents of both groups, A (6) and
B (26), were evaluated with regard to their influence on the body weight of male Wistar rats within
metabolic assays in vivo (Figure 5). Animals that were fed palatable feed, and treated with 6, exhibited
significantly less weight gain when compared to animals in the control group consuming a standard
feed. From day 16 of the experiment, t ere was a significant difference between the groups. The body
weight of rats treated with 6 having access to preferential feed differed significantly from the weight of
control animals fed standard feed. Results are shown in Figure 3A,B.
Similarly, animals fed palatable feed and treated with 26 showed significantly less weight gain
than animals in the control group consuming a preferential feed (Figure 5C,D), but there was a
significant difference between the groups from day 12 of the experiment,. Additionally, the body
weight of rats treated with 26 and having access to preferential feed did not differ significantly from
the weight of control animals fed st ndard feed. No effects on body weight were noted in animals
treated either with 6 or with 26 and consuming standard feed.
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Figure 5. Influence of t r administration of 6 or 26 on the body weight in male Wistar rats.
The change in body weight in Wistar rats fed palatable diet or stan ard diet and in Wistar rats fed
palatable diet or standard diet reated for 21 ( ,B) or 26 (C,D). Results are means ± SEM,
n = 6. Multiple comparison were performed by two- ay ANOVA, Sidak post-h c (A,C) or by ne-way
ANOVA, Sidak post-hoc (B,D); * p < 0.05, ** p < 0.01, *** p < 0.001 significant vs. control rats fed
standard diet; ˆ p < 0.05, ˆˆ p < 0.01 significant vs. control rats fed palatable diet.
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2.5. “Drug-Like” Properties
2.5.1. Lipophilicity
The lipophilicity for compounds considered in the search for lead structures (5–8) in particular
for the most active compounds found as derivatives of both lead modifications (18, 23, 25 and 26) was
determined with the standard RP-TLC method [22]. For comparison, the active arylmethyl-triazine
compounds previously found (1–3) were also examined. Stationary phase RP-18 and mixtures of
water/methanol (1:9, v/v) as a mobile phase were employed. RM values were calculated from the RF
data obtained. It was found that the RM parameters decreased linearly with increasing amounts of the
organic modifier (methanol) in the mobile phases tested. The regression coefficients (r2) determined
for all compounds were higher than 0.95. On the basis of the linear relationship between RM values
and the volume fraction of methanol, values of RM0 in the systems analyzed corresponding to 100% of
water were obtained by extrapolation. RM0 values received for the compounds tested ranged from
3.14 to 4.49 (Figure 6).
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Figure 6. Lipophilicity parameters evaluated using R-TLC: RM0 values for compounds 1–3, 5–8, 18, 23,
25 and 2
The most lipophilic character is associated with compound 23 (RM0 = 4.49), while the least
lipophilic hydantoin compound is a weak 5-HT6R agent 5 (RM0 = .22). The arylmethyl derivatives
previously investigated (1–3) displayed slightly less lipophilic properties th n those of the most active
hydantoin agents (18–26). Overall, these results indicate a good “drug-like” lipophilicity for the entire
series of compounds investigated, taking into consideration either classical rules (Rules of Five, Ghose
or Pfizer) or the latest CNS MPO approach [23].
2.5.2. Toxicity In Vitro
The preliminary evaluation of the safety profile for the most promising 5-HT6R ligands 6 and
26 was performed in vitro with the HEK-293 eukaryotic cell line. The compounds examined were
dissolved in culture growth media and incubated with cells for 72 h. Next, the MTS test was applied to
determine the viability of the cells. As shown in Figure 7, a statistically significant decrease of viability
(*** p < 0.001) was observed only for compound 6 and only at the highest concentration used, i.e.,
100 µM. The reference cytostatic drug doxorubicin (DX) at the very low concentration 1 µM was also
cytotoxic. Thus, the results obtained confirm a low or no significant toxicity for compounds 6 and
26, respectively.
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3. Computer-Aided SAR Analysis 
In order to expand the current knowledge about structural properties responsible for 5-HT6R 
activity in the group of recently discovered aryl derivatives of 1,3,5-triazine, this study took into 
account the crucial role of the linker, which was found by comparative SAR analysis for the 
previously active arylmethyl- and inactive aryl-triazine molecules [13]. The new series of 
hydantoin-triazines (5–26) were designed as an extension of the methylene linker of the most active 
2-arylmethyl-1,3,5-triaines, via an introduction of the inflexible, cyclic hydantoin insert, containing 
also hydrogen bond acceptors, and occurring in two topological variants found to be profitable in 
the preliminary lead identification (4–8). Both leads (6 and 7) and their derivatives (9–18 and 19–26, 
respectively) displayed significant submicromolar affinities for the target 5-HT6 receptors, much 
more potent than those of previously investigated linker-free aryl-triazines [13], but slightly less 
potent if compared to the arylmethyl ones (1–3, Figure 1). Interestingly, the influence of the topology 
of the aromatic moieties in the group of 1,3,5-triazine derivatives seems to be distinctly 
Figure 7. The influence of doxorubicin (DX) and 5-HT6R ligands on the viability of cultured
HEK-293 cells. Statistical significance was evaluated by one-way ANOVA, followed by Bonferroni’s
comparison test (*** p < 0.001 compared with the negative control).
2.5.3. Blood-Brain Barrier Permeability
In order to estimate an ability of the library synthetized (4–26) to penetrate the blood-brain
barrier (BBB), the permeability QPlogBB parameter was calculated (Table 2) using QikProp from
Schrodinger Suite 2017 [24]. QikProp predictions are for orally delivered drugs, and thus some natural
neurotransmitters, e.g., dopamine and serotonin, are CNS negative, because they are extremely polar
to cross the blood-brain barrier. Recommended values range for compounds that penetrate BBB is from
−3.0 to 1.2. All the hydantoin-triazines investigated (4–26) are predicted as BBB-permeable (Table 2)
with QPlogBB values from −0.98 (25) to −0.33 (12).
Table 2. The blood-brain barrier per eability para eter (QPlogBB) for compounds 4–26.
Cpd QPlogB QPlog B Cpd QPlogBB
4 −0.97 12 −0.33 20 −0.63
5 −0.60 −0.73 21 −0.46
6 −0.60 −0.46 22 −0.47
7 −0.89 15 −0.65 23 −0.38
8 −0.62 16 −0.92 24 −0.84
9 −0.84 17 −0.54 25 −0.98
10 −0.40 18 −0.63 26 −0.92
11 −0.37 19 −0.75
3. Computer-Aided SAR Analysis
In order to expand the current knowledge about structural properties responsible for 5-HT6R
activity in the group of recently discovered aryl derivatives of 1,3,5-triazine, this study took into account
the crucial role of the linker, which was found by comparative SAR analysis for the previously active
arylmethyl- and inactive aryl-triazine molecules [13]. The new series of hydantoin-triazines (5–26)
were esigned s an extension of the methylene linker f the most active 2-arylmethyl-1,3,5-triaines,
via an introduction of the inflexible, cyclic hydantoin insert, containing also hydrogen bond acceptors,
and occurring i two topological variants found to be profitable in the preliminary lead identification
(4–8). Both leads (6 nd 7) and their derivatives (9–18 a 19–26, respectively) displayed significant
submicromolar affinities for the target 5-HT6 receptors, much more potent than those of previously
investigated linker-free aryl-triazines [13], but slightly less potent if compared to the arylmethyl
ones (1–3, Figure 1). Interestingly, the influence of the topology of the aromatic moieties in the
group of 1,3,5-triazine derivatives seems to be distinctly linker-dependent. Although the bulky
aromatic area of the naphthalene was beneficial for all the groups considered, it was distinctly
predominant in the case of the 5-arylhydantoin (25, 26 vs. 7 and 19–24; Table 1), comparable with
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the 3-methylphenyl and 3-chlorophenyl compounds in the group arylmethyl triazines (1–3, Figure 1),
and slightly less favourable than the 4-chlorophenyl substituent within the 5,5-dimethylhydantoin
group (18 vs. 6, Table 1). Furthermore, the preferable m-substitution within the phenyl ring, found for
the benzyl 1,3,5-triazine 5-HT6R agents earlier [13], has not been confirmed in this study, either for the
5,5-dimethyl-1-benzylhydantoin- (6 vs. 10) or for the 5-phenyl-5-methylhydantoin triazine compounds
(7 vs. 20). Consequently, an influence of both variants of the hydantoin linkers (1,3,5-substitution,
group A or 3,5-substitution, group B) on the 5-HT6R activity was dependent on the properties of the
aromatic moiety. Thus, both variants appear to be comparable, although the most active compound
(26) is a member of the 5-aryl-5-methylhydantoin derivatives (group B).
Results of our docking studies have provided data useful to explain SAR on the molecular level
(Figure 8).
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1,3,5-triazine was linked with hydantoin via position 1 (5, Ki = 4275 nM). The analysis of the binding 
mode showed that a differently positioned hydantoin ring induces its different spatial orientation in 
the binding site (Figure 8A), and only the complex of 6 with the receptor is stabilized additionally by 
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Figure 8. Molecular docking results of the representative library members for the 5-HT6 receptor.
(A) Comparison of the binding mode of compounds 6 (cyan) and 7 (gray). (B) Binding mode of 18
(orange) and 26 (blue). (C) A superposition of the poses of compounds 9 (magenta), 17 (yellow), 6
(cyan), and 10 (violet) against the putative halogen binding pocket interaction spheres for the 5-HT6
receptor. The chlorine-oxygen theoretical interaction spheres illustrate the projected qualities of the
formed ligand-receptor halogen bonds. Key residues in the binding site are presented as thick dark-grey
sticks. The dotted yellow lines represent hydrogen bonds with polar residues.
In general, all of the newly synthesized derivatives of Lead 1 and Lead 2 exhibited a binding
mode to 5-HT6R, which was very consistent with derivatives of 1,3,5-tiazines studied previously [13].
In addition to the crucial salt bridge interaction with D3.32, all of the docked ligands formed CH–π
aromatic interactions with F6.52, and partially with F6.51. Additionally, the –NH2 group of the
1,3,5-triazine fragment was, usually, hydrogen-bonded with the carbonyl oxygen of A5.42 and V3.33
(Figure 8A). The methylene linker connecting 1,3,5-triazine and hydantoin rings, due to its tetrahedral
conformation, forced th terminal aromatic group into a hydrophobi cavity formed by transmembrane
helices 3–5 and extracellular loop 2. Thus, the structure-activity rel tionship i this series is et mined
by the different substitue ts at the terminal aromatic ring, and by the different rientation of hydantoin
ring induced by its different po itioning within the compound’s structure. A comparison of the
analogues with different positions of the 1,3,5-triazine substitution at the hydantoin ring indicated that
linking by the methylene group at position 3 of hydantoin is profitable (6, Ki = 127 nM), whereas a
significant decrease of activity was noted for the derivative where the 1,3,5-triazine was linked with
hydantoin via position 1 (5, Ki = 4275 nM). The analysis of the binding mode showed that a differently
positioned hydantoin ring induces its different spatial orientation in the binding site (Figure 8A),
and only the complex of 6 with the receptor is stabilized additionally by a hydrogen bond with a
Q6.58 side chain.
Interestingly, within the group A and B, the best activity showed 2-naphthyl derivatives (18 and 26,
respectively; Figure 8B). It should be noted, that apart from the length of the linker and the positioning
of the hydantoin ring, the difference of activity between 18 and 26 is negligible—a comparison of its
binding modes indicated that the most significant difference is noted for the hydantoin ring interaction.
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In both derivatives, the hydantoin ring is stabilized by hydrogen bonding, but due to its different
orientation, the hydrogen bonds form with S5.44 and N6.55 or Q6.58 for 18 and 26, respectively. It is
worth to note that the shift of the chlorine atom from 3- to 4-position resulted in a 4- (for modification B)
to 5-fold (for modification A) increase of affinity for 5-HT6R compared to its unsubstituted analogues.
This relationship was confirmed by molecular docking (Figure 8C) revealing that only the presence of
chlorine atom in 4-position stabilized the L–R complex through the formation of halogen bond with
the carbonyl oxygen of P4.60 residue (Cl···O distance = 3.31 Å, σ-hole angle = 151.47◦). As the halogen
bond appeared to possess a highly directional nature, to explain the decrease in activity by shifting the
chlorine atom from position 3 to 4 in the phenyl ring, the interaction sphere [25,26] was plotted onto
the relevant backbone carbonyl oxygens (Figure 8C). The 4-chloro substituent was positioned within
the energetically favorable areas of the sphere, whereas the 3-chloro substituent pointed outside of the
sphere, indicating no ability to form halogen bond.
4. Experimental Section
4.1. Chemistry
Reagents were purchased from Alfa Aesar (Karlsruhe, Germany) or Sigma Aldrich (Darmstadt,
Germany). Methanol was dried over calcium oxide Reaction progress was verified using thin layer
chromatography (TLC), which was carried out on 0.2 mm Merck silica gel 60 F254 plates. Spots were
visualized by UV light or treatment with Dragendorff reagent. Melting points (m.p.) were determined
using MEL-TEMP II apparatus (LD Inc., Long Beach, CA, USA) and are uncorrected. The 1H-NMR
and 13C-NMR spectra were obtained on a Mercury-VX 300 Mz spectrometer (Varian, Palo Alto, CA,
USA) in DMSO-d6 or CDCl3. Chemical shifts in 1H-NMR spectra were reported in parts per million
(ppm) on the δ scale using the solvent signal as an internal standard. Data are reported as follows:
Chemical shift, multiplicity (s, singlet; br.s., broad singlet; d, doublet; t, triplet; m, multiplet), coupling
constant J in Hertz (Hz), number of protons, proton’s position (Ind–indole, Naph—naphthalene,
Ph—phenyl, Pp—piperazine). LC-MS were carried out on a system Water TQ Detector (Water
Corporation, Milford, CT, USA) consisting of a Waters Acquity UPLC, coupled to a Waters TQD
mass spectrometer. Retention times (tR) are given in minutes. The UPLC/MS purity of all final
compounds was determined (%).
Synthesis of compounds 27, 29, 50–58, 63, 65 and 68–70 was obtained by our [15,27] or other research
groups [28–32] earlier and are reported in Chemical Abstract Database (see Supplementary Information).
4.1.1. Synthesis of Methyl 2-(3-(4-chlorobenzyl)-5,5-dimethyl-2,4-dioxoimidazolidin-1-yl)acetate (28)
A mixture of 3-(4-chlorobenzyl)-5,5-dimethylimidazolidine-2,4-dione 27 (20 mmol, 5.05 g), TEBA
(2.60 mmol, 0.60 g), K2CO3 (58 mmol, 8 g) in acetone (100 mL) was heated under reflux for 30 min.
Methyl bromoacetate (20 mmol, 3.06 g) in acetone (20 mL) was added. The mixture was heated under
reflux for 5 h and stirred at room temperature overnight. The inorganic precipitate was separated by
filtration. The filtrate was evaporated, and the residue was crystallized with methanol. White solid,
m.p. 78–80 ◦C, yield: 58% (11.60 mmol, 3.77 g), C15H17ClN2O4 (MW 324.76). 1H-NMR (300 MHz,
DMSO-d6) δ = 7.38–7.41 (d def., 2H, Ar-3,5-H), 7.22–7.25 (d def., 2H, Ar-2,6-H), 4.57 (s, 2H, Ar-CH2),
4.18 (s, 2H, CH2COO), 3.68 (s, 3H, OCH3), 1.30 (s, 6H, 2× 5-CH3) ppm. LC/MS+: Purity: 98.40%,
tR = 6.14, (ESI) m/z [M + H]+ 325.11.
4.1.2. General Procedure for the Synthesis of Alkyl
2-(1-arylmethyl-5,5-dimethyl-2,4-dioxoimidazolidin-3-yl)acetate (30–40)
A mixture of alkyl 2-(5,5-dimethyl-2,4-dioxoimidazolidin-3-yl)acetate 29 (12 mmol, 29a: 2.40 g
or 29b: 2.58 g), TEBA (1.20 mmol, 0.36 g), K2CO3 (12 mmol, 4.80 g) in acetone (60 mL) was heated
under reflux for 30 min. The appropriate arylmethyl halide (12 mmol) in acetone (15 mL) was added.
The mixture was heated under reflux for 5–7 h and stirred at room temperature for further 24–48 h.
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The inorganic precipitate was separated by filtration. The filtrate was collected, the solvent then
evaporated and the residue was dissolved in 30 mL of DCM and washed with 1% NaOH (2 × 30 mL)
and H2O (2 × 30 mL). The organic phase was dried on anhydrous Na2SO4 overnight, separated from
the drying agent and the solvent was evaporated. Then, Methods A or B were applied for purification.
Method A: The residue was crystallized with EtOH and charcoal to give crystals of the intermediates.
Method B: If Method A was applied, but no crystal appeared, the ethanolic solution was concentrated
to give crude ester intermediates in glue form. No ester intermediate (30–40) was isolated in pure
form (purity < 80%). The purity and identity of crude intermediates were evaluated using LC-MS.
Taking into consideration the results of LC-MS a desirable ester was used for the synthesis of the final
product in the amount suitable to its concentration in the crude product obtained (40–80%)
Ethyl 2-(1-(4-chlorobenzyl)-5,5-dimethyl-2,4-dioxoimidazolidin-3-yl)acetate (30). 1-Chloro-4-(chloromethyl)
benzene (1.93 g) and 29a were used. Method A. White crystals, m.p. 88–90 ◦C, yield: 68% (8.16 mmol,
2.65 g), C15H17ClN2O4 (MW 324.76). 1H-NMR (300 MHz, DMSO-d6) δ = 7.36–7.37 (d def., 4H, Ar),
4.52 (s, 2H, Ar-CH2), 4.25 (s, 2H, CH2COO), 3.70 (s, 3H, OCH3), 1.25 (s, 6H, 2× CH3) ppm. LC/MS+:
Purity: 81%, tR = 6.31, (ESI) m/z [M + H]+ 325.18.
Ethyl 2-(1-benzyl-5,5-dimethyl-2,4-dioxoimidazolidin-3-yl)acetate (31). Benzyl chloride (1.52 g) and 29a
were used. Method B. Glue mixture containing 44% of 31, yield: 61.37%, C15H18N2O4 (MW 304.15).
LC/MS+: Purity: 44%, tR = 6.09, (ESI) m/z [M + H]+ 304.14.
Ethyl 2-(1-(3-chlorobenzyl)-5,5-dimethyl-2,4-dioxoimidazolidin-3-yl)acetate (32). 1-Chloro-3-(chloromethyl)
benzene (1.93 g) and 29a were used. Method B. Sticky liquid, yield: 85.22%, C15H19ClN2O4 (MW
338.59). 1H-NMR (300 MHz, DMSO-d6) δ = 7.41–7.33 (m, 1H, Ph-5-H), 7.31–7.28 (m, 3H, Ph-2,4,6-H),
4.54 (s, 2H, Ph-CH2), 4.23 (s, 2H, CH2COO), 4.10 (q, J = 7.05 Hz, 2H, CH3–CH2), 1.26 (s, 6H, 2× CH3),
1.16 (t, J = 7.35 Hz, 3H, CH3–CH2) ppm. LC/MS+: Purity: 67.03%, tR = 6.73, (ESI) m/z [M + H]+ 339.59.
Ethyl 2-(1-(2,5-dichlorobenzyl)-5,5-dimethyl-2,4-dioxoimidazolidin-3-yl) acetate (33). 1-Bromo-2,5-(di-chloro
methyl) benzene (3.60 g) and 29a were used. Method A. yellowish Solid, m.p. 98 ◦C, yield: 98.21%,
C16H18Cl2N2O4 (MW 373.04). 1H-NMR (300 MHz, DMSO-d6) δ = 7.52–7.41 (m, 1H, Ph-6-H), 7.39–7.40 (m,
2H, Ph-3,4-H), 4.58 (s, 2H, Ph-CH2), 4.24 (s, 2H, CH2COO), 4.10 (q, J = 7.00 Hz, 2H,CH3–CH2), 1.29 (s, 6H,
2× CH3), 1.17 (d, J = 7.00 Hz, 3H, CH3–CH2) ppm. LC/MS+: Purity: 93.90%, tR = 7.28, (ESI) m/z [M +
H]+ 373.03.
Ethyl 2-(1-(2,4-dichlorobenzyl)-5,5-dimethyl-2,4-dioxoimidazolidin-3-yl)acetate (34). 1-Chloro-2,4-(di-chloro
methyl) benzene (2.34 g) and 29a were used. Method B. White Solid, m.p. 105 ◦C, yield: 91.52%,
C16H18Cl2N2O4 (MW 373.04). 1H-NMR (300 MHz, DMSO-d6) δ = 7.66 (d, J = 2.0 Hz, 1H, Ph-3-H), 7.47–7.37
(m, 2H-Ph-5,6-H), 4.60 (s, 2H-Ph-CH2), 4.26 (s, 2H, CH2COO), 4.16 (q, J = 7.1 Hz, 2H–CH3–CH2), 1.29
(s, 6H, 2× CH3), 1.21 (t, J = 7.1 Hz, 3H, CH3) ppm. 13C-NMR (75 MHz, DMSO-d6) δ = 175.83, 167.53,
154.84, 134.60, 133.22, 133.18, 130.71, 129.32, 127.98, 62.51, 61.83, 22.68, 14.38 ppm. LC/MS+: Purity: 91.74%,
tR = 7.52, (ESI) m/z [M + H]+ 374.04.
Ethyl 2-(1-(4-fluorobenzyl)-5,5-dimethyl-2,4-dioxoimidazolidin-3-yl)acetate (35). 4-Flouro benzyl chloride
(2.17 g) and 29a were used. Method B. Sticky liquid, yield: 90.72%, C16H19FN2O4 (MW 322.99).
LC/MS+: Purity: 69.51%, tR = 7.52, (ESI) m/z [M + H]+ 323.99.
Ethyl 2-(1-(3-fluorobenzyl)-5,5-dimethyl-2,4-dioxoimidazolidin-3-yl)acetate (36). 3-Flouro benzyl chloride
(1.74 g) and 29a were used. Method A. Sticky liquid, yield: 77.06%, C16H19FN2O4 (MW 322.99).
1H-NMR (300 MHz, DMSO-d6) δ = 7.41–7.36 (m, 1H, Ph-5-H), 7.19–7.13 (m, 3H, Ph-2,4,6-H), 4.55 (s,
2H, Ph-CH2), 4.23 (s, 2H, CH2COO), 4.10 (q, J = 7.05 Hz, 2H, CH3–CH2), 1.26 (s, 6H, 2× CH3), 1.16 (t,
J = 7.05 Hz, 3H, CH3–CH2) ppm. LC/MS+: Purity: 69.43%, tR = 6.23, (ESI) m/z [M + H]+ 323.99.
Ethyl 2-(1-(3-bromobenzyl)-5,5-dimethyl-2,4-dioxoimidazolidin-3-yl)acetate (37). 3-Bromo benzyl chloride
(3.75 g) and 29a were used. Method B. Sticky liquid, yield: 60%, C16H19BrN2O4 (MW 383.24). LC/MS+:
Purity: 78.26%, tR = 6.85, (ESI) m/z [M + H]+ 384.24.
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Ethyl 2-(1-(3-methoxybenzyl)-5,5-dimethyl-2,4-dioxoimidazolidin-3-yl)acetate (38). 3-Methoxy benzyl
chloride (1.88 g) and 29a were used. Method B. Sticky liquid, yield: 68.94%, C17H22N2O5 (MW
334.38). LC/MS+: Purity: 88.03%, tR = 6.65, (ESI) m/z [M + H]+ 335.38.
Ethyl 2-(1-(3-methylbenzyl)-5,5-dimethyl-2,4-dioxoimidazolidin-3-yl)acetate (39). 3-Methyl benzyl chloride
(1.69 g) and 29a were used. Method B. Sticky liquid, yield: 61.05%, C17H22N2O4 (MW 318.38). LC/MS+:
Purity: 81.94%, tR = 6.12, (ESI) m/z [M + H]+ 319.38.
Ethyl 2-(1-(2-naphthyl)-5,5-dimethyl-2,4-dioxoimidazolidin-3-yl)acetate (40). 2-(Chloromethyl)naphthalene
(2.65 g) and 29a were used. Method B. White solid, m.p. 95 ◦C, yield: 81.47%, C20H22N2O4 (MW
354.19). 1H-NMR (300 MHz, DMSO-d6) δ = 7.90–7.84 (m, 4H, naft-1,4,5,8-H), 7.52–7.45 (m, 3H, naft-3,6,7-H),
4.71 (s, 2H, Ph-CH2), 4.26 (s, 2H, CH2COO), 4.16–4.11 (q, J = 7.35 Hz, 2H, CH3–CH2), 1.26 (s, 6H, 2× CH3),
1.17(d, J = 7.00 Hz, 3H, CH3–CH2) ppm. LC/MS+: Purity: 90.56%, tR = 7.08, (ESI) m/z [M + H]+ 355.15.
4.1.3. General Procedures for the Synthesis of Methyl 2-(5-arylhydantoin-3-yl)acetates (60–67 and 71)
A mixture of a suitable arylhydantoin 50–58 (Scheme 1) or 70 (15–20 mmol) with K2CO3 (6–8 g),
TEBA (0.45–0.60 g) in acetone (75–100 mL) was stirred and refluxed for 30 min. Then, the solution
of methyl bromoacetate (15–20 mmol, 2.30–3.06 g) in acetone (15–20 mL) was added. The mixture
was stirred and refluxed for 3–6 h, then, stirred at room temperature overnight. The inorganic
components were separated by filtration. The filtrate was concentrated, and the residue was purified
using the similar methods as those for compounds 30–40, but MeOH in place of EtOH was used
for crystallization.
Methyl 2-(5-methyl-2,4-dioxo-5-phenylimidazolidin-3-yl)acetate (60). Compound 51 (2.85 g) and methyl
bromoacetate (2.30 g) were used. Sticky liquid, yield: 48.6%, C13H14N2O4 (MW 262.26).
1H-NMR (300 MHz, DMSO-d6) δ = 9.06 (s, 1H, N1–H), 7.47–7.50 (d, J = 7.00 Hz, 2H, Ph-2,6-H),
7.33–7.42 (m, 3H Ph-3,4,5-H), 4.19 (s, 2H, N3–CH2), 3.67 (s, 3H, O-CH3), 1.70 (s, 3H, CH3) ppm.
LC/MS+: Purity: 85.92%, tR = 4.43, (ESI) m/z [M + H]+ 263.11.
Methyl 2-(5-(3-chlorophenyl)-5-methyl-2,4-dioxoimidazolidin-3-yl)acetate (61). Compound 52 (4.49g) and
methyl bromoacetate (3.06 g) were used. White Chrystal, m.p. 102 ◦C, yield: 51.10%, C13H13ClN2O4
(MW 296.71). 1H-NMR (300 MHz, DMSO-d6) δ = 9.13 (s, 1H, N1–H), 7.51 (s, 1H, Ph-6-H), 7.43–7.47 (m,
3H, Ph-2,4,5-H), 4.20 (s, 2H, N3-CH2), 3.66 (s, 3H, O–CH3), 1.70 (s, 3H, CH3) ppm. LC/MS+: Purity:
100%, tR = 5.25, (ESI) m/z [M + H]+ 297.07.
Methyl 2-(5-(2,5-dichlorophenyl)-5-methyl-2,4-dioxoimidazolidin-3-yl)acetate (62). Compound 53 (4.14 g)
and methyl bromoacetate (2.45 g) were used. White solid, m.p. 214 ◦C, yield: 83.19%, C13H12Cl2N2O4
(MW 331.15). 1H-NMR (300 MHz, DMSO-d6) δ = 8.75 (s, 1H, N1-H), 7.69 (s, 2H, Ph-4-H), 7.52 (s, 2H,
Ph-3,6-H), 4.25 (s, 2H, N3–CH2), 3.68 (s, 3H, O–CH3), 1.80 (s, 3H, CH3) ppm. LC/MS+: Purity: 99.10%,
tR = 5.41, (ESI) m/z [M + H]+ 330.69.
Methyl 2-(5-(2,3,4-trichlorophenyl)-5-methyl-2,4-dioxoimidazolidin-3-yl)acetate (64). Compound 54 (5.18 g)
and methyl bromoacetate (3.06 g) were used. White solid, m.p. 172 ◦C, yield: 37.76%, C13H12Cl2N2O4
(MW 331.15). 1H-NMR (300 MHz, DMSO-d6) δ = 8.75 (s, 1H, N1–H), 7.68–7.71 (d, J = 8.8 Hz, 1H,
Ph-3-H), 7.65–7.66 (s, 1H, Ph-5-H), 7.48–7.52 (m, 1H, Ph-6-H), 4.25 (s, 2H, N3–CH2), 3.68 (s, 3H, O–CH3),
1.78 (s, 3H, CH3) ppm. LC/MS+: Purity: 96.70%, tR = 5.49, (ESI) m/z [M + H]+ 330.76.
Methyl 2-(5-methyl-5-(naphthalen-1-yl)-2,4-dioxoimidazolidin-3-yl)acetate (66). 5-Methyl-5-(naphthalen-1-
yl)imidazolidine-2,4-dione 57 (20 mmol, 4.80 g), K2CO3 (8 g), TEBA (0.60 g) in acetone (100 mL) and
methyl bromoacetate (20 mmol, 3.06 g) in acetone (20 mL) were stirred and refluxed for 6 h. Method B.
White glue-crystals, m.p. 105–109 ◦C, yield: 78% (15.60 mmol, 4.86 g), C17H16N2O4 (MW 312.11).
1H-NMR (300 MHz, DMSO-d6) δ = 8.98 (s, 1H, NH), 7.94–8.01 (m, 3H, Ar-4,5,8), 7.75 (d, J = 7.44 Hz,
1H, Ar-2), 7.48–7.57 (m, 3H, Ar-3,6,7), 4.33–4.39 (m, 2H, –CH2CO), 3.73 (s, 3H, –OCH3), 1.94 (s, 3H,
5-CH3) ppm. LC/MS+: Purity: 65.46%, tR = 5.47, (ESI) m/z [M + H]+ 312.95.
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Methyl 2-(5-methyl-5-(naphthalen-2-yl)-2,4-dioxoimidazolidin-3-yl)acetate (67). 5-Methyl-5-(naphthalen-2-
yl)imidazolidine-2,4-dione 58 (15 mmol, 3.60 g), K2CO3 (6 g), TEBA (0.45 g) in acetone (75 mL) and
methyl bromoacetate (15 mmol, 2.30 g) in acetone (15 mL) were stirred and refluxed for 5 h. Method A.
White crystals, m.p. 134–138 ◦C, yield: 58% (8.7 mmol, 2.72 g), C17H16N2O4 (MW 312.11). 1H-NMR
(300 MHz, DMSO-d6) δ = 9.15 (s, 1H, NH), 8.02 (s, 1H, Ar-1-H), 7.60 (dd, J1 = 8.72 Hz, J2 = 1.80 Hz, 2H,
Ar-6,7-H), 7.87–7.99 (m, 3H, Ar-4,5,8-H), 7.51–7.57 (m, 1H, Ar-3), 4.23 (s, 2H, –CH2CO), 3.66 (s, 3H,
–OCH3), 1.81 (s, 3H, 5-CH3) ppm. LC/MS+: Purity: 76.61%, tR = 5.63, (ESI) m/z [M + H]+ 312.82.
Methyl 2-(5,5-bis(4-chlorophenyl)-2,4-dioxoimidazolidin-3-yl)acetate (71). 5,5-bis(4-Chlorophenyl)-
imidazolidin-2,4-dione 70 (15 mmol, 4.80 g), K2CO3 (6 g), TEBA (0.45 g) in acetone (75 mL) and
methyl bromoacetate (15 mmol, 2.30 g) in acetone (15 mL) were stirred and refluxed for 4 h. Method A.
Creamy crystals, m.p. 120–121 ◦C, yield: 62%, C18H14Cl2N2O4 (MW 392.03). 1H-NMR (300 MHz,
DMSO-d6) δ = 7.53 (d, J = 8.7 Hz, 4H-ph), 7.37 (d, J = 8.7 Hz, 4H-ph), 4.31 (s, 2H–CH2), 3.70 (s, 3H-CH3),
1.04 (d, J = 6.1 Hz, 1H-NH) ppm. LC/MS+: Purity: 91.91%, tR = 7.26, (ESI) m/z [M + H]+ 393.10.
4.1.4. General Procedure for the Synthesis of 1,3,5-Triazine Final Products (5–26)
Sodium (8–10 mmol) was dissolved in 10 mL of absolute methanol, then 4-methylpiperazin-1-yl
biguanidine × 2HCl (4–5 mmol) and an appropriate ester 28, 30–40, 59–67 or 71 (4–5 mmol) were
added. The reaction mixture was refluxed for 15–30 h. After cooling to room temperature, water
(10 mL) was added and the mixture was stirred for 0.5 h. The triazine product precipitated (5–26) was
separated and purified using Methods C, D or E. Method C: Crystallization with methanol. Method D:
crystallization with methanol and charcoal. Method E: crystallization with ethanol.
3-(4-Chlorobenzyl)-1-((4-amino-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)methyl)-5,5-dimethylimidazolidine-
2,4-dione (5). Ester 28 (4.30 mmol, 1.40 g) and 4-methylpiperazin-1-yl biguanidine × 2HCl (4.30 mmol,
1.11 g) were used (48 h refluxed). Method C. White solid, m.p. 166–169 ◦C, yield: 34% (0.67 g),
C21H27N8O2Cl (MW 458.95). 1H-NMR (300 MHz, DMSO-d6) δ 7.34–7.52 (m, 2H, Ph-3,5-H), 7.21–7.32
(m, 2H, Ph-2,6-H), 6.82 (br. s., 2H, NH2), 4.55 (s, 2H, Ph-CH2), 4.19 (s, 2H, TR-CH2), 3.72–3.37 (br s, 4H,
Pp-2,6-H), 2.15 (s, 7H, Pp-3,5-H + Pp-CH3), 1.31 (s, 6H, 2× CH3) ppm. 13C-NMR (75 MHz, DMSO-d6)
δ = 176.83, 173.77, 167.04, 164.65, 154.86, 136.23, 132.52, 129.73, 129.03, 62.11, 54.67, 46.19, 44.19, 42.75, 41.08,
22.84 ppm. LC/MS+: Purity: 99.46%, tR = 3.75, (ESI) m/z [M + H]+ 459.23.
1-(4-Chlorobenzyl)-3-((4-amino-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)methyl)-5,5-dimethylimidazolidine-
2,4-dione (6). Ester 30 (4.30 mmol, 1.40 g) and 4-methylpiperazin-1-yl biguanidine × 2HCl (4.30 mmol,
1.11 g) were used (50 h refluxed). Method C. White solid, m.p. 204–205 ◦C, yield: 19% (0.38 g),
C21H27N8O2Cl (MW 458.95). 1H-NMR (300 MHz, DMSO-d6) δ = 7.38 (s, 4H, Ph-2,3,5,6-H), 6.87 (br. s.,
2H, NH2), 4.51 (s, 2H, Ph-CH2), 4.27 (s, 2H, TR-CH2), 3.55 (br. s., 4H, Pp-2,6-H), 2.15 (s, 7H, Pp-3,5-H +
Pp-CH3), 1.26 (s, 6H, 2× CH3) ppm. LC/MS+: Purity: 100%, tR = 3.94, (ESI) m/z [M + H]+ 459.23.
3-((4-Amino-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)methyl)-5-(4-chlorophenyl)-5-methylimidazolidine-2,4-
dione (7). Ester 59 (5 mmol, 1.48 g) and 4-methylpiperazin-1-yl biguanidine × 2HCl (4.30 mmol, 1.11 g)
were used (13.5 h refluxed). Method C. White solid, m.p. 218–220 ◦C, yield: 23% (0.42 g), C19H23N8O2Cl
(MW 430.89). 1H-NMR (300 MHz, DMSO-d6) δ = 9.02 (s, 1H, Hyd-1-H), 7.51–7.69 (m, 2H, Ph-3,5-H),
7.36–7.51 (m, 2H, Ph-2,6-H), 6.83 (br. s., 2H, NH2), 4.21 (s, 2H, TR-CH2), 3.53 (br. s., 2H, Pp-2,6-He),
3.27–3.32 (m, 2H, Pp-2,6-Ha), 2.13 (s, 7H, Pp-3,5-H + Pp-CH3), 1.68 (s, 3H, Hyd-CH3) ppm. 13C-NMR
(75 MHz, DMSO-d6) δ = 175.25, 171.94, 166.94, 164.54, 155.78, 139.22, 133.15, 128.87, 127.93, 62.99, 54.57,
46.16, 42.63, 42.45, 25.92 ppm. LC/MS+: Purity: 100%, tR = 3.23, (ESI) m/z [M + H]+ 431.19.
3-((4-Amino-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)methyl)-5,5-bis(4-chlorophenyl)imidazolidine-2,4-dione
(8). Ester 71 (4.80 mmol, 1.90 g) and 4-methylpiperazin-1-yl biguanidine × 2HCl (4 mmol, 1.03 g) were
used (30 h refluxed). Method C. White solid, m.p. 266–268 ◦C, yield: 40% (0.83 g), C24H24N8O2Cl2 (MW
526.14). 1H-NMR (300 MHz, DMSO-d6) δ = 9.79 (s, 1H, Hyd-1-H), 7.34–7.59 (m, 8H, 2× Ph-2,3,5,6-H), 6.85
(br. s, 2H, NH2), 4.30 (s, 2H, TR-CH2), 3.55 (br. s, 2H, Pp-2,6-He), 3.09 (br. s, 2H, Pp-2,6-Ha), 1.76–2.35 (m,
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7H, Pp-3,5-H + Pp-CH3) ppm. 13C-NMR (75 MHz, DMSO-d6) δ = 173.01, 171.74, 166.92, 164.52, 155.38,
138.75, 133.57, 129.12, 129.01, 68.59, 54.58, 46.16, 42.77, 42.53 ppm. LC/MS+: Purity: 100%, tR = 3.23, (ESI)
m/z [M]+ 527.16.
3-((4-Amino-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)methyl)-1-benzyl-5,5-dimethylimidazolidine-2,4-dione (9).
Ester 31 (3 mmol, 2.03 g) and 4-methylpiperazin-1-yl biguanidine × 2HCl (3 mmol, 0.77 g) were used
(36 h refluxed). Method D. White solid, m.p. 206 ◦C, yield: 3.94%, C21H28N8O2 (MW 424.23). 1H-NMR
(300 MHz, DMSO-d6) δ = 7.36–7.25 (m, 5H-Ph), 6.87 (s, 2H, NH2), 4.52 (s, 2H, CH2), 4.28 (s, 2H, TR-CH2),
3.62 (s, 4H, Pp-2,6-H), 2.15–2.23 (m, 7H, Pp-3,5-H, Pp-CH3), 1.25 (m, 6H, 2× CH3) ppm. LC/MS+: Purity:
98.30%, tR = 3.50, (ESI) m/z [M]+ 425.20.
1-(3-Chlorobenzyl)-3-((4-amino-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)methyl)-5,5-dimethylimidazolidine-
2,4-dione (10). Ester 32 (5 mmol, 2.52 g) and 4-methylpiperazin-1-yl biguanidine× 2HCl (5 mmol, 0.92 g)
were used (6 h refluxed), and stirred for another 24 h in a room temperature. Method D. White solid, m.p.
168 ◦C, yield: 24.81%, C21H28N8O2 (MW 458.19). 1H-NMR (300 MHz, DMSO-d6) δ = 7.42 (s, 1H, Ph-6-H),
7.33 (m, 3H, Ph-2,4,5-H), 6.86 (s, 2H, NH2), 4.52 (s, 2H–CH2), 4.27(s, 2H, TR-CH2), 3.58 (s, 4H, Pp-2,6-H),
2.13 (m, 7H, Pp-3,5-H, Pp-CH3), 1.27 (s, 6H, 2× CH3) ppm. LC/MS+: Purity: 96.12%, tR = 5.34, (ESI) m/z
[M]+ 459.23.
1-(2,5-Dichlorobenzyl)-3-((4-amino-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)methyl)-5,5-dimethylimidazolidine-
2,4-dione (11). Ester 33 (5 mmol, 2.01 g) and 4-methylpiperazin-1-yl biguanidine× 2HCl (5 mmol, 0.92 g)
were used (6 h refluxed), and stirred for another 144 h in room a temperature. Method D. White solid, m.p.
163 ◦C, yield: 27.32%, C21H26Cl2N8O (MW 492.16). 1H-NMR (300 MHz, DMSO-d6) δ = 7.53–7.50 (s, 1H,
Ph-4-H), 7.41–7.38 (m, 2H, Ph-3,6-H), 6.84 (s, 2H, NH2), 4.58 (s, 2H, CH2), 4.29 (s, 2H, TR-CH2), 3.63 (s,
4H, Pp-2,6-H), 2.23–2.15 (m, 7H, Pp-3,5-H, Pp-CH3), 1.30 (s, 6H, 2× CH3) ppm. LC/MS+: Purity: 100%,
tR = 4.40, (ESI) m/z [M]+ 493.13.
1-(2,4-Dichlorobenzyl)-3-((4-amino-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)methyl)-5,5-dimethylimidazolidine-
2,4-dione (12). Ester 34 (5 mmol, 2.03 g) and 4-methylpiperazin-1-yl biguanidine× 2HCl (5 mmol, 0.92 g)
were used (3 h refluxed), and stirred for another 24 h in room a temperature. Method D. White solid, m.p.
123 ◦C, yield: 23.98%, C21H26Cl2N8O (MW 492.16). 1H-NMR (300 MHz, DMSO-d6) δ = 7.65–7.64 (s, 1H,
Ph-6-H), 7.40–7.41 (m, 2H, Ph-3,5-H), 6.88 (s, 2H, NH2), 4.58 (s, 2H, CH2), 4.28 (s, 2H, TR-CH2), 3.62 (s,
4H, Pp-2,6-H), 2.52–2.26 (m, 7H, Pp-3,5-H, Pp-CH3), 1.29 (s, 6H, 2× CH3) ppm. LC/MS+: Purity: 100%,
tR = 4.56, (ESI) m/z [M]+ 493.13.
1-(4-Fluorobenzyl)-3-((4-amino-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)methyl)-5,5-dimethylimidazolidine-
2,4-dione (13). Ester 35 (5 mmol, 2.32 g) and 4-methylpiperazin-1-yl biguanidine× 2HCl (5 mmol, 0.92 g)
were used (10 h refluxed), and stirred for another 24 h in room a temperature. Method D. White solid, m.p.
180 ◦C, yield: 9.23%, C21H27FN8O2 (MW 442.22). 1H-NMR (300 MHz, DMSO-d6) δ = 7.38–7.43 (m, 2H,
Ph-2,6-H), 7.11–7.17 (m, 2H, Ph-3,5-H), 6.86 (s, 2H, NH2), 4.51 (s, 2H, CH2), 4.27 (s, 2H, TR-CH2), 3.57 (s,
4H, Pp-2,6-H), 2.14–2.23 (m, 7H, Pp-3,5-H, Pp-CH3), 1.26 (m, 6H, 2× CH3) ppm. LC/MS+: Purity: 100%,
tR = 3.68, (ESI) m/z [M]+ 443.28.
1-(3-Fluorobenzyl)-3-((4-amino-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)methyl)-5,5-dimethylimidazolidine-
2,4-dione (14). Ester 36 (5 mmol, 2.34 g) and 4-methylpiperazin-1-yl biguanidine× 2HCl (5 mmol, 0.92 g)
were used (10 h refluxed), and stirred for another 24 h in room a temperature. Method D. White solid, m.p.
207 ◦C, yield: 9.32%, C21H27FN8O2 (MW 442.22). 1H-NMR (300 MHz, DMSO-d6) δ = 7.34 (m, 1H, Ph-6-H),
7.13 (m, 3H, Ph-2,4,5-H), 6.86 (s, 2H, NH2), 4.53 (s, 2H, CH2), 4.27 (s, 2H, TR-CH2), 3.58 (s, 4H, Pp-2,6-H),
2.14 (m, 7H, Pp-3,5-H, Pp-CH3), 1.27 (s, 6H, 2× CH3) ppm. LC/MS+: Purity: 100%, tR = 3.59, (ESI) m/z
[M]+ 443.22.
1-(3-Bromobenzyl)-3-((4-amino-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)methyl)-5,5-dimethylimidazolidine-
2,4-dione (15). Ester 37 (5 mmol, 2.51 g) and 4-methylpiperazin-1-yl biguanidine× 2HCl (5 mmol, 0.92 g)
were used (4 h refluxed), and stirred for another 24 h in room a temperature. Method D. White powder,
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m.p. 125 ◦C, yield: 56%, C21H27BrN8O2 (MW 502.14). 1H-NMR (300 MHz, DMSO-d6) δ = 7.59 (s, 1H,
Ph-4-H), 7.51–7.44 (m, 1H, Ph-2-H), 7.38 (d, J = 7.8 Hz, 1H, Ph-6-H), 7.30 (t, J = 7.7 Hz, 1H, Ph-5-H), 6.88
(s, 2H, NH2), 4.54 (s, 2H, CH2), 4.29 (s, 2H, TR-CH2), 3.77–3.44 (m, 4H, Pp-2,6-H), 2.16 (m, 7H, Pp-3,5-H,
Pp-CH3), 1.29 (s, 6H, 2× CH3) ppm. LC/MS+: Purity: 97.66%, tR = 4.07, (ESI) m/z [M]+ 505.16.
1-(3-Methoxybenzyl)-3-((4-amino-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)methyl)-5,5-dimethylimidazolidine-
2,4-dione (16). Ester 38 (5 mmol, 2.42 g) and 4-methylpiperazin-1-yl biguanidine× 2HCl (5 mmol, 0.92 g)
were used (10 h refluxed), and stirred for another 24 h in room a temperature. Method D. White solid,
m.p. 111 ◦C, yield: 13.79%, C22H30N8O3 (MW 454.24). 1H-NMR (300 MHz, DMSO-d6) δ = 7.25–7.20 (m,
1H, Ph-3-H), 6.93 (m, 2H, Ph-2,4-H), 6.84–6.82 (m, 1H, Ph-6-H, 2H, NH2), 4.49 (s, 2H, CH2), 4.28 (s, 2H,
TR-CH2), 3.71 (s, 3H, CH3), 3.59 (s, 4H, Pp-2,6-H), 2.15(m, 7H, Pp-3,5-H, Pp-CH3), 1.25 (m, 6H, 2× CH3)
ppm. LC/MS+: Purity: 97.60%, tR = 3.55, (ESI) m/z [M]+ 455.24.
1-(3-Methylbenzyl)-3-((4-amino-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)methyl)-5,5-dimethylimidazolidine-
2,4-dione (17). Ester 39 (5 mmol, 2.61 g) and 4-methylpiperazin-1-yl biguanidine× 2HCl (5 mmol, 0.92 g)
were used (5 h refluxed) and stirred for another 24 h in room a temperature. Method D. White solid, m.p.
154 ◦C, yield: 13.79%, C22H30N8O (MW 438.25). 1H-NMR (300 MHz, DMSO-d6) δ = 7.22–7.07 (m, 4H, Ph),
6.86 (s, 2H, NH2), 4.48 (s, 2H, CH2), 4.27 (s, 2H, TR-CH2), 3.59 (s, 4H, Pp-2,6-H), 2.27–2.15(m, 10H, Pp-3,5-H,
Pp-CH3, Ph-CH3), 1.25 (s, 6H, 2× CH3) ppm. LC/MS+: Purity: 98.88%, tR = 3.94, (ESI) m/z [M]+ 439.23.
3-((4-Amino-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)methyl)-5,5-dimethyl-1-(naphthalen-1-ylmethyl)
imidazolidine-2,4-dione (18). Ester 40 (5 mmol, 1.96 g) and 4-methylpiperazin-1-yl biguanidine ×
2HCl (5 mmol, 0.92 g) were used (5 h refluxed) and stirred for another 24 h in room a temperature.
Method D. White powder, m.p. 116 ◦C, yield: 13.79%, C25H30N8O2 (MW 474.25). 1H-NMR (300 MHz,
DMSO-d6) δ = 7.88–7.84 (m, 4H, naft-1,4,5,8-H), 7.50–7.48 (m, 3H, naft-3,6,7-H), 6.86 (s, 2H, NH2), 4.70
(s, 2H, CH2), 4.30 (s, 2H, TR-CH2), 3.55 (s, 4H, Pp-2,6-H), 2.22–2.02 (m, 7H, Pp-3,5-H, Pp-CH3), 1.29 (s,
6H, 2× CH3) ppm. LC/MS+: Purity: 100%, tR = 4.31, (ESI) m/z [M]+ 475.25.
3-((4-Amino-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)methyl)-5-methyl-5-phenylimidazolidine-2,4-dione (19).
Ester 60 (5 mmol, 1.31g) and 4-methylpiperazin-1-yl biguanidine × 2HCl (5 mmol, 0.92 g) were used
(4.5 h refluxed) and stirred for another 24 h in room a temperature. Method C. White solid, m.p. 270 ◦C,
yield: 50%, C19H24N8O2 (MW 396.45). 1H-NMR (300 MHz, DMSO-d6) δ = 9.00 (s, 1H, N1-H), 7.54–7.56
(d, J = 7.5 Hz, 2H, Ph-2,6-H), 7.39–7.43 (t, J = 7.25 Hz, Ph-3,5-H), 7.33–7.36 (d, J = 7.5 Hz,1H, Ph-4-H), 6.85
(s, 2H, NH2), 4.24 (s, 2H, N3-CH2), 3.61 (s, 2H, Pp-2,6-Hb), 3.40–3.50 (m, 2H, Pp-2,6-Ha), 2.16–2.24 (s, 4H,
Pp-3,5-H), 2.16 (s, 3H, N–CH3), 1.73 (s, 3H, 5-CH3) ppm. 13C-NMR (75 MHz, DMSO-d6) δ = 175.62, 172.08,
166.96, 164.61, 155.92, 140.14, 128.88, 128.31, 125.98, 63.40, 54.64, 46.20, 42.72, 42.47, 25.82 ppm. LC/MS+:
Purity: 96.38%, tR = 2.62, (ESI) m/z [M]+ 397.22.
3-((4-Amino-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)methyl)-5-(3-chlorophenyl)-5-methylimidazolidine-2,4-
dione (20). Ester 61 (5 mmol, 1.49 g) and 4-methylpiperazin-1-yl biguanidine× 2HCl (5 mmol, 0.92 g) were
used (5 h refluxed). Method C. White solid, m.p. 234 ◦C, yield: 56.80%, C19H23ClN8O2 (MW 430.89).
1H-NMR (300 MHz, DMSO-d6) δ = 9.00 (s, 1H, N–H), 7.54–7.58 (m, 2H, Ph-2,6-H), 7.45–7.49 (m, 2H,
Ph-4,5-H), 6.85 (s, 2H, NH2), 4.25 (s, 2H, N3–CH2), 3.60 (s, 2H, Pp-2,6-Hb), 3.30 (s, 2H, Pp-2,6-Ha), 2.26 (s,
2H, Pp-3,5-Hb), 2.16 (s, 3H, N–CH3), 2.09 (s, 2H, Pp-3,5-Ha), 1.72 (s, 3H, 5-CH3) ppm. 13C-NMR (75 MHz,
DMSO-d6) δ = 175.08, 171.94, 166.96, 164.55, 155.74, 142.65, 133.63, 130.92, 128.38, 125.80, 124.85, 63.11, 54.60,
46.19, 42.67, 42.50, 26.21 ppm. LC/MS+: Purity: 100%, tR = 3.23, (ESI) m/z [M]+ 431.12.
3-((4-Amino-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)methyl)-5-(2,5-dichlorophenyl)-5-methylimidazolidine-
2,4-dione (21). Ester 62 (5 mmol, 1.65 g) and 4-methylpiperazin-1-yl biguanidine× 2HCl (5 mmol, 0.92 g)
were used (3.5 h refluxed). Method C. White solid, m.p. 166 ◦C, yield: 79.10%, C19H22Cl2N8O2 (MW
465.34). 1H-NMR (300 MHz, DMSO-d6) δ = 8.66 (s, 1H, N1–H), 7.72 (s, 1H, Ph-4-H), 7.54 (s, 2H, Ph-3,6-H),
6.89 (s, 2H, NH2), 4.30 (s, 2H, N3–CH2), 3.67 (m, 4H, Pp-2,6-H), 2.29 (s, 4H, Pp-3,5-H), 2.19 (s, 3H, N–CH3),
1.87 (s, 3H, 5-CH3) ppm. 13C-NMR (75 MHz, DMSO-d6) δ = 174.90, 172.31, 167.02, 164.70, 156.23, 137.56,
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133.13, 132.49, 132.26, 130.68, 130.05, 62.65, 54.71, 46.21, 42.90, 42.49, 25.18 ppm. LC/MS+: Purity: 99.11%,
tR = 3.53, (ESI) m/z [M]+ 465.15.
3-((4-Amino-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)methyl)-5-(2,4-dichlorophenyl)-5-methylimidazolidine-
2,4-dione (22). Ester 63 (5 mmol, 1.66 g) and 4-methylpiperazin-1-yl biguanidine× 2HCl (5 mmol, 0.92 g)
were used (4.5 h refluxed). Method C. White solid, m.p. 228 ◦C, yield: 76.56%, C19H22Cl2N8O2 (MW
465.34). 1H-NMR (300 MHz, DMSO-d6) δ = 8.65 (s, 1H, N1–H), 7.71–7.73 (d, 1H, Ph-3-H), 7.67–7.68 (s, 1H,
Ph-5-H), 7.50–7.53 (d, 1H, Ph-6-H), 6.89 (s, 2H, NH2), 4.30 (s, 2H, N3–CH2), 3.67 (s, 4H, Pp-2,6-H), 2.29 (s,
4H, Pp-3,5-H), 2.19 (s, 3H, N–CH3), 1.86 (s, 3H, 5-CH3) ppm. 13C-NMR (75 MHz, DMSO-d6) δ = 175.12,
172.34, 167.02, 164.70, 156.25, 134.70, 134.66, 134.57, 131.70, 130.83, 127.80, 62.49, 54.71, 46.21, 42.88, 42.47,
25.29 ppm. LC/MS+: Purity: 100%, tR = 3.66, (ESI) m/z [M]+ 465.08.
3-((4-Amino-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)methyl)-5-(2,3,4-trichlorophenyl)-5-methylimidazolidine-
2,4-dione (23). Ester 64 (5 mmol, 1.83 g) and 4-methylpiperazin-1-yl biguanidine× 2HCl (5 mmol, 0.92 g)
were used (4 h refluxed). Method C. White crystal, m.p. 256 ◦C, yield: 83.68%, C19H21Cl3N8O2 (MW
499.78). 1H-NMR (300 MHz, DMSO-d6) δ = 7.74 (s, 2H, Ph-5,6-H), 6.89 (s, 2H, NH2), 4.32 (s, 2H, N3–CH2),
3.67 (s, 4H, Pp-2,6-H), 2.29 (s, 4H, Pp-3,5-H), 2.19 (s, 3H, N–CH3), 1.88 (s, 3H, 5-CH3) ppm. 13C-NMR
(75 MHz, DMSO-d6) δ = 175.94, 172.32, 167.01, 164.70, 156.33, 136.85, 133.94, 133.58, 132.24, 129.48, 129.09,
63.11, 54.71, 46.21, 42.90, 42.59, 25.56 ppm. LC/MS+: Purity: 98.93%, tR = 4.07, (ESI) m/z [M]+ 499.05.
3-((4-Amino-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)methyl)-5-(4-methylphenyl)-5-methylimidazolidine-
2,4-dione (24). Ester 65 (5 mmol, 1.38 g) and 4-methylpiperazin-1-yl biguanidine × 2HCl (5 mmol,
0.92 g) were used (4.5 h refluxed). Method C. White solid, m.p. 240 ◦C, yield: 49.27%, C20H26N8O2
(MW 410.47). 1H-NMR (300 MHz, DMSO-d6) δ = 7.41–7.43 (d, J = 8.3 Hz, 2H, Ph-2,6), 7.20–7.22 (d,
J = 7.9 Hz, 2H, Ph-3,5-H), 6.84 (s, 2H, NH2), 4.23 (s, 2H, N3–CH2), 3.59 (s, 4H, Pp-2,6-H), 2.30 (s, 3H,
Ph-CH3), 2.16 (s, 4H, Pp-3,5-H), 2.10 (s, 3H, N–CH3), 1.69 (s, 3H, 5-CH3) ppm. 13C-NMR (75 MHz,
DMSO-d6) δ = 175.74, 172.10, 166.96, 164.61, 155.91, 137.49, 137.29, 129.39, 125.87, 63.21, 54.65, 46.20,
42.70, 42.44, 25.83, 21.03 ppm. LC/MS+: Purity: 98.31%, tR = 3.10, (ESI) m/z [M]+ 411.18.
3-((4-Amino-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)methyl)-5-methyl-5-(naphthalen-1-yl)imidazolidine-
2,4-dione (25). Ester 66 (5 mmol, 1.56 g) and 4-methylpiperazin-1-yl biguanidine× 2HCl (5 mmol, 0.92 g)
were used (5 h refluxed). Method E. White solid, m.p. 208 ◦C, yield: 32.87%, C23H26N8O2 (MW 446.50).
1H-NMR (300 MHz, DMSO-d6) δ = 8.95 (s, 1H, N1-H), 8.05–8.07 (m, 1H, Naft-8-H), 7.96–8.00 (t, 2H,
Naft-4,5-H), 7.76–7.78 (d, J = 7.5 Hz; 1H, Naft-2-H), 7.51–7.55 (t, J = 7.7 Hz, 3H, Naft-3,6,7-H), 6.90 (s, 2H,
NH2), 4.40 (s, 2H, N3–CH2), 3.63 (s, 4H, Pp-2,6-H), 2.17 (s, 4H, Pp-3,5-H), 2.07 (s, 3H, N–CH3), 2.02 (s, 3H,
5-CH3) ppm. 13C-NMR (75 MHz, DMSO-d6) δ = 176.31, 172.32, 167.07, 164.73, 156.03, 134.61, 134.21, 130.87,
130.22, 129.62, 126.92, 126.43, 126.10, 125.43, 125.11, 64.18, 54.66, 46.20, 42.88, 42.71, 26.74 ppm. LC/MS+:
Purity: 99.06%, tR = 3.55, (ESI) m/z [M]+ 447.20.
3-((4-Amino-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)methyl)-5-methyl-5-(naphthalen-2-yl)imidazolidine-
2,4-dione (26). Ester 67 (5 mmol, 1.56 g) and 4-methylpiperazin-1-yl biguanidine × 2HCl (5 mmol,
0.92 g) were used (3 h refluxed). Method E. White solid, m.p. 144 ◦C, yield: 34.57%, C23H26N8O2 (MW
446.50). 1H-NMR (300 MHz, DMSO-d6) δ = 9.12 (s, 1H, N1–H), 8.07 (s, 1H, Naft-1-H), 7.93–7.99 (m, 3H,
Naft-4,5,8-H), 7.72–7.74 (d def., 1H, Naft-3-H), 7.54–7.57 (m, 2H, Naft-6,7-H), 6.85 (s, 2H, NH2), 4.27 (s, 2H,
N3–CH2), 3.40–3.60 (m, 2H, Pp-2,6-Hb), 3.05–3.20 (m, 2H, Pp-2,6-Ha), 2.09 (s, 4H, Pp-3,5-H), 2.00 (s, 3H,
N–CH3), 1.83 (s, 3H, 5-CH3) ppm. 13C-NMR (75 MHz, DMSO-d6) δ = 175.56, 172.01, 166.95, 164.53, 155.92,
137.75, 132.96, 132.81, 128.62, 128.57, 127.89, 126.95, 126.90, 124.51, 124.33, 63.56, 53.90, 46.00, 42.56, 42.47,
25.94 ppm. LC/MS+: Purity: 99.11%, tR = 3.49, (ESI) m/z [M]+ 447.20.
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4.2. Molecular Modeling
4.2.1. Optimization of the 5-HT6R Binding Site Using Induced-Fit Docking Procedure
The 5-HT6R homology model (build on β2 adrenergic template) was optimized using the
induced-fit docking (IFD) [33] protocol from Schrödinger. The IFD combines flexible ligand docking,
using the Glide algorithm [34], with receptor structure prediction and side chain refinement in Prime.
The structures of Lead 1 and Lead 2 were used as inputs to IFD. In each case, the centroid of the grid
box was anchored on D3.32 and allowed on residues refinement within 12 Å of ligand poses. The ten
top-scored L–R complexes were inspected visually to select those showing the closest compliance
with the common binding mode for monoaminergic receptor ligands [35]. The final validation of the
receptor conformations selected was performed by docking (Glide SP mode) the synthetized library,
retaining only those with a coherent binding mode for the whole set.
4.2.2. Molecular Docking
The 5-HT6R models selected in IFD procedure were used to study the binding mode of the library
synthesized. 3-dimensional structures of the ligands were prepared using LigPrep v3.6 (Schrödinger,
New York, NY, USA) [36], and the appropriate ionization states at pH = 7.4 ± 1.0 were assigned using
Epik v3.4 (Schrödinger, New York, NY, USA) [37]. Compounds with unknown absolute configuration
were docked in all configurations. The Protein Preparation Wizard was used to assign the bond
orders, appropriate amino acid ionization states and to check for steric clashes. The receptor grid was
generated (OPLS3 force field [38]) by centering the grid box with a size of 12 Å on the D3.32 side chain.
Automated flexible docking was performed using Glide at SP level [39].
4.2.3. Plotting Interaction Spheres for Halogen Bonding
The halogen bonding web server was used (accessed on 22 February 2018, http://www.
halogenbonding.com/) to visualize (plotting interaction spheres) the potential contribution of halogen
bonding to ligand–receptor complexes.
4.3. Lipophilicity Study
4.3.1. Thin-Layer Chromatography
The mobile phases were prepared by mixing the respective amounts of water and organic modifier
(methanol) in a range from 40 to 90% (v/v) in 5% increments. TLC was performed on Silica gel 60RP-18 F254
plates (7× 10 cm) plates (Merck, Darmstadt, Germany). Methanol was used to prepare the solutions of
the substances. Solutions (10 µL) of the analyzed compounds were applied to the plates as 5 mm bands,
10 mm apart and 10 mm from the lower edge and sides of the plates, by using Linomat V applicator
(Camag, Basel, Switzerland). The vertical chamber (Sigma–Aldrich, St. Louis, MI, USA), 20× 10× 18 cm
in size, was saturated with mobile phase for 20 min. Development was carried out over 9 cm from the
starting line at a temperature of 20 ◦C. Next, the plates were dried at room temperature, and the spots were
observed under ultraviolet light at 254 nm and/or 366 nm (UV lamp, Camag, Basel, Switzerland). In each
case, sharp and symmetric spots without a tendency for tailing were obtained. Each experiment was run
in triplicate and mean RF (retardation factor) values were calculated.
Starting from the RF values, the RM parameters were computed as described in the formula:
RM = log(1/RF − 1)
The linear correlations between the RM values of the substances and the concentration of methanol
in mobile phases were calculated for each compound with the Soczewiński-Wachtmeister equation [22]:
RM = RM0 + aC
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where C is the concentration of the organic modifier (in %) in the mobile phase, a is the slope, and RM0
is the concentration of organic modifier extrapolated to zero.
4.3.2. Statistical Methods
Statistical analysis was performed using Statistica v10 software (StatSoft, Tulsa, OK, USA).
The correlation coefficients (r, r2), and the standard errors of the slope, interception, and estimate (Sa,
Sb, Se) were used as the basis for testing the linearity of regression plots.
4.4. Studies In Vitro
4.4.1. Radioligand Binding Assay
Radioligand binding assays were used to determine the affinity of the synthesized compounds
for human serotonin 5-HT6R, which were stably expressed in HEK-293 cells. This procedure was
accomplished via the displacement of [3H]-LSD (85.2 Ci mmol−1) for 5-HT6R. Each compound was
tested in triplicate at 7 to 8 different concentrations (10−11 to 10−4 M). The inhibition constants (Ki)
were calculated using the Cheng–Prusoff equation [40], and the results are expressed as the mean of at
least two independent experiments.
4.4.2. Toxicity In Vitro Test
The ATCC CRL 1573 HEK-293 cells were seeded in 96-well plates (NuncTM) at a concentration of
1 × 104 cells/well in 200 µL in Dulbecco’s Modified Eagle’s Medium (Gibco®) supplemented with 10%
fetal bovine serum (Gibco®), and cultured at 37 ◦C in an atmosphere containing 5% of CO2 for 24 h to
reach 60% confluence. The 10 mM stock solutions of 5-HT6R ligands 6 and 26 in DMSO were diluted
into fresh growth medium and added into the microplates at the final concentrations 0.1 µM –100
µM. Total DMSO concentration did not exceed 1% in growth media. The cytostatic drug doxorubicin
(Sigma-Aldrich) at the concentration 1 µM was used as a reference. After 72 h of incubation 20 µL
of CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (MTS) (Promega®) was added
to each well and the cells were incubated under the same conditions for 2 h. The absorbance of the
samples was measured using a microplate reader EnSpire (PerkinElmer, Waltham, MA, USA) at 490 nm.
Statistical significance was analyzed by GraphPad Prism™ software v. 5.01 (GraphPad Software, La
Jolla, CA, USA) using One-way ANOVA and Bonferroni’s Multiple Comparison Post Test.
4.5. Studies In Vivo
4.5.1. Animals
The experiments were performed on male Wistar rats (200–220 g—behavioural test or
170–190 g—metabolic assay) obtained from an accredited animal facility at the Jagiellonian University
Medical College, Poland. The animals were housed in a group of four in a controlled environment
(ambient temperature 21 ± 2 ◦C; relative humidity 50–60%; 12 h light/dark cycles (lights on at
8:00). Standard laboratory food (LSM-B) and filtered water were freely available (behavioral tests).
Animals were assigned randomly to treatment groups. All the experiments were performed by two
observers unaware of the treatment applied between 9:00 and 14:00 on separate groups of animals.
All animals were used only once.
The experimental protocols and procedures described in this manuscript were approved by the I
Local Ethics Commission in Cracow (no 293/2015) and complied with the European Communities
Council Directive of 24 November 1986 (86/609/EEC) and were in accordance with the 1996 NIH
Guide for the Care and Use of Laboratory Animals.
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4.5.2. Drugs
Compounds were suspended in 1% Tween 80 immediately before administration in a volume
of 2 mL/kg—behavioral tests or 1 mL/kg—body weight measures. Compounds were administered
intraperitoneally (i.p.) 60 min before testing—behavioral tests. Control animals received vehicle (1%
Tween 80) according to the same schedule.
4.5.3. Behavioral Procedures in Rats
Forced Swim Test (FST Test)
The experiment was carried out according to the method of Porsolt et al. [41]. On the first day of
an experiment, the animals were gently individually placed in Plexiglas cylinders (40 cm high, 18 cm
in diameter) containing 15 cm of water maintained at 23–25 ◦C for 15 min. On removal from water,
the rats were placed for 30 min in a Plexiglas box under 60-W bulb to dry. On the following day (24 h
later), the rats were replaced in the cylinder and the total duration of immobility was recorded during
the whole 5-min test period. The immobility was assigned when no additional activity was observed
other than that necessary to keep the rat’s head above the water. Fresh water was used for each animal.
Vogel Conflict Drinking Test
The testing procedure was based on a method of Vogel et al. [42] and used the Anxiety Monitoring
System “Vogel test” produced by TSE Systems (Germany). It was consisted of polycarbonate cages
(dimensions 26.5× 15× 42 cm), equipped with a grid floor made from stainless steel bars and drinking
bottles containing tap water. Experimental chambers were connected to PC software by control chassis
and on electric shocks’ generator. On the first day of the experiment, the rats were adapted to the
test chambers and drink water from the bottle spout for 10 min. Afterward, the rats were returned to
their home cages and were given 30 min free access to water followed by a 24 h water deprivation
period. The adaptation session and water deprivation protocols were repeated on the second day of the
experiment. On the third day, the rats were placed again in the test chambers 60 min after compound
26 and diazepam administration and were given free access to the drinking tube. Recording data
started immediately after the first lick and rats were punished with an electric shock (0.5 mA, lasting
1 s) delivered to the metal drinking tube every 20 licks. The number of licks and the number of shocks
received during a 5 min experimental session were recorded automatically.
4.5.4. Metabolic Assays In Vivo
The Effect of compound 6 or 26 on Body Weight by Non-Obese Rats Fed Palatable Diet (Model of
Excessive Eating)
In order to determine the anorectic activity of 6 or 26, the model of excessive eating was
used [43,44]. Male Wistar rats (170–190 g) were housed in a pair in plastic cages in constant temperature
facilities exposed to a light-dark cycle. Water and food were available ad libitum. Two groups of 6 rats
were fed with diets consisting of milk chocolate with nuts, cheese, salted peanuts, and 7% condensed
milk and also had access to standard feed (Labofeed B, Morawski Manufacturer Feed, Kcynia, Poland)
and water ad libitum for 3 weeks. Palatable control group (palatable diet + vehicle) received vehicle
(1% Tween 80, intraperitoneally), while palatable test group (palatable diet + 6 or palatable + 26)
was injected (intraperitoneally) with 6 or 26 at the dose of 5 mg/kg b.w. dissolved in 1% Tween 80
(1 mL/kg). Body weights were measured daily, immediately prior to administration of drugs.
The palatable diet contained: 100 g peanuts—614 kcal; 100 mL condensed milk—131 kcal; 100 g
milk chocolate—529 kcal; 100g cheese (Greek type)—270 kcal. The standard diet contained 100 g
feed—280 kcal.
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The Effect of compound 6 or 26 on Body Weight by Non-Obese Rats Fed Only with Standard Diet
Male Wistar rats (170–190 g) were housed in a pair in plastic cages in constant temperature
facilities exposed to a light-dark cycle. Control group (standard diet + vehicle) received vehicle (1%
Tween 80, intraperitoneally), while the test group (standard diet + 6 or standard diet + 26) was injected
(intraperitoneally) with 6 or 26 at the dose of 5 mg/kg b.w. dissolved in 1% Tween 80 (1 mL/kg).
Body weights were measured daily immediately prior to administration of drugs.
4.6. Statistical Analysis
4.6.1. Lipophilicity
Statistical analysis was performed using Statistica v10 software (StatSoft, Tulsa, OK, USA).
The correlation coefficients (r, r2), and the standard errors of the slope, interception, and estimate (Sa,
Sb, Se) served as the basis for testing the linearity of regression plots.
4.6.2. Studies In Vitro and In Vivo
Statistical calculations were performed using GraphPad Prism 6 software (GraphPad Software,
La Jolla, CA, USA). Results are provided as arithmetic means with a standard error of the mean.
The data of behavioral studies were evaluated by an analysis of variance one-way ANOVA followed by
Bonferroni’s post hoc test (statistical significance set at p < 0.05). Statistical significance of body weight
was calculated using one-way ANOVA with Sidak’s multiple comparison test post-hoc or two-way
ANOVA with Sidak’s multiple comparison test post-hoc. Differences were considered statistically
significant at: p ≤ 0.05, p ≤ 0.01, p ≤ 0.001.
5. Conclusions
These comprehensive studies, including: Computer-aided design, synthesis, pharmacological
screening in vitro and in vivo, “drugability” experiments and an extensive docking-based SAR analysis,
have provided an insight into chemical properties, ligand–receptor interactions and potential therapeutic
perspectives for the new group of 1,3,5-triazine molecules. Lead structures with two topological variants
of the hydantoin linker have been identified, followed by the synthesis of numerous lead modifications.
As result, a new series of 18 active 5-HT6 agents, with submicromolar affinities confirmed in the
radioligand binding assays, has been obtained (groups A and B). Computer-aided SAR analysis indicates
the significance of both, linker and aromatic moiety properties, and their mutual dependences, for the
5-HT6R affinity of the 1,3,5-triazine derived compounds. Thus, the combination of 1-unsubstituted
hydantoin (group B) with the β-naphthyl moiety at position 5 (26) was found as the most profitable,
followed by either the corresponding α-naphthyl analogue (25) and the tri-substituted combination of
1-(4-chlorobenzyl)-3-((4-amino-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)methyl)-5,5-dimethylimidazolidine-
2,4-dione (6, group A). The most active agent (26) displayed also antidepressant-like and anxiolytic-like
activities in vivo, whereas the best members of both groups (6 and 26) demonstrated anti-obesity properties
in animals fed palatable feed, as well as lipophilicity favorable for CNS drugs with a low risk of toxicity
in vitro.
The interesting pharmacological properties together with a promising “drugability” designate this
group of chemical molecules as a good starting point for further consideration in order to explore
molecular mechanisms of the 5-HT6R–ligand interaction, and even to search of new drug candidates for the
treatment of depression and obesity. In this context, 3-((4-Amino-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-
yl)methyl)-5-methyl-5-(naphthalen-2-yl)imidazolidine-2,4-dione (26) can be selected as a new lead structure.
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This research has provided the most active 5-HT6R agents among 1,3,5-triazine derivatives investigated
to date and has also identified the world's first selenium-containing 5-HT6R ligands. The studies are
focused on design, synthesis, biological evaluation and docking-supported SAR analysis for novel 5-HT6R
agents as derivatives of lead structure 4-(4-methylpiperazin-1-yl)-6-(phenoxymethyl)-1,3,5-triazin-2-
amine (7). The lead modifications included an introduction of: (i) various small substituents at ben-
zene ring, (ii) a branched ether linker or (iii) the ether oxygen replacement with other chalcogen (S, Se)
or sulfonyl moiety. Hence, a series of new compounds (7e24) was synthesized and examined on their
affinities for 5-HT6R and selectivity, in respect to the 5-HT1AR, 5-HT2AR, 5-HT7R and dopamine D2 re-
ceptor, in the radioligand binding assays. For representative most active compounds functional bioassays
and toxicity profile in vitro and antidepressant-like activity in vivo were examined. The 2-isopropyl-5-
methylphenyl derivative (10) was found as the most active triazine 5-HT6R antagonist (Ki¼ 11 nM).
SAR analysis indicated, that an exchange of oxygen to selenium (7 vs. 22), and especially, to sulfur (7 vs.
19) was beneficial to increase both affinity and antagonistic action for 5-HT6R. Surprisingly, an intro-
duction of SO2 caused a drastic decrease of the 5-HT6R affinity, which was explained at a molecular level
based on docking studies. All in vivo tested compounds (10,18 and 21) did not show any risk of toxicity in
the safety studies in vitro.
© 2019 Elsevier Masson SAS. All rights reserved.1. Introduction
The 5-hydroxytryptamine (5-HT: serotonin) subtype 6 receptor
(5-HT6R) has gained a great interest as an attractive target for drug
discovery [1]. The growing appeal of this receptor stems, at least in
part, from its almost exclusive expression in the central nervousserved.system (CNS), and the potential therapeutical indications of the 5-
HT6R ligands which encompass a spectrum of diseases; including
depression, cognitive dysfunction associated with Alzheimer's
disease, anxiety, schizophrenia, and obesity [2e8]. Intriguingly,
both 5-HT6R agonists and antagonists may paradoxically evoke
pro-cognitive, antidepressant-like, or anti-anxiety-like effects [8].
Lines of evidence indicated several selective 5-HT6R agonists (e.g.
WAY-181187), partial agonists (e.g. EMDT 386088) and antagonists
(e.g. SB-271046, SB-399885) [9e11], intensively explored in pre-
clinical and clinical trials but none of them has reached the
W. Ali et al. / European Journal of Medicinal Chemistry 178 (2019) 740e751 741pharmaceutical market as an accepted drug (Fig. 1a). Recent years
have provided new groups of 5-HT6R antagonists, based on pyrrolo
[2,3-b]pyridine- (1) [12], pyrrolo [3,2-c]quinoline- (2) [13] or non-
sulfonyl imidazo [4,5-b]pyridine (3) [14] derivatives (Fig. 1b). The
compounds (1e3) displayed potent nanomolar affinities, none-
theless their structures resemble known ligands (Fig. 1a vs. Fig. 1b)
due to the presence of an indole-like core and/or sulfonyl moieties.
Thus, more efforts of medicinal chemists are needed to search for 5-
HT6R agents in more diverse chemical groups which could provide
both potent and selective action on 5-HT6R and satisfying CNS-
drugability properties. In this context, we started to explore a
new group of piperazine 1,3,5-triazine derivatives as potent and
linker-dependent 5-HT6R agents [15]. Hence, compounds with
methylene linker (4 and 5, Fig. 1c) displayed significant affinities,
whereas those with direct aromatic substituents (6) were very
weak 5-HT6-agents. The decrease in activity was also observed for
triazine compounds with stiffened linker, i.e. incorporating vinyl-
[16] or hydantoin [17] moieties. Wider investigations of the role of
linkers have provided an ether compound (7) with a moderate
activity towards 5-HT6R. The unsubstituted phenyl ring of 7 pro-
vides various possibilities for substitutions in order to improve
pharmacophoric properties of the hydrophobic feature. Thus,
compound 7 was selected as a new lead structure for further
modifications which were performed within this study.
Apart from pharmacomodulation focused on benzene sub-
stituents, the lead structure allows for variety of linker modifica-
tions, such as branching the ether linker or a heteroatom exchange.
Based on interesting pro- or/and antioxidant properties ofFig. 1. Structures of the 5-HT6R ligands found within previous studies; a) explored in preclin
1,3,5-triazine derivatives [15,16].chalcogen compounds [18,19], the significance of sulfur in previous
5-HT6R ligands [12,13] and growing interest of selenium-
compounds as neuroprotective agents with therapeutic potential
[20e22], especially confirmed for selenides [23,24], we sought to
explore the potency of S and Se-containing 1,3,5-triazine de-
rivatives of the lead 7 as 5-HT6R ligands with pharmacological ac-
tivity in vivo.
In this context, the design and synthesis of new derivatives of
lead 7 with (un)branched linker and a different substitution at
phenyl ring as well as their respective S- or Se analogs (8e24,
Table 1), including one sulfone analogue (24), were performed. The
5-HT6R affinity and selectivity for the series were tested in the
radioligand binding assay. For selected compounds intrinsic activity
in functional bioassays, toxicity profile in vitro and antidepressant-
like activity in vivo were examined.
2. Results
2.1. Synthesis
The synthesis of the compounds (8e24) investigated followed
several chemical approaches due to different availability of starting
materials (Scheme 1). The common step for compounds 8e23
(Scheme 1a) was the formation of the triazine ring via cyclic
condensation of 4-methyl piperazine-1-yl biguanide dihydro-
chloride (25) with an appropriate ester (26e41), according to a
method already described [15e17,25,26]. In the case of synthesis of
sulfone 24, selective oxidation of the thioether sulfur atom of 20ical or clinical trials [9e11]; b) found by other research teams in 2016e2017 [12e14]; c)
Scheme 1. Synthesis route for final compounds 8e24 (a, b) and intermediates 32e36, 40
15e30 h. b) The selective oxidation for 24; (ii) ethanol, Na2WO4$2H2O, H2O2, rt. c) O- or S-alk
methanol, concentrated H2SO4, reflux; (v) dried toluene, DBU, iodomethane, rt. e) Synthesi
Table 1
Structure of the compounds investigated.
Cpd R1 R2 X Cpd R1 R2 X
7 H H O 16 3-Me, 4-Cl H O
8 2-Cl H O 17 3-Cl Me O
9 3-Cl H O 18 2-Cl Me O
10 2-i-Pr, 5-Me H O 19 H H S
11 2-Me H O 20 2-Cl H S
12 3-Me H O 21 2-Cl Me S
13 4-Me H O 22 H H Se
14 2-Me, 4-Cl H O 23 H Me Se
15 2,4-diCl H O 24 2-Cl H SO2
W. Ali et al. / European Journal of Medicinal Chemistry 178 (2019) 740e751742was performed according to Scheme 1b. The ester intermediates
necessary for synthesis of 8e28 were obtained via five different
routes. For preparation of compounds 11, 12, 16e18 and 21,
commercially available (thio)ether derivatives of methyl esters
(26e31) were purchased. For the compounds 8, 9, 13, 19 and 20,
related (thio)ether derivatives of methyl- or ethyl esters (32e36,
Scheme 1c) were obtained during O- or S-alkylation of adequate
(thio)phenols (42e46) with suitable alkyl bromoacetates (47, 48).
Moreover, methyl ester 37 was obtained via acid-catalyzed esteri-
fication of corresponding commercial phenylacetic acid (49),
whereas reactions of suitable carboxylic acids (50, 51) with iodo-
methane in the presence of DBU were carried out for esters 38 and
39 [15] (Scheme 1d). The synthesis of Se-containing esters 40 and
41 was performed starting from diphenyl diselenides, and com-
mercial bromoesters (48, 52) were employed as alkylation agents
(Scheme 1e).2.2. Molecular modelling
Molecular docking was employed to study the mechanism of
action of a newly synthesized library of compounds with the 5-and 41 (cee). a) The cyclic condensation for 8e23; (i) absolute methanol, Na, reflux
ylation for 32e36; (iii) acetonitrile, K2CO3, reflux. d) Esterification for 37e39; (iv) dried
s of Se-intermediates 40 and 41; (vi) THF/water, NaBH4, N2, rt.
Table 2
Radioligand binding assays results for the investigated compounds (7e24).
Cpd Ki [nM]a
5-HT6R D2R 5-HT1AR 5-HT2AR 5-HT7R
7 507 1348 8726 2628 9531
8 129 2362 5467 nt 9247
9 148 674 7505 nt 5818
10 11 1094 12530 430 11950
11 87 4247 14160 17170 514
12 207 740 15070 2274 10660
13 235 2916 28510 nt 16050
14 911 4369 7688 nt 15180
15 128 1234 1610 nt 3804
16 355 1224 3584 197 5840
17 118 566 3438 590 8361
18 23 1001 4540 1830 38730
19 26 734 4389 197 2871
20 126 329 1680 nt 614
21 19 520 3384 407 4570
22 242 506 3176 406 2329
23 111 656 5311 376 4247
24 3574 50140 >106 11590 98430
Refb-d 7b 9b 20c - 18d
b-d Reference ligands for GPCRs investigated.
a Tested experimentally in the radioligand binding assay; binding affinity, Ki,
expressed as the average of at least two independent experiments. Radioligands
used: [3H]-8-OH-DPAT (5- HT1A), [3H]-Ketanserin (5-HT2A), [3H]-LSD (5-HT6), [3H]-
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mology models used for studying the interaction of other 1,3,5-
triazine derivatives [15,16] have been applied. In general, results
revealed that newly synthesized compounds (7e24) had a very
consistent binding mode with the previously reported 1,3,5-
triazine derivatives [15,16]. Small structural modifications intro-
duced in the obtained library, and their influence on 5-HT6R ac-
tivity was reflected in the ligand-receptor complexes obtained.
Emphasis was placed on: (i) the influence of the oxygen replace-
ment in the linker on the sulfur and sulfone group, (ii) the influence
of different substituents in the phenyl ring, and (iii) the role of the
branching in the linker (Fig. 2).
2.3. Radioligand binding assays
Radioligand binding assays were applied to determine the af-
finity and selectivity profiles of the newly synthesized compounds
for human serotonin 5-HT6R in comparison to 5-HT7, 5-HT1A, 5-
HT2A and dopaminergic D2 receptors. All derivatives tested,
except 14 and 24, displayed higher affinity towards 5-HT6R
(Ki< 400 nM) than that of lead 7 (Table 2). Compounds 10,11,18,19,
21 demonstrated high affinities for 5-HT6R (Ki< 100 nM), particu-
larly potent in the case of 10, 18, 19 and 21 (Ki 30 nM). Each of the
active compounds featured predominant affinity toward 5-HT6R in
comparison to both 5-HT1AR and D2R. Compounds 10, 11, 18, 19 and
21 exhibited the highest selectivity to 5-HT6R over D2, 5-HT1A, 5-
HT2A and 5-HT7 receptors. Compound 10 was identified as the
most active one with an affinity for 5-HT6R in the range of the
standard 5-HT6R antagonist olanzapine. In parallel, compound 10
wasmuchmore selectivewith respect to the D2-dopamine receptor
when compared to the dual target reference olanzapine.
2.4. Functional assays
For selected active 5-HT6R ligands (10, 18, 21), their intrinsic
activity was investigated in vitro by the cellular aequorin-based
functional assay with recombinant CHOeK1 cells expressing
mitochondrially targeted aequorin, human GPCR and the promis-
cuous G protein a16 for 5-HT6R. Compound SB-742457 served as
the highly potent antagonist, mianserin as moderate one, and se-
rotonin as reference agonist (Table 3). The results obtained indi-
cated a lack of agonistic activity, and rather pointed towards a
potent antagonist action for the triazines tested, with Kb values in
the nanomolar range (Kb¼ 2.9e4.6 nM).Fig. 2. The interactions of selected 1,3,5-triazine analogs with 5-HT6R. (A) A difference of the
the linker. (B) A comparison of the binding modes of selected analogs with different subst
binding modes for analogs with hydrogen (20ecyan) and methyl (21eyellow) linker substit
referred to the Web version of this article.)2.5. In vivo studies
2.5.1. Antidepressant-like activity of compounds investigated
Compounds 10, 18 and 21 were selected for behavioral studies
in vivo in male Wistar rats. Their potential antidepressant-like
properties were assessed in the forced swim test (FST) [27]. These
compounds exhibited different activity in the FST (Fig. 3). Com-
pound 10, for instance, decreased about 20% immobility at the
doses of 0.3e3mg/kg (but not at 0.1mg/kg) compared to the
vehicle group (one-way ANOVA, F (4,35)¼ 4.5546; p< 0.01).
Compound 18 showed antidepressant-like activity only in one
medium (1mg/kg) dose; it decreased the immobility time about
22% vs the respective vehicle treated group (one-way ANOVA F
(3,24)¼ 4.0751; p< 0.05) (Fig. 3). Compound 21 was not active in
the FST (one-way ANOVA F (3,24)¼ 2.4252; NS; Fig. 3). reference 5-binding modes of derivatives with O (8egreen), S (20ecyan), and sulfonyl (24ered) in
ituents in the phenyl ring (10eorange, 14emagenta, 11ebrown). (C) Illustration of the
uent. (For interpretation of the references to colour in this figure legend, the reader is
Table 3
Functional-vs. Radioligand binding assays results for 10, 18 and 21.
Compound 5-HT6R
Binding affinity (RBA) Ki [nM] Antagonist modea Kb [nM] Agonist modeb Emax [%]
10 11 4.60 1
18 23 3.00 1
21 19 2.90 1
Serotonin e nc 100
SB-742457 e 0.67 2
Mianserin e 30.0 1
a Results were normalized as percentage of maximal response in the absence of antagonist.
b Results were normalized as percentage of maximal agonist response (serotonin 10-6M). Emax is the maximum possible effect; nc - not calculable.
Fig. 3. Effects of compounds 10,18, 21 and SB-399885 on the immobility time of rats in
the forced swim test. Compounds 10, 18, and 21 were administered i. p. 60 min, whilst
SB-399885was given 30 min before the test. The animals were observed for 5 min. The
data are presented as the mean ± SEM of 6e8 rats. The data were statistically evaluated
by one-way ANOVA followed by Bonferroni's post-hoc test, *p< 0.05, vs. respective
vehicle group.
W. Ali et al. / European Journal of Medicinal Chemistry 178 (2019) 740e751744HT6 receptor antagonist, compound SB-399885, was active in the
FST only at the dose of 10mg/kg (F (3,28)¼ 9.7153; p< 0.0001;
Fig. 3) [28]. An U-shaped dose-response in the FST test for com-
pounds 18 and SB-399885 was observed. This effect seems to be
typical for some antidepressants with different mechanisms of
action also producing U-shaped dose-response effects in some
animal models and tests for antidepressant-like activity [29,30].
Moreover this effect was also observed for other 5-HT6 ligands,
such as standard potent 5-HT6R antagonist SB-258585 [31].2.5.2. Locomotor activity
For compounds 10 and 18, locomotor activity assays in rats were
also performed. These triazine derivatives, especially compound
10 at the doses active in the FST, slightly increased locomotor ac-
tivity measured in the open field (OF) test (Table 4).
These results indicate that the antidepressant-like effects in the
FST observed may not be specific ones. Compound SB-399885 did
not change the rats’ locomotor activity under identical experi-
mental settings [31].Table 4
Effects of compounds 10 and 18 on the rat locomotor activity measured in the OF test.
Treatment Dose (mg/kg) Total distance (cm) AmbulationX
Vehicle 0 2165± 119 190± 12
10 0.3 2833 ± 157 *** F (1,10) ¼ 11.502;
p < 0.01
307 ± 19 *** F (1
p < 0.001
Vehicle 0 929± 36 213± 13
18 1 1005± 68 F (1,10)¼ 0.9711; NS 269 ± 8 ** F (1,1
p < 0.01
Compounds were administered i.p. 60 min before the test. The animals were observed
statistically evaluated by one-way ANOVA followed by Bonferroni's post-hoc test, *p < 02.6. Drug-likeness
The safety profile of the most active triazine 5-HT6R agents (10,
18 and 21) was estimated in, both neurotoxicity and mutagenicity
assays in vitro.
Neurotoxicity was examined in the SH-SY5Yeukaryotic cell line.
The colorimetric MTS assay allowed the determination of SH-SY5Y
cell viability after 72 h of incubationwith 10,18 and 21, respectively.
A statistically significant decrease in cell viability was observed
only for the highest dose for each of the 5-HT6R agents tested
(100 mM, Fig. 4).
The mutagenicity of 10, 18 and 21was determined following the
Ames microplate fluctuation protocol (MPF) with Salmonella
typhimurium strain TA100, which enabled the detection of base-
pair mutations [32]. The results were compared to the reference
mutagen nonyl-4-hydroxyquinoline-N-oxide (NQNO) at 0.5 mM.
The numbers of revertants were estimated colourimetrically and
the mutagenicity potential was evaluated according to the pro-
cedure provided by the manufacturer [32]. The medium control
baseline (MCB) was calculated first, as a number of revertants
observed in the growth mediumwith 1% DMSO as negative control
plus standard deviation. A compound was considered as mutagenic
one if data point with fold increase 2 of MCB, and Binomial B-
value  0.99 (Table 5). The results of the study did not indicate any
risk of mutagenicity for the triazine derivatives 10,18 and 21 tested.
In summary, compounds 10, 18 and 21 displayed statistically
significant neurotoxicity only at > 4000-fold higher concentrations
than the one required for 5-HT6R activity (Ki¼ 11e23 nM, Table 1)
and 100efold higher concentrations than the one for the positive
control doxorubicin. Furthermore, none of the compounds inves-
tigated caused any mutagenic effects. Thus, results of the study
usingmodels in vitro indicated high pharmaceutical safety for these
active 5-HT6R antagonists.
3. Discussion
The modifications performed on the lead 7 were addressed in
order to analyse an influence on the affinity for 5-HT6R of three
following structural factors: (i) the substituents at phenyl ring,AmbulationY Rearings
187± 15 57± 6
,10) ¼ 27.956; 290 ± 19 ** F (1,10) ¼ 18.645;
p < 0.01
56± 3 F (1,10)¼ 0.0157; NS
187± 14 68± 7
0) ¼ 14.308; 227± 14 F (1,10)¼ 4.5275; NS 46 ± 4 * F (1,10) ¼ 6.4150;
p < 0.05
for 5 min. The data are presented as the mean ± SEM of 5e6 rats. The data were
.05, **p < 0.01, ***p < 0.001 vs vehicle group, NS ¼ not significant.
Fig. 4. The impact of doxorubicin (DX), 10, 18 and 21 on the viability of the neuroblastoma SH-SY5Y cell line after 72 h of incubation. Statistical significance was evaluated by one-
way ANOVA, followed by Bonferroni's comparison test (***p< 0.001 compared with the negative control).
Table 5
The mutagenicity potential of 10, 18 and 21.
Conc.[mM] Cpd Fold increase over MCB Binomial B-valuea Number of revertants± SD
0.5 NQNO 5.41 1.0000 46.00± 2.29
1 10 0.55 0.0570 4.67± 1.53
18 0.73 0.1755 8.00± 2.65
21 0.94 0.7035 10.33± 1.53
10 10 0.47 0.0172 4.00± 1.00
18 1.00 0.8259 11.00± 2.65
21 0.76 0.2366 8.33± 3.06
a Binomial B-value indicates the probability that spontaneous mutation events alone. The result 0.99 indicates that chances of spontaneous mutation are 1%.
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linker and (iii) different chalcogen-ether linker with respect to the
S-oxidized form (SO2) that is an indispensable structural feature of
more than 80% 5-HT6R agents found within the 20-year global
studies on this receptor [33]. The results obtained within this study
allow to perform comprehensive structure-activity relationship
discussion.
The first subseries of 11 unbranched ether derivatives (7e16,
Table 1) enabled to estimate SAR for substituents at the phenyl ring.
On the basis of previous results, we took into consideration a va-
riety of alkyl- and chlorine substituents only, since they were found
as beneficial, in contrast to alkoxyl moieties [15]. Thus, the
following order of the 5-HT6R affinity decrease can be observed: 2-
iPr-5-Me[2-Me>2-Cl~2,4-diCl>3-Cl>3-Me>4-Cl>4-Me>3-Me-4-
Cl>H> 2-Me-4-Cl (Table 2) [16]. This order confirmed the general
preference of electrodonating and hydrophobic substituents at the
phenyl ring that was also observed for previous methylene- [15]
and hydantoin-linked aromatic triazine 5-HT6R agents [17]. The
isopropyl derivative (10) seems to be a special example of optimal
electrodonating-hydrophobic balance for the substituent that, as
more hydrophobic than methyl- (10 vs. 11, Table 1), and stronger
electro-donating than the hydrophobic chlorine substituent (10 vs.
8), provided an outstanding 5-HT6 affinity, not only in the consid-
ered series but also among all 1,3,5-triazines 5-HT6R agents
investigated so far [15e17]. As position of substituents at phenyl
ring, the previous studies indicated the preferablemeta-position in
the case of benzyltriazine derivatives [15], while para one was
emphatically beneficial for the 5-HT6R affinity of the hydantoin-
linked series [17]. In contrast, the presently considered ether-
linked 1,3,5-triazines distinctly favour ortho-position in the
binding with 5-HT6R in comparison to both meta and para.
Furthermore, the following trend of the 5-HT6R affinity increase:
para<meta< ortho, can be observed, either for Cl- (5-HT6R Ki:
226 nM > 148 nM > 129 nM) [16] or for Me- (5-HT6R Ki:
235 nM > 207 nM > 87 nM) substituents. Otherwise, an impact of
di-substitution is not so clear and seems to be rather unprofitable
(16, 14) or at best indifferent (15), and also responsible for selec-
tivity decrease (16 vs. 12).In concordance to previous studies [15e17], results of this work
underline the linker-dependent influence of Ph-substituents on the
activity towards 5-HT6R. In the case of S- and Se-ether linked tri-
azines (19e23), the impact of substituents at the phenyl ring seems
to be less meaningful than that observed for O-ether compounds
(7e16), and significantly dominated by the impact of methyl-
branching. It is particularly evident during analysis of results for
S-ether compounds 19e21, where the methyl-branched o-Cl-
phenyl- (21) and the unbranched phenyl-unsubstituted (19) de-
rivatives displayed comparable affinities for 5-HT6R, and signifi-
cantly more potent than that of the o-Cl-phenyl-, but linker-
unbranched, derivative 20 (Table 1). The similar trend is also
observed for selenoethers (22 and 23) demonstrating in 2-fold in-
crease of the 5-HT6R affinity with the appearance of methyl-
branching within the linker.
Two parallel comparative analyses of the linker-activity rela-
tionship, performed for o-Cl- (8, 18, 20, 21 and 24) and (un)
substituted phenyl (7,19, 22 and 23) derivatives, respectively, allow
to assess the role of hetero-atom within the linker, connecting
phenyl moiety with 1,3,5-triazine. In the case of o-chlorophenyl
derivatives, the following activity order was found: S (Me-
branched)O (Me-branched)> S (unbranched)O (unbranched)
[ SO2, while the 5-HT6R affinity decrease for the phenyl de-
rivatives was as follows: S (unbranched)> Se (Me-branched)> Se
(unbranched)>O (unbranched). Both sequences distinctly indicate
the beneficial impact of the sulphide linker, whereas the sele-
noether seems to be slightly more profitable than the simple O-
ether. It is worth to emphasize that presence of SO2 drastically
decreased the desirable pharmacological activity. This is a break-
through observation against the majority of world's lines of evi-
dence [33]. Thus, we have carried out computer-aided analysis to
explain this and other SAR-observations in the molecular level.
The docked compounds showed very consistent binding mode,
i.e. they formed the salt bridge interaction with D3.32, an aromatic
interaction (CHep or pep stacking) with F6.52, and a hydrogen
bond between NH2 group of 1,3,5-triazine ring and carbonyl oxygen
of V3.33 and/or A5.42 (Fig. 2). These contacts were crucial for
recognition the active scaffolds by the 5-HT6 receptor, however, the
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found to have a significant influence on the activity modulation
[15,16]. This fragment interacted with the hydrophobic cavity
formed by transmembrane domains (TM) 3e5 and extracellular
loop 2 (ECL2), and the positioned into this cavity was resulted by
the tetrahedral conformation of the linker.
Two used modifications of the linker, namely: (1) changing the
oxygen on the chalcogen atoms (S and Se) or a sulfone group and
(2) branching the linker by adding the methyl group, were also
explored within this simulation in silico. The derivatives with ox-
ygen, sulfur and selenium atom in the linker showed high-to-
medium activity to 5-HT6R (11e911 nM). Analysis of the docking
results (Fig. 2A) indicated that these compounds had a very similar
bindingmode, and the potential role of the atomsmentioned above
is to bend the conformation of the molecule and further directing
the aryl fragment into the hydrophobic pocket formed by TM3e5
and ECL2. However, a significant decrease in the activity was found
for derivative with sulfonyl group 24 (Ki¼ 3574 nM). The analysis of
binding mode revealed that it may be caused by forcing a
straightened conformation (in which the phenyl and triazine rings
are in one plane and do not form an angle of 90⁰), and thus no
interaction with the hydrophobic pocket is probable. In order to
confirm this hypothesis, the geometry optimization for compound
24 was additionally performed using quantum-mechanical
methods (DFT: B3LYP/6e31þþG**, PCM model with water as a
solvent). The calculations confirmed that the most energetically
stable conformation is straightened and the repulsion interaction
between free electron pairs of one of the triazine nitrogen atoms
and oxygen of the sulfone group was responsible for inducing such
conformation.
A comparison of the binding modes for analogs having different
substituents at phenyl fragment (Fig. 2B) showed that modulation
of the activity can be related with the position and the size of the
substituents. The most active compound 10 (Ki¼ 11 nM) was very
well fitted to the hydrophobic sub-pocket formed by helices 3e5
and extracellular loop 2. However, the less active 14 (Ki¼ 911 nM)
showed that improper configuration of substituents at the phenyl
ring may even lead to destabilization of the complex and breaking
some key interactions (the NH2 group does not form hydrogen
bonds, Fig. 2B).
The branching of the linker by a methyl group increased the
affinity for each of the compared pairs, i.e.: 8 vs. 18; 20 vs. 21; 22 vs.
23. Molecular docking indicated (Fig. 2C) that in each case the
methyl group was located in a small binding cavity formed by he-
lices 5 and 6 which increased the stability of the resulting
ligandereceptor complexes.
Our comprehensive studies allowed also to examine the selec-
tivity of series (7e24) towards the target 5-HT6R as well as the
intrinsic activity, the primary antidepressive-like action in vivo and
safety properties in vitro for themost active compounds elected (10,
18 and 21). Although some of the assays were performed for a few
members only, different results are noteworthy for an initial qual-
itative SAR analysis. Results of the receptor screening have indi-
cated a favourable 5-HT6R-selectivity, in respect to 5-HT7, 5-HT1A,
5-HT2A and dopaminergic D2L receptors, for almost whole inves-
tigated ether 1,3,5-triazine derivatives (7e24), with one exception
of the 3-methyl-4-chlorophenyl derivative 16 that acted almost 2-
fold stronger towards 5-HT2A (Table 1). However, the affinity of
16 for either 5-HT6R or 5-HT2AR was rather moderate (Ki> 100 nM).
Hence, the results for the whole series indicate that this chemical
family, consisting the skeleton of 2-amine-1,3,5-traizine core with
methyl piperazine at position 4 and ether-linked phenyl at position
6, tend to selective action towards desirable 5-HT6R over other
GPCR-competitors.
The functional assays have confirmed a strong antagonisticaction for the tested compounds (10,18 and 21), the most potent in
the case of the thioether 21 (Kb¼ 2.8 nM). However, this potent
antagonist did not demonstrate antidepressant-like activity in the
behavioral tests in vivo, while both the 2-isopropylphenyl (10) and
2-chlorophenyl (18) O-ether derivatives were active in the FST
assay with probable non-specific action, estimated on the basis of
the open field test results. Taking into account, still not enough
recognized mechanisms of physiological actions mediated by 5-
HT6R receptor and lines of evidence indicating wider pharmaco-
logical abilities of its ligands, including: pro-cognitive, anxiolytic
and anti-obesity properties, the obtained lack of anti-depressive
potency in vivo for the potent sulfide antagonist 21 does not
exclude other possible pharmacological directions for this agent,
and even suggests some selectivity in comparison to the O-analogs
(10 and 18). Furthermore, results of both, the neurotoxicity (MTS-
test) and the mutagenicity AMES screening, confirmed profitable
CNS-drug-likeness properties for all the investigated compounds
(10, 18 and 21).
Results obtained for the two “pilot” selenoethers (22 and 23) are
worth emphasizing since both 22 and 23 displayed significant af-
finities, although they do not possess any beneficial substituents at
the phenyl moiety. The unbranched Se-ether 22was two-fold more
active than corresponding O-ether derivative 7.
4. Conclusions
The studies reported here are concerned with the design, syn-
thesis, molecular modelling and biological screening, including:
(i) RBA-evaluated affinity and selectivity towards 5-HT6R in
respect to 5-HT1AR, 5-HT2AR, 5-HT7R and dopamine D2 receptor, (ii)
functional assays, (iii) behavioral assays in vivo and (iv) safety
screening in vitro for a new series of phenoxyalkyl derivatives
of 1,3,5-triazine. On the basis of the data obtained, an insightful
SAR-analysis was performed. In the course of the study, a new
family of active and selective 5-HT6R antagonists was obtained,
which may serve as a tool for deeper insight into the mechanisms
of action of this most intriguing member of the serotonin
GPCRs. Although this series was not such SAR-regular as the aryl-
methyl-1,3,5-triazines described previously, it has provided the
most active 1,3,5-triazine 5-HT6R agents to date, i.e. 4-((2-
isopropyl-5-methylphenoxy)methyl)-6-(4-methylpiperazin-1-yl)-
1,3,5-triazin-2-amine (10) and 4-(1-((2-chlorophenyl)thio)ethyl)-
6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-amine (21), with
Ki< 20 nM. Furthermore, the world's first selenium-containing 5-
HT6R agents (22 and 23, Ki< 250 nM) were identified within
these studies. SAR-analysis indicated that presence of sulphide is
especially beneficial, while the SO2-containing derivative (24)
investigated proved to be distinctly less active than the other
members of the series (Ki> 3 mM). This result, contrary to amajority
of lines of evidence, was justified in the molecular level by our
docking studies. Taking into account lines of evidence indicating
antidepressive, procognitive and neuroprotective roles of selenides,
in addition to awide range of pharmacomodulation possibilities for
these unsubstituted-phenyl derivatives, the selenocompounds 22
and 23 seem to represent an excellent starting point for new
chemical modifications in search for successful CNS-selenoagents
acting via 5-HT6 receptor.
Themost active agents 10 and 21 requirewider pharmacological
evaluation with a prospect to produce new CNS-drug candidate.
Compounds 10 and 21 and the most active selenocompound 23 can
be considered as suitable new lead structures for further chemical
modifications in search for highly potent and selective 5-HT6R
antagonists.
The series of phenoxyalkyl-1,3,5-triazine derivatives presented
seems to be a new promising alternative in search for 5-HT6R
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dominating derivatives of sulfone and indole, may form a basis for a
breakthrough in the search for new therapies of the civilization CNS
diseases related to this exceptional serotonin GPCR.
5. Experimental
5.1. Chemical synthesis
Melting points (mp) were determined using MEL-TEMP II
apparatus and are uncorrected.
1H NMR and 13C NMR spectra were recorded on a Varian
Mercury-VX 300MHz PFG instrument or FT-NMR JEOL (JNM-
ECZR500 RS1 v. ECZR) 500MHz instrument (13C NMR for 8e10,
12e16 and 21) in DMSO‑d6 (for most compounds) or MeOD (13C
NMR for 19 and 24) at ambient temperature using the solvent
signal as an internal standard: the values of the chemical shifts
expressed as d values in (ppm) and the coupling constants (J) in Hz.
Data are reported as follows: chemical shift, multiplicity (s, singlet;
br. s, broad singlet; d, doublet; t, triplet; dd, doublet of doublet, q,
quintet, td triplet of doublet, m, multiplet), coupling constant J,
number of protons, proton's position (Ph-phenyl, Pp-piperazine).
Mass spectra recorded on a UPLCeMS/MS system consisted of a
Waters ACQUITY® UPLC® (Waters Corporation, Milford, MA, USA)
coupled to a Waters TQD mass spectrometer (electrospray ioniza-
tion mode ESI-tandem quadrupole). The UPLC/MS purity of all the
final compounds was confirmed to be higher than 95% (except 24).
Retention time values (tR) are given in minutes. Elemental analyses
(C, H, N) were performed on an Elemental Analyser Vario El III
(Hanau, Germany) and agreed with theoretical values within
±0.4%.Thin-layer chromatography (TLC) was performed on pre-
coated Merck silica gel 60 F254 aluminum sheets. The reactions
at fixed temperature were carried out using a magnetic stirrer with
a contact thermometer Heidolph MR 2001. Esters 32e41 have been
synthesized due to their high commercial costs. However, all of
them are already described in Chemical Abstract Database, thus,
their CAS numbers and 1H NMR or LC/MSþ are indicated in Sup-
plementary Information.
5.1.1. General procedure for the synthesis of final 1,3,5-triazine
derivatives (8e23)
Sodium (10mmol) was dissolved in 10ml of absolute methanol,
then 4-methylpiperazine-1-yl biguanide HCl (5mmol) and a suit-
able carboxylic acid ester containing O- S- or Se-ether, respectively,
(26e41, 5 mmol) was added. The reaction mixture was refluxed for
15e30 h. After cooling to room temperature, the solvent was
evaporated, and the residue was dissolved in water (10ml), stirred
for 30min at room temperature and kept overnight at the fridge.
The precipitated triazine product was isolated by filtration and
crystallized from methanol to give the desire final products as
solids in basic form (method A). In case of lack of desirable pre-
cipitate, the methanol solution was saturated with gaseous HCl to
give pure final product in hydrochloric salt form (method B)
5.1.1.1. 4-((2-Chlorophenoxy)methyl)-6-(4-methylpiperazin-1-yl)-
1,3,5-triazin-2-amine (8). Method A. White solid, Yield 23%, mp
141e142 C. C15H19ClN6O (MW 334.80). LC/MSþ: purity: 100%,
tR¼ 3.25, (ESI) m/z [MþH]þ 335.31.1H NMR d: 7.41e7.37 (dd,
J1¼7.8 Hz, J2¼1.67Hz, 1H, Ph), 7.27e7.24 (m, 1H, Ph), 7.05e6.98
(m, 4H, Ph-2,6-H, NH2), 4.88 (s, 2H, CH2), 3.62 (s, 4H, Pp-2,6-H), 2.23
(s, 4H, Pp-3,5-H), 2.15 (s, 3H, CH3). 13C NMR (125MHz, DMSO‑d6) d:
173.01; 167.28; 164.75; 154.46; 130.44; 128.61; 122.04; 121.78;
114.73; 70.53; 54.79; 46.27. Anal. calcd. for C15H19ClN6O: C 53.81%,
H 5.72%, N 25.10%. Found: C 53.86%, H 5.86%, N 25.19%5.1.1.2. 4-((3-Chlorophenoxy)methyl)-6-(4-methylpiperazin-1-yl)-
1,3,5-triazin-2-amine (9). Method A. Pale yellow solid. Yield 30%,
mp 140e141 C. C15H19ClN6O (MW 334.80). LC/MSþ: purity: 100%,
tR¼ 3.45, (ESI)m/z [MþH]þ 335.31.1H NMR d: 7.26 (t, J¼ 8.1 Hz, 1H-
Ph), 7.00e6.86 (m, 2H, NH2), 7.00 (m, 1H, Ph), 6.98e6.94 (m, 1H,
Ph), 4.80 (s, 2H, CH2), 3.65e3.62 (m, 4H, Pp-2,6-H), 2.24 (s, 4H, Pp-
3,5-H), 2.15 (s, 3H, CH3). 13C NMR (125MHz, DMSO‑d6) d: 173.03;
167.29; 164.76; 159.95; 134.06; 131.27; 121.12; 115.38; 114.33;
70.25; 54.80; 46.28. Anal. calcd. for C15H19ClN6O: C 53.81%, H 5.72%,
N 25.10%. Found: C 53.80%, H 5.72%, N 25.20%
5.1.1.3 . 4-( (2-Isopropyl-5-methylphenoxy)methyl)-6-(4-
methylpiperazin-1-yl)-1,3,5-triazin-2-amine (10). Method A. White
solid. Yield 23%, mp 92e93 C. C19H28N6O (MW 356.47). LC/MSþ:
purity: 100%, tR¼ 4.57, (ESI) m/z [MþH]þ 357.38.1H NMR d: 7.02 (d,
J¼ 7.7 Hz, 1H, Ph), 6.87 (br. s, 2H, NH2), 6.71 (s, 1H, Ph), 6.67 (d,
J¼ 7.9 Hz,1H, Ph), 4.74 (s, 2H, CH2), 3.65 (t, J¼ 4.7 Hz, 4H, Pp-2,6-H),
3.30e3.22 (m, 1H, CH), 2.25 (s, 4H, Pp-3,5-H), 2.20 (s, 3H, CH3), 2.15
(s, 3H, CH3), 1.14 (d, J¼ 6.9 Hz, 6H, 2x-CH3). 13C NMR (125MHz,
DMSO‑d6) d: 173.70; 167.31; 164.93; 156.03; 136.14; 133.82; 126.09;
121.67; 113.31; 70.30; 54.80; 46.27; 26.76; 23.12; 21.52. Anal. calcd.
for C19H28N6OxH2O C 60.88%, H 8.01%, N 22.43%. Found: C 60.60%, H
7.90%, N 22.39%.
5.1.1.4. 4-(4-Methylpiperazin-1-yl)-6-(o-tolyloxymethyl)-1,3,5-
triazin-2-amine (11). Method A. White solid. Yield 45%, mp
252e254 C. C16H22N6O (MW 314.39). LC/MSþ: purity: 100%,
tR¼ 3.19, (ESI) m/z [MþH]þ 315.14.1H NMR d: 7.12e7.04 (m, 2H, Ph-
3,5-H), 6.83e6.77 (m, 4H, 2H, Ph-2,6-H, NH2), 4.78 (s, 2HeCH2),
3.65 (s, 4H, Pp-2,6-H), 2.25 (s, 4H, Pp-3,5-H), 2.18 (s, 3H, CH3), 2.15
(s, 3H, CH3). 13C NMR (DMSO‑d6) d: 173.62, 167.23, 164.78, 157.06,
130.83, 127.21, 126.33, 120.75, 112.18, 70.22, 54.72, 46.20, 16.60.
5.1.1.5. 4-(4-Methylpiperazin-1-yl)-6-(m-tolyloxymethyl)-1,3,5-
triazin-2-amine (12). Method A. White solid. Yield 10%, mp
132e135 C. C16H22N6O (MW 314.39). LC/MSþ: purity: 100%,
tR¼ 3.11, (ESI) m/z [MþH]þ 315.21.1H NMR d: 7.11 (t, J¼ 7.6 Hz, 1H,
Ph), 7.05e6.78 (br. s, 2H, NH2), 6.78e6.61 (m, 3H, Ph), 4.72 (s, 2H,
CH2), 3.65 (s, 4H, Pp-2,6-H), 2.34e2.19 (m, 7H, 4H, Pp-3,5-H, Pp-
CH3), 2.16 (s, 3H, CH3). 13C NMR (125MHz, DMSO‑d6) d: 173.52,
167.34, 164.84, 159.00, 139.34, 129.64, 121.91, 115.91, 112.09, 70.12,
54.83, 46.29, 42.99, 21.65.
5.1.1.6. 4-(4-Methylpiperazin-1-yl)-6-(p-tolyloxymethyl)-1,3,5-
triazin-2-amine (13). Method A. White solid. Yield 21%, mp
144e145 C. C16H22N6O (MW 314.39). LC/MSþ: purity: 96.95%,
tR¼ 3.18, (ESI)m/z [MþH]þ 315.30.1H NMR d: 7.03 (d, J¼ 8.7 Hz, 2H,
Ph), 6.96e6.84 (m, 2H, NH2), 6.78 (dd, J1¼6.41 Hz, J2¼ 2.05 Hz, 2H,
Ph), 4.69 (s, 2H, CH2), 3.64 (s, 4H, Pp-2,6-H), 2.25 (s, 4H, Pp-3,5-H),
2.20 (s, 3H, CH3), 2.16 (s, 3H, CH3). 13C NMR (125MHz, DMSO‑d6) d:
173.60; 167.34; 164.85; 156.87; 130.23; 129.75; 114.98; 70.25;
54.83; 46.29; 20.59. Anal. calcd. for C16H22N6O C 61.13%, H 7.05%, N
26.73%. Found: C 61.10%, H 7.09%, N 26.69%
5 .1.1. 7 . 4 - ( (4 -Ch l o ro -2 -me thy lphenoxy )me thyl ) -6 - (4 -
methylpiperazin-1-yl)-1,3,5-triazin-2-amine (14). Method A. White
solid. Yield 44%, mp 132e133 C. C16H21ClN6O (MW 348.83). LC/
MSþ/-: purity: 99.71%, tR¼ 4.05, (ESI) m/z [MþH]þ 349.33.1H NMR
d: 7.19 (d, J¼ 2.6 Hz, 1H, Ph), 7.11 (dd, J1¼8.71 Hz, J2¼ 2.82 Hz, 1H,
Ph), 6.90 (br. s, 2H, NH2), 6.83 (d, J¼ 8.7 Hz, 1H, Ph), 4.79 (s, 2H,
CH2), 3.63 (s, 4H, Pp-2,6-H), 2.24 (br. s, 4H, Pp-3,5-H), 2.17 (s, 3H,
Ph-CH3), 2.15 (s, 3H, CH3). 13C NMR (125MHz, DMSO‑d6) d: 173.46;
167.33; 164.84; 154.42; 148.32; 141.70; 108.46; 106.48; 101.51;
98.51; 71.06; 54.83; 46.29. Anal. calcd. for C16H21ClN6O: C 55.09%, H
6.07%, N 24.09%. Found: C 55.31%, H 6.10%, N 24.19%
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yl)-1,3,5-triazin-2-amine (15). Method A. White solid. Yield 35%,
mp 104e105 C. C15H18Cl2N6O (MW 369.25). LC/MSþ: purity: 100%,
tR¼ 4.06, (ESI) m/z [M]þ 369.28.1H NMR d: 7.53 (d, J¼ 2.6 Hz, 1H,
Ph), 7.29 (dd, J1¼8.86 Hz, J2¼ 2.56 Hz, 1H, Ph), 7.02 (d, J¼ 8.9 Hz,
1H-Ph), 6.95e6.88 (br s, 2H, NH2), 4.91 (s, 2H, CH2), 3.61 (s, 4H, Pp-
2,6-H), 2.22 (br s, 4H, Pp-3,5-H), 2.15 (s, 3H, CH3). 13C NMR
(125MHz, DMSO‑d6) d: 172.69; 167.23; 164.68; 153.64; 129.72;
128.39; 124.94; 116.02; 70.58; 54.77; 46.27. Anal. calcd. for
C15H18Cl2N6O: C 48.79%, H 4.91%, N 22.76. Found: C 49.1%, H 5.08%,
N 22.63%5 .1.1. 9 . 4 - ( ( 4 -Ch l o ro -3 -me thylphenoxy )me thyl ) -6 - (4 -
methylpiperazin-1-yl)-1,3,5-triazin-2-amine (16). Method A. White
solid. Yield 19%, mp 131e134 C. C16H21N6OCl (MW 348.83). LC/
MSþ: purity: 100%, tR¼ 3.85, (ESI) m/z [MþH]þ 349.10.1H NMR d:
7.24 (d, J¼ 8.7 Hz,1H, Ph), 7.03e6.79 (m, 3H, Ph-5-H, NH2), 6.74 (dd,
J1¼3.1 Hz, J2¼ 9.0 Hz, 1H, Ph), 4.74 (s, 2H, CH2), 3.64 (t, J¼ 4.5 Hz,
4H, Pp-2,6-H), 2.30e2.20 (m, 7H, Pp-3,5-H, CH3), 2.16 (s, 3H, CH3).
13C NMR (125MHz, DMSO‑d6) d: 173.20, 167.30, 164.78, 157.75,
136.82, 129.88, 125.17, 118.08, 117.65, 114.28, 70.27, 68.56, 54.81,
46.29, 42.95, 20.33.5.1.1.10. 4-(1-(3-Chlorophenoxy)ethyl)-6-(4-methylpiperazin-1-yl)-
1,3,5-triazin-2-amine (17). Method A. Brown solid. Yield 16%, mp
138 C. C16H21N6OCl (MW 348.83). LC/MSþ: purity: 100%, tR¼ 3.60,
(ESI) m/z [MþH]þ 349.17.1H NMR d: 7.25 (t, J¼ 8.1 Hz, 1H, Ph),
7.07e6.92 (m, 3H, Ph), 6.91e6.77 (m, 2H, NH2), 4.95 (q, J¼ 6.5 Hz,
1H, CH), 3.66 (s, 4H, Pp-2,6-H), 2.27 (s, 4H, Pp-3,5-H), 2.18 (s, 3H,
CH3), 1.53 (d, J¼ 6.5 Hz, 3H, CH3)$13C NMR (DMSO‑d6) d: 176.59,
167.46, 164.89, 159.41, 133.90, 131.17, 120.85, 115.72, 114.61, 76.56,
54.69, 46.20, 20.59.5.1.1.11. 11.4-(1-(2-Chlorophenoxy)ethyl)-6-(4-methylpiperazin-1-
yl)-1,3,5-triazin-2-amine (18). Method A. White solid. Yield 30%,
mp 156 C. C16H21N6OCl (MW 348.83). LC/MSþ: purity: 100%,
tR¼ 3.57, (ESI) m/z [MþH]þ 349.17.1H NMR d: 7.40 (dd, J1¼7.9 Hz,
J2¼1.6 Hz, 1H, Ph), 7.30e6.93 (m, 3H-Ph), 7.00e6.80 (m, 2H, NH2),
4.98 (q, J¼ 6.5 Hz, 1H, CH), 3.67 (s, 4H, Pp-2,6-H), 2.38e2.19 (m, 4H,
Pp-3,5-H), 2.17 (s, 3H, CH3), 1.57 (d, J¼ 6.5 Hz, 3H, CH3). 13C NMR
(DMSO‑d6) d: 176.56, 167.44, 164.88, 154.01, 130.41, 128.46, 122.03,
121.87, 115.37, 77.20, 54.68, 46.21, 20.74.5.1.1.12. 4-(4-Methylpiperazin-1-yl)-6-((phenylthio)methyl)-1,3,5-
triazin-2-amine hydrochloride (19). Method B. White solid. Yield
33%; mp 250 C. C15H21ClN6S (MW 352.89, MW 316.15- basic form).
LC/MSþ: purity: 100%, tR¼ 2.92, (ESI)m/z [MþH]þ 317.14.1H NMR d:
11.95 (br. s, 1H, NHþ), 8.40e7.87 (br, 2H, NH2), 7.49e7.46 (m, 2H,
Ph), 7.36e7.33 (m, 2H, Ph), 7.27e7.23 (m, 1H, Ph), 4.13 (s, 2H, CH2),
3.45 (s, 4H, Pp-2,6-H), 3.16e2.72 (m, 7H, Pp-3,5-H, CH3). 13C NMR
(MeOD-d4) d: 166.58, 161.54, 157.07, 132.88, 131.30, 128.97, 127.72,
52.30, 52.03, 42.08, 40.73, 40.55, 36.62.5.1.1.13. 13. ((2-Chlorophenyl)thio)methyl)-6-(4-methylpiperazin-1-
yl)-1,3,5-triazin-2-amine (20). Method A. White solid. Yield 37%,
mp 170 C. C15H19ClN6S (MW 350.11). LC/MSþ: purity: 98.94%,
tR¼ 3.40, (ESI) m/z [MþH]þ 351.36.1H NMR d: 7.58 (dd, J1¼8.0 Hz,
J2¼1.4 Hz, 1H, Ph-3-H), 7.41 (dd, J1¼7.9 Hz, J2¼1.4 Hz, 1H, Ph-6H),
7.27 (td, J1¼7.7 Hz, J2¼1.4 Hz, 1H, Ph-5-H), 7.18e7.11 (m, 1H, Ph-4-
H), 6.97e6.87 (br, 2H, NH2), 3.94 (s, 2H, CH2), 3.67e3.60 (m, 4H, Pp-
2,6-H), 2.24 (s, 4H, Pp-3,5-H), 2.15 (s, 3HeCH3). 13C NMR (DMSO‑d6)
d: 173.78, 167.24, 164.67, 136.51, 131.00, 129.67, 128.15, 128.01,
126.76, 54.72, 49.00, 46.20.5.1.1.14. 4-(1-((2-Chlorophenyl)thio)ethyl)-6-(4-methylpiperazin-1-
yl)-1,3,5-triazin-2-amine hydrochloride (21). Method B. White solid.
Yield 65%, mp 271 C. C16H22Cl2N6S (MW 401.36, MW 364.12 e
basic form). LC/MSþ: purity: 99.49%, tR¼ 3.90, (ESI) m/z [MþH]þ
365.12.1H NMR d: 11.87 (br. s, 1H, NHþ), 8.05 (br, 2H, NH2), 7.66 (dd,
J1¼7.5 Hz, J2¼1.7 Hz, 1H, Ph), 7.53 (m, 1H, Ph), 7.39e7.29 (m, 2H,
Ph), 4.39 (q, J¼ 7.0 Hz, 1H, CH), 3.46 (d, J¼ 10.5 Hz, 4H, Pp-2,6-H),
2.92 (m, 7H, Pp-3,5-H, Pp-CH3), 1.60 (d, J¼ 7.0 Hz, 3H, CH3). 13C
NMR (DMSO‑d6) d: 171.21, 162.27, 160.33, 135.37, 133.83, 132.24,
130.34, 130.32, 128.40, 51.92, 45.03, 42.42, 18.04.
5.1.1.15. 4-(4-Methylpiperazin-1-yl)-6-((phenylselenyl)methyl)-1,3,5-
triazin-2-amine hydrochloride (22). Method A. White solid. Yield
39%; mp 249 C. C15H20N6Se (MW 364.09). LC/MSþ: purity: 100%,
tR¼ 2.82, (ESI)m/z [MþH]þ 365.12.1H NMR d: 7.60e7.47 (m, 2H, Ph),
7.31e7.15 (m, 3H, Ph), 6.85 (s, 2H, NH2), 3.82 (d, J¼ 5.4 Hz, 2H, CH2),
3.60 (s, 4H, Pp-2,6-H), 2.23 (s, 4H, Pp-3,5-H), 2.15 (s, 3H, CH3). 13C
NMR (DMSO‑d6) d: 175.48, 171.16, 167.35, 164.82, 134.10, 131.78,
131.40, 130.45, 129.49, 129.25, 127.03, 125.59, 54.77, 46.23, 42.84,
34.62, 33.19.
5.1.1.16. 4-(4-Methylpiperazin-1-yl)-6-(1-(phenylselenyl)ethyl)-
1,3,5-triazin-2-amine hydrochloride (23). White solid. Yield 12%;
mp 238 C. C16H23ClN6Se (MW 413.81, MW 378.11- basic form). LC/
MSþ/: purity: 100%, tR¼ 3.23, (ESI) m/z [MþH]þ 379.08.1H NMR d:
11.88 (br. S, 1H, NHþ), 8.16 (br, ,2H, NH2), 7.56 (d, J¼ 6.7 Hz, 2H, Ph),
7.38 (m, 3H, Ph), 4.32 (q, J¼ 7.1 Hz, 1H, CH), 3.45 (s, 4H, Pp-2,6-H),
2.75 (s, 7H, Pp-3,5-H, Pp-CH3), 1.61 (s, 3H, CH3). 13C NMR d: 162.14,
136.07, 131.31, 129.97, 129.62, 129.20, 128.32, 51.75, 42.45, 42.37,
22.49, 18.24.
5.1.2. Synthesis of 4-(((2-chlorophenyl)sulfonyl)methyl)-6-(4-
methylpiperazin-1-yl)-1,3,5-triazin-2-amine (24)
A solution of 20 (2mmol, 701mg) in ethanol (4ml) was cooled
to 0 C and sodium tungstate dehydrate (Na2WO4$2H2O)
(0.23mmol, 303mg) was added. After 5min at 0 C, 35% aqueous
solution of H2O2 (4.5ml) was added dropwise. The resulting
mixture was stirred at 0 C for 30min. Subsequently, the reaction
mixture was stirred at room temperature for 24 h. Saturated
aqueous sodium thiosulfate anhydrous Na2S2O3 (15mL) was added
and resulting layers were separated. The aqueous layer was
extracted with ethyl acetate three times and the combined organic
layers was washed with brine, dried over MgSO4 anhydrous,
filtered and the solvents was removed under reduced pressure. The
pure product was obtained by recrystallization from methanol to
give beige crystals of desired product.
White solid. Yield 37%, mp 170 C. C15H19ClN6O2S (MW 382.10).
LC/MSþ: purity: 93.49%, tR¼ 2.77, (ESI), m/z [MþH]þ 383.20.1H
NMR d: 7.80 (d, J¼ 7.1 Hz, 1H, Ph-3-H), 7.66e7.55 (m, 3H, Ph-4,5,6-
H), 7.13e7.00 (m, 2H, NH2), 4.06 (m, 2H, CH2), 3.68 (m, 8H, Pp), 1.11
(s, 3H, CH3). 13C NMR (125MHz,MeOD-d4) d: 170.24,168.40,165.75,
134.02, 131.79, 131.14, 129.45, 127.22, 65.82, 59.93, 38.69.
5.2. Molecular modelling procedures
The procedure of 5-HT6R homologymodels generation based on
the b2 adrenergic receptor template and these further validation
for the support of structure-activity relationship analyses of our
earlier 1,3,5-triazine derivatives was described previously [15,16].
In order to select the best subset of the receptor conformations, all
the newly synthesized derivatives (7e24) were docked. Only
models showing coherent binding mode to the previously
described triazine derivatives and explained the main structure-
activity relationships were used.
The LigPrep [34] and Epik [35] were used to prepare the 3-
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states at pH¼ 7.4± 1.0 of the ligands, respectively. If not specified,
the all possible R/S or Z/E isomers were generated and used in the
docking. The Protein Preparation Wizard was used to assign the
bond orders, appropriate amino acid ionization states and to check
for steric clashes. The receptor grid was generated (OPLS3 force
field [36]) by centering the grid box with a size of 12 Å on the D3.32
side chain. Automated flexible docking was performed using Glide
at SP level [37]. All of the used programs are a part of Schr€odinger
Suite.
5.3. Radioligand binding assay
Radioligand binding assays to determine affinities of the tested
compounds towards 5-HT6R and competitive GPCRs were carried
out, using [3H]-8-OH-DPAT (135.2 Ci/mmol), [3H]-Ketanserin
(53.4 Ci/mmol), [3H]-LSD (83.6 Ci/mmol), [3H]-5-CT (80.1 Ci/mmol)
and [3H]-Raclopride (76.0 Ci/mmol) for 5- HT1A, 5-HT2A, 5-HT6, 5-
HT7 and D2, respectively. Non-specific binding is defined with
10mM of 5-HT in 5-HT1AR and 5-HT7R binding experiments,
whereas 10mM of chlorpromazine, 10mM of methiothepine or
10mM of haloperidol were used in 5-HT2AR, 5- HT6R and D2L as-
says, respectively. Each compound was tested in triplicate at 7e8
concentrations (1011e104M). The inhibition constants (Ki) were
calculated from the Cheng-Prusoff equation [38]. HEK293 cells with
stable expression of human serotonin 5-HT1AR, 5-HT6R, 5-HT7bR or
dopamine D2LR as well as CHOeK1 cells with stable expression of
human serotonin 5-HT2AR purchased from PerkinElmer BioSignal
Inc were used in the assays, accroding to the procedures described
previously [14e17].
5.4. Functional assays for 5-HT6 receptor
Test and reference compounds were dissolved in dimethyl
sulfoxide (DMSO) at a concentration of 1mM. Serial dilutions were
prepared in 96-well microplate in assay buffer and 8 to 10 con-
centrations were tested. A cellular aequorin-based functional assay
was performed with recombinant CHOeK1 cells expressing mito-
chondrially targeted aequorin, human GPCR and the promiscuous G
protein a16 for 5-HT6R. Assay was executed according to previously
described protocol [39]. After thawing, cells were transferred to
assay buffer (DMEM/HAM's F12 with 0.1% protease free BSA) and
centrifuged. The cell pellet was resuspended in assay buffer and
coelenterazine h was added at final concentrations of 5 mM. The
cells suspension was incubated at 16 C, protected from light with
constant agitation for 16 h and then diluted with assay buffer to the
concentration of 100,000 cells/ml. After 1 h of incubation, 50 ml of
the cell's suspension was dispensed using automatic injectors built
into the radiometric and luminescence plate counter MicroBeta2
LumiJET (PerkinElmer, USA) into white opaque 96-well microplates
preloaded with test compounds. Immediate light emission gener-
ated following calcium mobilization was recorded for 60 s. In
antagonist mode, after 30min of incubation the reference agonist
was added to the above assay mix and light emission was recorded
again. Final concentration of the reference agonist was equal to
EC80 (40 nM serotonin).
5.5. Safety in vitro
SH-SY5Y (ATCC® CRL-2266™) cell line was purchased from
American Type Culture Collection ATCC (Manassas, VA, USA). The
CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay
(MTS) was purchased from Promega (Madison, WI, USA). The cells
were cultured in Dulbecco's Modified Eagle's Medium (DMEM/F12)
with 10% fetal bovine serum (FBS) (Gibco, Carlsbad, CA, USA) at37 C in an atmosphere containing 5% of CO2. The cells were seeded
in 96-well plates at a concentration of 1.5 104 cells/well in 100 ml
culture medium and cultured for 24 h to reach 60% confluence. The
10mM stock solutions of 5-HT6R ligands in DMSOwere diluted into
fresh growth medium and added into the microplates at the final
concentrations 0.1e100 mM (DMSO concentration did not exceed
1%). After 72 h of incubation, the MTS labeling mixture was added
to the each well, and the cells were incubated under the same
conditions for 5 h. The absorbance of the samples was measured
using amicroplate reader EnSpire (PerkinElmer,Waltham,MAUSA)
at 490 nm. Each compound was tested in at least three repetitions.
GraphPad Prism™ software (version 5.01, San Diego, CA, USA) was
used to calculate statistical significances.
The Salmonella typhimurium TA100 strain with base pair sub-
stitution (hisG46 mutation, which target is GGG) was purchased
from Xenometrix, Allschwil, Switzerland. The reference mutagen
nonyl-4-hydroxyquinoline-N-oxide (NQNO) was purchased from
Sigma-Aldrich, (St. Louis, MO, USA). All experiments were per-
formed as described before [40,41]. The mutagenic potential was
calculated according to the procedure provided by Xenometrix
[32]. Each compound was tested in triplicate.
5.6. In vivo studies
5.6.1. Animals
The experiments were performed on male Wistar rats
(200e250 g) obtained from an accredited animal facility at the
Jagiellonian University Medical College, Poland. The animals were
housed in group of four in controlled environment (ambient tem-
perature 21± 2 C; relative humidity 50e60%; 12-h light/dark cy-
cles (lights on at 8:00). Standard laboratory food (LSM-B) and
filtered water were freely available. Animals were assigned
randomly to treatment groups. All the experiments were per-
formed by two observers unaware of the treatment applied be-
tween 9:00 and 14:00 on separate groups of animals. All animals
were used only once. Procedures involving animals and their care
were conducted in accordance with current European Community
and Polish legislation on animal experimentation. Additionally, all
efforts were made to minimize animal suffering and to use only the
number of animals necessary to produce reliable scientific data.
Animal testing was limited to the study only for compounds that
have previously demonstrated enough interest in in vitro experi-
ments. The experimental protocols and procedures described in
this manuscript were approved by the I Local Ethics Commission in
Cracow (no 293/2015) and compliedwith the EU Directive 2010/63/
EU for animal experiments, and were in accordance with the Na-
tional Institutes of Health guide for the care and use of Laboratory
animals (NIH Publications No. 8023, revised 1978).
5.6.2. Drugs
The following drugs were administered: SB-399885 (N-[3,5-
dichloro-2-(methoxy)-phenyl]-4-(methoxy)-1-(piperazinyl)benze-
nesulfonamide; GlaxoSimthKline, UK).
All the compounds were suspended in 1% Tween 80 immedi-
ately before administration in a volume of 2ml/kg. Compounds
investigated were administered intraperitoneally (i.p.) 60min,
while SB-399885 i. p. 30min before testing. Control animals
received vehicle (1% Tween 80) according to the same schedule.
5.6.3. Behavioral procedures in rats
5.6.3.1. Forced swim test (FST test). The experiment was carried out
according to the method of Borsini andMeli [30]. On the first day of
an experiment, the animals were gently individually placed in
Plexiglas cylinders (40 cm high, 18 cm in diameter) containing
15 cm of water maintained at 23e25 C for 15min. On removal
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60-W bulb to dry. On the following day (24 h later), the rats were
re-placed in the cylinder and the total duration of immobility was
recorded during the whole 5-min test period. The immobility was
assigned when no additional activity was observed other than that
necessary to keep the rat's head above the water. Fresh water was
used for each animal.
5.6.3.2. Open field (OF) test. The experiment was performed
employing a Motor Monitor System (Campden Instruments, Ltd.,
UK) consisting of two SmartFrame Open Field stations (40 x
40 38 cm) with 16 x 16 beams, located in sound attenuating
chambers and connected to PC software by control chassis. Indi-
vidual vehicle- or drug-injected animals were gently placed in the
center of the station. An automated Motor Monitor System recor-
ded ambulation (in X and Y axis), the number of rearing episodes,
and total distance covered by a rat for 5min.
5.6.4. Statistical analysis
The data of behavioral studies were evaluated by an analysis of
variance one-way ANOVA followed by Bonferroni's post hoc test
(statistical significance set at p< 0.05).
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Multidrug resistance (MDR) in cancer cells is a crucial aspect to consider for a successful cancer therapy.
P-gp/ABCB1, a member of ABC transporters, is involved in the main tumour MDR mechanism, responsible
for the efflux of drugs and cytotoxic substances. Herein, we describe a discovery of potent selenium-
containing ABCB1 MDR efflux pump modulators with promising anticancer activity. On three groups
of selenoethers comprehensive studies in terms of design, synthesis, and biological assays, including an
insight into cellular mechanisms of anticancer action as well as an ADMET-screening in vitro were
performed, followed by in-depth SAR analysis. Among the investigated new phenylselenoether hybrids,
four compounds showed significant cytotoxic and anti-proliferative effects, in particular, in resistant
cancer cells. Hydantoin derivatives (5e7) were significantly more effective than the reference inhibitor
verapamil (up to 2.6-fold at a 10-fold lower concentration) modulating ABCB1-efflux pump, also pos-
sessing a good drug-drug interaction profile. The best compound (6) was further evaluated in human
JURKAT T-lymphocytic cancer cells for its impact on cell proliferation rate. Mechanistically, the expres-
sion of cyclin D1, an enhancer of the cell cycle, decreases, while p53, an inhibitor of cell proliferation, was
up-regulated upon the treatment with compound 6 alone or in combination with the chemotherapeutic
agent doxorubicin. In summary, a new chemical space of highly active selenium-containing anticancer
agents has been discovered, with a new lead compound 6 that warrants more in-depth biological
evaluation and further pharmacomodulation.
© 2020 Elsevier Masson SAS. All rights reserved.. Jacob), clemens.zwergel@
zlik).
served.1. Introduction
During the last decades, numerous new classes of anti-cancer
drugs emerged, which usually support the natural body defence.
At the same time, the cancer cells developed different mechanisms
to face the cytotoxic effect of these drugs. In this field, the term of
multidrug resistance (MDR) is defined as the low sensitivity for
W. Ali et al. / European Journal of Medicinal Chemistry 200 (2020) 1124352certain cells against drugs, often found in cancer for tumour ther-
apy [1e5]. MDR is now a deeply investigated issue in the field of
chemotherapy. It can result in the upregulation of drug efflux/drug
efflux pumps, cell growth, and survival signalling. MDR can also be
related to the down-regulation of apoptosis signals or drug uptakes.
Nevertheless, key players of the MDR action are ATP-binding
cassette (ABC) transporters, such as the P-glycoprotein (Pgp,
ABCB1), MRP1 (ABCC1) and BCRP (ABCG2) ones [6], which are
involved in essential processes in cancer cells’ defence. Moreover,
the inhibition of these transporters could be beneficial to overcome
drug resistance [7]. In more detail, P-glycoprotein/ABCB1 (P-gp/
ABCB1) is a member of the ABC transporter family, which is enco-
ded by the MDR1 (ABCB1) gene, found in a plethora of healthy and
cancerous cells. In the latter ones, they are often overexpressed and
work as a self-defence against cytotoxic substances [8,9] by acting
as an efflux pump for various drugs, including anticancer agents.
One critical key in the battle against cancer is to overcome drug
resistance thus to resume the activity of current or well-known
anti-cancer drugs, e.g. topotecan, doxorubicin, vincristine,
cisplatin, cyclophosphamide, methotrexate or 5-fluorouracil. A
successful and well-accepted method in this field is the inhibition
of P-gp function during chemotherapy [10]. The co-administration
of efflux pump inhibitors (EPIs), which are specific compounds
able to modulate the efflux action of MDR drug transporters, has
been reported and well-reviewed [1e5]. Due to the complexity of
cancer aetiology, a combined approach targeting these MDR
proteins as well as hitting known antitumoral pathways such as
p53 is more and more considered to be a successful strategy to
fight cancer.
Recently, plenty of compounds that modulate P-gp in various
assays conditions were synthesized and studied. Mainly, three
generations of reversal MDR agents, e.g. verapamil (I), dexniguldi-
pine (II) and zosuquidar (III) (Fig. 1A) have been widely investi-
gated [1,3,7,11]. Furthermore, a group of inhibitors for other ABC
family members involved in cancer MDR, i.e. MRP1 (MK571,
LY171883 and BAYu9773, Fig. 1B) and BCRP (Ko143 and FTC, Fig. 1C),
have been evaluated [6]. However, their therapeutic usage is
restricted by insufficient pharmaceutical profile, in particular, in the
field of safety. Thus, further search for EPIs among new chemical
groups is in great medical importance, but it is worth tu emphasize
that rational design of new EPIs is a high challenge. Although recent
scientific achievements provided crystal structures of some MDR
ABC transporters, the computer aided structure-based design is
significantly limited in this protein family due to a variety of key-
points that could be targeted by inhibiotors, and thus providing
various structurally different “binding pockets”. For instance, some
structures can inactivate pump as enrgy users acting on ATP, while
different structures can act via a competitionwith a drug-substrate
to one of the binding sites.
On the other hand, the structure-activity relationship analysis
(SAR) in the vast group of Pgp-modulators allowed to indicate a
beneficial role for hydrophobic/aromatic ending within their
structures and also some flexibility in the middle (Fig. 1A).
Although the number of modulators found for either MRP1 or BCRP
is much smaller, SAR for their several agents shows that both
groups differ from the Pgp pharmacophores. In contrast to bulky
aromatic ends of members of the three generations of Pgp-
inhibitors (Fig. 1A), the inhibitors MRP1 (MK571, LY171883, BAY
u9773, Fig. 1B) tend to have an amphiphilic structure with the clear
hydrophilic moiety at the end opposite to the aromatic/hydro-
phobic one, while BCRP inhibitors (Ko143, FTC, Fig. 1C) seem to
prefer 4- or 5-fused ring structures. Thus, the ligand-based design is
still a predominant approach in the rational design of cancer EPIs,in particular in the case of ABCB1, thanks to the rich library of
modulators identified so far.
In the last decade, our research team described numerous
compounds targeting ABCB1 inhibitors in cancer cell lines
belonging to the types of inhibitors shown in Fig. 1A [12e16]. In
more detail, we were able to show highly potent ABCB1-inhibitory
properties for aryl-piperazine hydantoin compounds [12,14,15]. The
5-aromatic substituted hydantoins were particularly potent [12,15],
while the potency decreased when the aromatic moiety wasmoved
into position 3 [13]. Among the most active hydantoin-compounds
found so far, the 5,5-diphenylhydantoin derivative 1 and spiro-
fluorene derivative 2 (Fig. 2) were 4-7-fold more potent than the
reference P-gp inhibitor verapamil, but they did not display either
cytotoxic or antiproliferative activity towards cancer cell lines, i.e.,
T-lymphoma [15] and NCI60 cell line panel (https://dtp.cancer.gov/
discovery_development/nci-60/, data not published). In contrast,
recent evidence indicates an increasing role of the triazine scaffold
in potent hybrid anticancer agents [16], including 1,3,5-triazine-
2,4-diamines [17,18], especially, piperazine and morpholine de-
rivatives displayed strong cytotoxic effects in vitro against NCI60
cancer cell lines [18].
Furthermore, our recent follow-up study was focused on aro-
matic selenoesters and seleno-anhydrides, possessing both anti-
cancer and P-gp inhibitory properties [10]. The most active
compounds 3 and 4 (Fig. 2), were tested in MDR mouse T-lym-
phoma cells overexpressing P-gp, displaying at the same time up to
3.4-fold more potent P-gp modulatory effect compared to the
reference verapamil [19]. The main drawback of those selenoesters
and seleno-anhydride lies in their low chemical stability and their
very unpleasant intensive smell, limiting their further evaluation
and potential therapeutic application.
Taking into consideration the conclusions of previous studies
[10,12e19], and the fact that selenium in the form of ethers is
chemically much more stable and devoid of any unpleasant
smell, we decided to design and investigate a series of new
phenylselenoethers with different aromatic/heterocyclic termi-
nation. In this study, a new series of compounds was designed as
hybrid structures of both selenoethers and moieties found in the
previous active P-gp inhibitors. We designed phenylselenoether
derivatives, which can be divided into three main groups: (i)
aryl-hydantoins and their bioisosteres with variable alkyl chain
lengths (5e7, group A), (ii) (aryl)piperazines with various sub-
stituents at N-piperazine, including aromatic, alkyl and ester
moieties (8e13, group B), as well as (iii) the 1,3,5-triazine scaffold
with small C1-linker branches (5e17, group C, Table 2). The new
hybrid compounds were synthesized and tested against P-gp in
mouse T-lymphoma cells, then, their possible ability to regulate
the cell proliferation rate and their cytotoxic effects were eval-
uated, as well. The best compounds 5e7 were further studied
regarding the mechanism of ABCB1 modulation. For the most
active compound (6), we extended our studies from the mouse
cells to a cellular model of human T-lymphocytic cancer (JURKAT)
[20], in order to evaluate its effects alone or in combination with
the reference chemotherapeutic agent doxorubicin, as well as
potential molecular mechanisms of action for the selenoether at
a cellular level. Selected compounds, active in lymphocytic can-
cer cells, were also examined on their antiproliferative action in
neuroblastoma cancer cell lines. Furthermore, we evaluated their
drug-like properties, including lipophilicity, possible metabolic
pathways, and potential drug-drug interactions (DDI) risks.
Finally, qualitative SAR were discussed.
Thus, the goal of this work was a comprehensive study
regarding differently substituted seleno-ethers (5e17, Table 1), in
Fig. 1. Selected structures of cancer efflux ABC efflux pump inhibitors; (A) three generations (I-III) of ABCB1 inhibitors; (B) inhibitors of MRP1: MK571, LY171883 and BAYu9773; (C)
inhibitors of BCRP: Ko143 and FTC [6].
Fig. 2. Hydantoin Pgp-modulators, 1 and 2, and seleno-compounds (3 and 4) with both anticancer and Pgp-modulatory properties found previously.
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cancer drugs to overcome cancer MDR mechanisms.2. Results and discussion
2.1. Chemical synthesis
Compounds 5e17 (Table 1) were obtained according to the syn-
thesis route shown in Scheme 1. The hydantoin derivatives 5e7
(group A) were prepared applying a one-pot synthesis method,
including Se-alkylation of previously described hydantoin in-
termediates 18e20 [14,21e23]. In more detail, a reduction of the
diphenyl diselenide to produce sodium selenolate was performed
using sodiumborohydride inwater/tetrahydrofuranmixture (THF) 1/
1 under a nitrogen atmosphere [23]. Upon decolourization of the
solution, a suitably substituted hydantoin in dichloromethane (DCM)
was injectedwithout any need of a deprotonation salt to produce the
corresponding phenyl selenium hydantoins 5e7 in moderate yields
and with excellent purity, within 3e4 days. (Scheme 1A).
In the case of the phenyl selenium piperazine derivatives
(8e13), the appropriate commercially available piperazines were
alkylated using 1-bromo-3-chloropropane in the presence of
anhydrous potassium carbonate in acetone as solvent at room
temperature [24]. The so obtained crude intermediates were usedapplying the Se-alkylation method described for 5e7 (Scheme 1B).
1,3,5-Triazine selenium derivatives (14e17) were obtained as
follows: firstly, the preparation of the sodium selenoate was carried
out in a similar way as described for group A. The subsequent Se-
alkylation was performed within 3e4 h, without any need to use
higher temperatures or deprotonation salt. The next step involved
cyclic condensations in basic conditions with methyl piperazine
biguanide, as previously described [23,24].
Spectral and chromatographic analytical methods confirmed
the structures and purity of the final compounds 5e17. The in-
termediates (21e30) were either bought (22 and 24) or synthesized
in the case of compounds 21, 23, and 25e30 according to the pre-
vious methods [24e29]. The compounds 9e17 have been trans-
formed into the corresponding crystalline hydrochloric salts for the
relative biological studies.2.2. Pharmacology
2.2.1. Efflux modulating effects
Compounds 5e17 (Table 1) were evaluated for their efflux
modulating effects in mouse T-lymphoma cell line transfected with
the human MDR1 gene that codes for the ABC transporter ABCB1
measuring the accumulation of rhodamine 123, which is a sub-
strate for ABCB1 [12,30e32]. The percentage of mean fluorescence
Table 1
Chemical structures of compounds 5-17.
Cpd Gr. Ar R n
5 A -CH2COOCH3 4
6 A -CH2COOCH3 6
7 A -CH3 4
8 B e Ph e
9 B e 2-MeO-Ph e
10 B e 4-F-Ph e
11 B e 3,4-diCl-Ph e




14 C e -H e
15 C e -CH3 e
16 C e C2H5 e
17 C e diCH3 e
Table 2
Effects of compounds 5e17 on rhodamine 123 retention by human MDR1 (ABCB1) gene-transfected mouse lymphoma cells.
FAR (Control)
DMSO (2 v/v%) 0.84
Compounds FAR (0.2 mM) FAR (2 mM) FAR (20 mM)
Verapamil e e 17.59
5 2.47 42.91 e
6 2.77 24.20 e
7 1.09 45.05 e
8 e 1.07 1.57
9 e 0.92 1.02
10 e 1.07 4.25
11 1.07 2.27 e
12 e 0.97 0.85
13 e 0.75 0.96
14 e 0.82 0.87
15 e 0.83 0.95
16 e 0.93 1.13
17 e 1.11 1.40
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untreated cells, and then a fluorescence activity ratio (FAR) was
determined. Verapamil was tested at the commonly used concen-
tration (20 mM). All compounds (5e17) were investigated at the 10-
fold lower concentration (2 mM) while weakly-active ones (8e10,
12e17) also at the concentration of verapamil. In the case of the
active modulators at 2 mM (FAR>2, 5e7, 11), the FAR values were
determined at a low concentration of 0.2 mM, as well. Results are
presented in Table 2.
FAR, Fluorescence activity ratio was calculated using the
following equation.FAR¼ MDR treated=MDR control
parental treated= parental control
The inhibition of ABCB1 transporter is evident when FAR >1
[32]. Since the treatment had no effect on the parental cells (PAR)
lacking the overexpressed ABCB1 system, the intensity of fluores-
cence did not change in the treated cells compared to the control
ones, for this reason, the denominator was considered as 1.
Among the evaluated derivatives, the compounds 5e7 (tested at
2 mM) displayed strong inhibitory potency, being up to 2.6-fold
Scheme 1. Synthesis pathways of the final compound 5e17 and the relative intermediates 18e30.
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Other compounds (10, 11), had significantly lower inhibitory ac-
tivities (FAR 2.27 at 2 mM or 4.25 at 20 mM), while compounds 8, 9
and 12e17 were inactive (Table 2).
2.2.1.1. Studies on ABCB1 modulating mechanisms of compounds 5-7.
The most active compounds found in the rhodamine 123 accu-
mulation assay (5e7) were tested at 100 mM on their influence on
ATPase activity of Pgp pump in the luminescence Pgp-Glo™ Assay,
according to previously described methods and protocols [33e35]
(Fig. 3). In this assay, the Pgp-dependent decreases in luminescence
are measured to reflect its increased ATP consumption. The ABCB1
basal ATP consumption (basal activity) is considered as a difference
between the luminescent signal of samples treated with sodium
orthovanadate, the selective and potent Pgp inhibitor (100% inhi-
bition observed), and the luminescence of untreated Pgp samples.
Thus, inhibitors give lower values (<100% of the basal activity),
while the pump stimulators/substrates cause a statistically signif-
icant increase of the basal activity. Verapamil at 200 mMwas used as
a reference modulator with the substrate/ATPase stimulatory mode
of action, and caffeine as a reference inactive towards ABCB1
transporter to give negative control.The obtained results showed that all compounds 5e7 signifi-
cantly increased (p < 0.001, p < 0.0001) the Pgp basal activity in a
similar way, but stronger, than verapamil (Fig. 3). These results are
in line with those from the rhodamine 123 efflux assay, where
stronger effects for 5e7 in respect verapamil were also found.
Summing up, compounds 5e7 did not inhibit the work of Pgp
pump in this assay but displayed a substrate property. Thus, the
putative mechanism of the dye-substrate efflux inhibition caused
by 5e7 (Table 2) was the most probably associated with a
competitive displacement in the substrate-binding site of this MDR
transporter.
2.2.2. Cytotoxic and anti-proliferative effects
The whole series (5e17) was also examined on their cytotoxic
and anti-proliferative activity in both sensitive (PAR) and resistant
(MDR) mouse T-lymphoma cell lines (Table 3).
The tested compounds 5e7 and 11 showed very high cytotoxic
effects in both MDR and PAR cell lines (IC50 < 5 mM), with com-
pound 6 presenting the highest activity among the tested sele-
noethers. Most compounds of the series displayed lower cytotoxic
concentrations for PAR T-lymphoma cells in comparison to MDR
ones. This difference is particularly evident in the case of compound
Fig. 3. The effect of the ABCB1 substrate verapamil (VER) (200 mM), ABCB1-negative
compound caffeine (CFN) (100 mM) and compounds 5, 6 and 7 (100 mM) on ABCB1
basal activity. The compounds are recognized as an ABCB1 substrate if they stimulate
their basal activity (>100%). Data are presented as the mean ± SD. Statistical signifi-
cance was evaluated by one-way ANOVA, followed by Bonferroni’s comparison test
(***p < 0.001, ****p < 0.0001 compared with the basal activity).
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cytotoxic compounds (5e7 and 11). Compounds 12, 13 with low
cytotoxic effects in PAR cell lines were less potent in MDR cells too,
while compounds 9 and 14e17 displayed no cytotoxicity in both
PAR and MDR cell lines, even at a concentration of 100 mM (84 mM
for 16 tested in PAR).
The series demonstrated unexpectedly interesting anti-
proliferative properties in MDR mouse T-lymphoma cells, as each
member caused more potent antiproliferative effects in MDR than
in PAR cells. Almost the whole series displayed IC50 (MDR) lower
than 100 mM, while 5e7, 10, 11, and 17 lower than 10 mM. Similar to
the cytotoxicity test results, compound 6 also displayed the most
potent antiproliferative action for both PAR (IC50 ¼ 3.83 mM) and
MDR (IC50 ¼ 1.33 mM) cells, being the only member with
IC50 < 10 mM in PAR cells. To sum up, most of the compounds
showed moderate antiproliferative properties in PAR cells, with
IC50 in the range of 12e65 mM, excluding 9 and 14, which were
inactive up to a concentration of 100 mM.
2.2.3. Anticancer properties in JURKAT human T-lymphoblastic
leukaemia cell line
2.2.3.1. Effects of compound 6 on proliferation rate in JURKAT cells.
Compound 6was the best compound of our series so far in terms ofTable 3
Cytotoxic and antiproliferative effect of the compounds 5e17 on sensitive parental (PAR
Cytotoxic effects
Compound PAR mean IC50 (mM) ± SD MDR mean IC50 (mM) ±
5 2.91 ± 0.18 3.39 ± 0.09
6 0.67 ± 0.03 0.90 ± 0.07
7 3.25 ± 0.11 4.21 ± 0.40
8 21.50 ± 0.24 44.35 ± 2.88
9 >100 >100
10 6.55 ± 0.53 29.09 ± 0.97
11 2.27 ± 0.26 3.50 ± 0.29
12 60.59 ± 0.98 98.56 ± 0.64
13 51.56 ± 1.30 75.70 ± 3.31
14 >100 >100
15 >100 >100
16 84.93 ± 1.36 >100
17 >100 >100antiproliferative and cytotoxic activities, as well endowed with
significant efflux pump inhibitory properties in mouse T-lym-
phoma. In order to extend the analysis to a human cell context,
representing an immortalized T lymphocyte cell line used as a
model for acute lymphoblastic leukaemia (ALL) [36], we decided to
explore the effect of compound 6 on proliferating JURKAT
leukaemia cells. This cellular system represents a useful model for
testing the effects of different compounds on cell metabolism [37]
and proliferation rate [38]. The effects of compound 6 on either
proliferation rate or cell cycle-related gene expression were
examined alone or in combination with doxorubicin (a chemo-
therapeutic agent able to block tumour growth in vivo) in order to
find whether the co-treatment should enhance the effect of doxo-
rubicin [38e40]. Doxorubicin is a well-known and successful
antineoplastic drug commonly used as a chemotherapeutic agent
in various cancers, including ALL, but, at present, drug resistance is
common [41,42].
For these reasons, we performed proliferation assays in JURKAT
cells treated with compound 6 at 0.1e0.5 and 2 mM concentrations,
alone or in combination with doxorubicin, tested at 50 and
250 nM at two distinct time points (24 and 72 h).
While at early time compound 6 did not significantly affect cell
proliferation rate, doxorubicin alonewas able to block proliferation,
especially at higher concentrations (Fig. 4A). Notably, at 72 h post-
treatment, a significant reduction in proliferation was observed in
cells treated with compound 6 alone and with doxorubicin alone,
but a more significant effect was detected in cells co-treated with
both compound 6 and doxorubicin. These data highlighted a syn-
ergistic effect of compound 6 with doxorubicin, especially when
compound 6 was added to cell cultures at a higher dose (2 mM)
(Fig. 4B). In summary, these results indicate that the co-treatments
with compound 6 and doxorubicin counteracted cell proliferation
in JURKAT cells and that the co-treatment with compound 6 en-
hances the effect of doxorubicin.2.2.3.2. Effects of compound 6 on cell cycle-related gene expression in
JURKAT. In order to estimate a potential molecular mechanism for
the anticancer activity found for 6, we focused on the expression
levels of cyclin D1, a well-known gene related to cell cycle pro-
gression contributing to uncontrolled proliferation and found to be
negatively regulated in a previous study by the treatment with a
selenium-containing compound in gastric cancer [20]. In addition,
we analysed the expression level of p53 involved in apoptotic
response, cell cycle arrest, and senescence [43].
In order to understand whether compound 6 was able to limit
cell proliferation through gene expression regulation of cyclin D1
and p53, we treated JURKAT cells with compound 6 at three) and resistant (MDR) mouse T-lymphoma cells.
Antiproliferative effects
SD PAR mean IC50 (mM) ± SD MDR mean IC50 (mM) ± SD
16.75 ± 1.37 7.82 ± 0.57
3.84 ± 0.05 1.34 ± 0.05
12.53 ± 0.95 4.67 ± 0.38
28.96 ± 2.30 13.07 ± 0.97
>100 71.94 ± 4.30
13.92 ± 0.07 7.67 ± 0.84
17.04 ± 2.22 3.66 ± 1.23
62.91 ± 3.03 23.40 ± 1.22
53.72 ± 1.71 37.67 ± 1.95
>100 >100
38.12 ± 1.74 28.93 ± 1.89
65.16 ± 1.36 48.47 ± 2.56
35.29 ± 1.07 8.28 ± 1.47
Fig. 4. Dose-response curves for anti-proliferation activity of compound 6 and doxorubicin in a dose range (0.1, 0.5, and 2 mM for compound 6 and 50 and 250 nM for doxorubicin)
on JURKAT cells after 24 h (A) and 72 h (B) of treatment. The results represent the average cell number ±SEM of three independent experiments. Significance is represented as
*p < 0.05 and **p < 0.01 related to control groups.
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lysing with RT-PCR the mRNA transcripts levels of cyclin D1 and
p53. DMSO was used as a negative control.
The results depicted in Fig. 5 show that compound 6was able to
significantly reduce cyclin D1 expression and increase the level of
p53 (Fig. 5A), already after 24 h of treatment. Moreover, the co-
treatment with both compound 6 and doxorubicin enhanced the
effect of the single treatments on gene expression.
To sum up, these results indicate that compound 6 inhibited
cell cycle progression through the reduction of the expression of
cyclin D1 and inhibited cell proliferation by inducing p53
expression.
2.2.4. Anticancer action against neuroblastoma cancer cells
In order to estimate a broader range of anti-cancer potency,
including also non-lymphocytic cancer cells, an influence of the
most active selenoethers 5e7 on neuroblastoma cancer prolifera-
tion was investigated in SH-SY5Y cells affecting their viability
(Fig. 6). The results show that all tested compounds at a concen-
tration of 10 mM significantly inhibited cell proliferation up to 60%.
Compounds 6 and 7 were the most active ones, inhibiting cell
growth by 12% and 8%, respectively, already at a concentration of
0.5 mM, while the compound 5 was active only at 10 mM.2.3. Drug-likeness in vitro
2.3.1. Lipophilicity
In the presented work, the lipophilicity of the selenoethers was
estimated using standard RP-TLCmethod. Retention parameters for
the compounds were designated and analysed to give RM0 values
that reflect the lipophilic properties of the tested compounds (de-
tails in Table S1, Supplementary).
The RM0 values of the tested compounds ranged from 0.79 to
6.05 (Fig. 7) and were corresponding to structural differences of the
compounds. Thus, group A of hydantoin derivatives (5e7) was
more lipophilic than both, group B of phenylpiperazine sele-
noethers (9e13) and C of 1,3,5-triazine derivatives (14e17). In the
case of group B, the significant internal diversity of lipophilic
properties between aromatic- (9e11) and non-aromatic piperazine
(12, 13) compounds was seen in good accordance with the piper-
azine substituent properties. In contrast, most of the members of
group C (14, 15 and 17) demonstrated almost identical lipophilic
character. Taking into consideration the results, lipophilic-
dependent trends can be observed for the ABCB1 modulatory ac-
tion examined (Table 2). Thus the most lipophilic hydantoin de-
rivatives (6e7) displayed significantly stronger action than either
piperazine (9e13) or triazine (14e17) ones. Furthermore,
Fig. 5. (AeC) JURKAT cells were treated with compound 6 (0,1e0,5 or 2 mM) alone or (BeD) in combination with doxorubicin (50 nM) or with DMSO (CTR), as a control, for 24 h.
Expression of cyclinD1 (AeB) and p53 (CeD) mRNAs were evaluated on total RNA by qRT-PCR. Bars represent means ± SEM of 6 experiments.
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antiproliferative properties in the cancer cells, was also the most
lipophilic within the series.2.3.2. Metabolic stability in vitro
The metabolic stability of selenoorganic compounds 5e7 was
investigated using mouse liver microsomes (MLMs). The UPLC
spectra of the reaction mixtures after 120 min incubation with
MLMs showed that all examined compounds were metabolically
unstable (Fig. 8).
Compound 5 was metabolized completely into four metabolites
M1-M4, as no parent compound was observed at UPLC spectra
(Fig. 8A). Only a slight amount (4.5%) of compound 6 remained in
the reaction mixture. This compound was biotransformed mainly
into metabolite M1 and small amounts of three more metabolites
M2-M4 (Fig. 8B). Compound 7 was metabolized mainly into
metabolite M1 and four more metabolites M2-M5 (Fig. 8C).
According to UPLC spectra, compound 7 was determined as the
most stable among the tested series, as around 30% of this com-
pound remained in the reaction mixture. The performed next MS
and precise ion fragment analyses of the parent compounds and
their metabolites allowed for a determination of the metabolicpathways and the most probable structures of metabolites among
tested series. Generally, the most commonmetabolic pathways of 5
and 6 were ester hydrolysis and hydroxylation (Figs. S1AeC and
S2A-D, Supplementary information). Compound 7 was mostly hy-
droxylated and decomposed at Se atom (Figs. S3AeE, Supplemen-
tary information). A similar to 7 decomposition pattern for Se was
also observed for compound 5 (Figs. S1D and S3B, Supplementary
information). All metabolic pathways of the tested selenoethers
were summarized in Table 4.2.3.3. Drug-drug interactions prediction
The potential drug-drug interactions (DDI) of selenoethers 5e7
were predicted by in vitro assessment of their effect on CYP3A4
isoform being the most involved in drug metabolism. The com-
pounds 5e7 were screened at 10 mM, and the results were
compared to the reference selective CYP3A4 inhibitor ketocona-
zole. All examined compounds in a statistically significant manner
(****p < 0.0001) reduced CYP3A4 activity (Fig. 9).
The weakest inhibition was shown for compound 6, which
reduced CYP3A4 activity up to ~53% of untreated control, whereas 5
and 7 decreased its activity up to 28 and 20%, respectively. How-
ever, the observed effects of 5e7 were much weaker than that for
Fig. 6. Effect of selenoethers 5e7 on neuroblastoma cell viability. SH-SY5Y cells were
incubated for 72 h in the presence of the compounds 5e7 at a concentration of 0.1, 0.5,
2, 10 [mM]. Cell viability was measured by MTS assay. Each point (mean ± SEM of two
independent experiments, each of which consisted of six replicates per treatment
group) represents absorbance units and is expressed as a percentage of control
compared to 0.1% DMSO control cells (set as 100%). Statistical analysis by one-way
ANOVA showed significant differences between the groups (p<0.05) and was fol-
lowed by the Bonferroni multiple comparison test. Data indicated with ****p0.0001,
***p0.001, **p0.01 reflects statistically significant differences between control and
experimental groups.
Fig. 7. Lipophilicity data for compounds 5e17. * Lipophilicity tested for the basic form
(8), unlike the hydrochloric salts of the rest of group B (9e17). This relatively over-
stated lipophilicity of 8, as not comparable, was excluded from the discussion on
results.
W. Ali et al. / European Journal of Medicinal Chemistry 200 (2020) 112435 9the reference drug ketoconazole, which reduced almost entirely
CYP3A4 activity at 1 mM (Fig. 9).
2.4. General and SAR discussion
In order to find new anticancer hybrids able to overcome MDR
mechanisms, we explored the chemical space of moieties that were
useful to join the phenylselenoether fragment as a fixed scaffold,
including selenoether linkers. Our rational design of suitable moi-
eties based on results coming from recent literature evidence
[16e18] or our previous experiences in searching anticancer and
anti-MDR agents [10e15]. In this context, our presentmodifications
divided the chemical space of the phenylselenoether derivatives
into three main groups, i.e., 5-arylhydantoin derived compounds
(5e7, group A), aryl- (8e11), alkyl- (12) or ester- (13) piperazine
derivatives (group B) and 1,3,5-triazine derivatives with different
alkyl branches within the Se-ether linker (14e17, group C). The
comprehensive biological screening, including cancer efflux pump
inhibitory-, cytotoxic and antiproliferative properties for whole
series (5e17) on the one hand, and ADMET in vitro studies for
selected compounds 5e7, on the other hand, has provided excitingand even unexpected qualitative structure-activity relationship
(Fig. 10).
Among the three considered groups, hydantoin derivatives
(group A, 5e7) were found to be the most promising structural
moiety, being up to 2.6-fold more effective MDR EPI (at a 10-fold
lower concentration) than the reference ABCB1-inhibitor verap-
amil. These compounds possessed also significant ABCB1 substrate
potency in Pgp ATPase test, significantly higher than that of refer-
ence verapamil. Both assays indicated the realtively strongest effect
for the compound with the rigid spirofluorene moiety (7), if
comparing to 5 and 6 containing roteable 5,5-diphenyl moiety
(marked in green, Fig. 10). Furthermore, all three members (5e7)
displayed significant cytotoxic and antiproliferative properties in
the MDR cancer cells of T-lymphoma. The length of the linker
seems to be of considerable importance, as 5,5-diphenylhydantoin
compound 6 (IC50 < 1.5 mM in both cases, Table 3) with the longest
(C6) linker was the best one of the present study. Taking into ac-
count our previous results, both 5,5-diphenylhydantoin and 5-
spirofluorenehydantoin moieties, appeared in the structures of
highly potent arylpiperazine ABCB1-inhibitors [14]. Their combi-
nation with a phenylpiperazine moiety gave even stronger inhibi-
tory effects than those observed in this study, more than 20-fold
stronger than verapamil [32]. However, those compounds dis-
played neither cytotoxic nor antiproliferative actions on cancer
cells (T-lymphoma).
Furthermore, a too potent ABCB1-inhibitory property can be
considered as risky for host organisms, taking into consideration
the role of ABC-transporters in healthy human cells, which protect
them from toxic substances or drugs. From a therapeutic point of
view, the identified pharmacological properties of seleno-
diphenylhydantoin 6 seem to be much more promising, and thus
provides a new therapeutic direction for structural derivatives of
anticonvulsant drug phenytoin (5,5-diphenylhydantoin). It should
be noted that the hydantoin scaffold is a common motive in other
anticancer drugs, e.g., the 5,5-dimethylhydantoin derivative, nilu-
tamide. However, our previous studies on the series of 5,5-
dimethylhydantoin derivatives indicated a weaker (usually negli-
gible) ABCB1-inhibitory properties in T-lymphoma in comparison
to their 5,5-diphenyl analogues [13,14,32].
Comparing the piperazine phenylselenoethers (8e13, group B)
to hydantoins (5e7), the phenylpiperazine subgroup demonstrated
generally lower pharmacological effects but with notable mutual
differences, almost regular and highly corresponding to their
structural traits. The structural difference of compounds 8e13
concerns substituents at N-piperazine, including aromatic, alkyl
and ester moieties, which influence the hydrophobic properties of
the subseries, in the following order: 3,4-diClPh (11) > 4-FPh (10)>
Ph (8) > 2-MeOPh (9)>Me (12)>EtOCO (13). Almost an identical
order can be observed for both ABCB1-inhibitory and anticancer
properties, including cytotoxic and antiproliferative actions
(Tables 2 and 3). The biggest and most hydrophobic 3,4-
dichlorophenyl substituted compound (11) was outstanding in
the field of the efflux pumpmodulatory action (FAR¼ 2.27 at 2 mM),
also exceeding the rest of group B in cytotoxic (IC50 ¼ 3.50 mM) and
antiproliferative action (IC50 ¼ 3.66 mM). The 4-fluorophenyl de-
rivative (10), the next in the hydrophobicity order, displayed some
EPI properties at the high concentration (FAR ¼ 4.25 at 20 mM), but
was especially potent in terms of antiproliferative action in the
MDR T-lymphoma (IC50 ¼ 3.50 mM). It is worth to underline that
both, 11 and 10, displayed corresponding or even slightly stronger
antiproliferative properties than those of hydantoin derivatives 5
and 7, respectively (Table 3).
The last subseries of the triazine phenylselenoethers (14e17,
group C) was surprisingly inactive, taking into consideration
increasing literature evidence indicating a beneficial role of the
Fig. 8. UPLC spectra of the reaction mixtures after 120 min incubation of selenoethers 5 (A), 6 (B) and 7 (C) with MLMs. The peak at the retention time 6.26 minwas identified as the
contamination.
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Table 4
The molecular masses and metabolic pathways of compounds 5e7.
Substrate Molecular mass (m/z) Number of identified metabolites Molecular mass of the metabolite (m/z) Metabolic pathway
5 537.14 4 539.13 (M1) ester bond hydrolysis, hydroxylation
555.08 (M2) ester bond hydrolysis, double hydroxylation
523.11 (M3) ester bond hydrolysis
379.21 (M4) decomposition at the Se atom
6 565.18 4 551.22 (M1) ester bond hydrolysis,
567.18 (M2) ester bond hydrolysis, hydroxylation
568.44 (M3) ester bond hydrolysis, ketone reduction, hydroxylation
568.37 (M4) ester bond hydrolysis, ketone reduction, hydroxylation
7 477.11 5 493.13 (M1) hydroxylation
319.20 (M2) decomposition at the Se atom
493.13 (M3) hydroxylation
337.21 (M4) decomposition at the Se atom, hydroxylation
509.15 (M5) double hydroxylation
Fig. 9. The influence of selenoethers 5e7, and the reference inhibitor ketoconazole
(KE) on CYP3A4 activity. The statistical significance was evaluated by a one-way
ANOVA, followed by Bonferroni’s Multiple Comparison Test (****p < 0.0001
compared with untreated control).
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series differs only in the field of the C1-linker branches, which
undoubtedly influence slightly hydrophobicity and the steric hin-
drance/flexibility due to the variety of the spacer. In this group, only
the dimethyl-branched derivative 17 displayed notable anti-
proliferative property in MDR T-lymphoma (IC50 ¼ 8.28 mM). It
should be noted that the antiproliferative action of compound 17 is
almost 4-fold more potent in the MDR-than in the PAR cells.
The trends of more potent antiproliferative activity in the
resistant T-lymphoma (MDR), than that in sensitive (PAR) cells, was
noted for all three series A-C (Table 3). It suggests that the phe-
nylselenoether moiety, as the characteristic common feature, is
responsible for this favourable behaviour (marked in red, Fig. 10),
while changeable moieties could modulate the intensity of this
effect. The strongest result was observed for the 3,4-
dichlorophenylpiperazine derivative 11 and the aforementioned
triazine derivative 17.
Comparing the lack of anticancer action in previous studies for
the hydantoin-phenylpiperazines [14,32] to the significant effects
found in this study (groups A and B), it is not hard to recognize that
the selenoether linker is the most probable structural factor,
responsible for an introduction of both, the cytotoxic and anti-
proliferative, properties into the considered chemical families of
hydantoin and phenylpiperazines. Likewise, the length of the linker
seems to be crucial. It catches the eye that the most active hydan-
toin derivative 6, distinctly predominant in the whole series is onlyone that contains the longest C6-linker, while the anticancer action
is decreasing with C4-linker (5 and 7) and C3-linker of phenyl-
piperazine derivatives (8e13, group B), to be the weakest in the
case of short and rather stiff C1-linkers of 1,3,5-triazine derivatives
14e17 (group C). This is especially noticeable in the results of
cytotoxic properties in both MDR and PAR T-lymphoma cells
(Table 3).
Analysing the present results for the new Se-ether compounds
(5e17) in comparison to those for the previous selenoesters (4) and
selenoanhydride (3, Fig. 1) [15], corresponding efflux pump inhib-
itory and cytotoxic effects in MDR T-lymphoma can be observed. In
more detail, the ABCB1-inhibitory properties of the most active
hydantoin-selenoethers (5e7) were in the range of 1.38e2.56 of the
action of verapamil (at a 10-fold higher concentration), while they
were 1.57 and 3.43, tested in the same conditions for the sele-
noanhydride 3 and selenoester 4, respectively. In the case of cyto-
toxic action in MDR T-lymphoma, the IC50 values were 4.65 mM (3)
and 1.03 mM (4) vs 0.90e4.21 mM for the best selenoethers found in
this study. Interestingly the most active compounds (5e7) were
also active in neuroblastoma SH-SY5Y cells.
On the other hand, an undeniable advantage of these new-
discovered hydantoin selenoethers, referring to previous Se-
esters, is the lack of any unpleasant smell and their higher chemi-
cal stability observed in the test conditions. Furthermore, the re-
sults of the assays using an in vitro CYP3A4 model for most active
compounds (5e7) demonstrated their low DDI risk in comparison
to ketoconazole (Fig. 9). However, their metabolic stability tested in
mouse microsomes was rather low; the highest stability was
observed in the case of the spirofluorene derivative (7). These re-
sults require further scientific considerations, i.e., more compre-
hensive studies on biotransformation of 5e7 and their potential
metabolites, also using human metabolism models, as well as an
estimation of the intrinsic anticancer/MDR EPI properties of the
most probable metabolites. On the other hand, further rational
pharmacomodulations to improve metabolic stability and general
“drugability” within this interesting new group of hydantoin-
selenoethers is needed.
This study also provided an insight into potential molecular
mechanisms of actions for the hydantoin-selenoether compounds.
In order to explore the biological effects of the best compound
determined from themouse T-lymphoma assays, the longest-linker
hydantoin derivative 6, was evaluated in JURKAT human lympho-
blastoid cells since these cells represent a good system to study
drug resistance, cell death and proliferation in response to drugs
treatment [38]. It has been reported in colon cancer cells that se-
lenium shows chemotherapeutic potential against cancer cells by
inactivating AKT and leading to suppression of cyclin D1 while
Fig. 10. SAR overview of compounds 5e17. The common phenylselenoether (red) moiety is probably responsible for the trend of more potent antiproliferative activity in the
resistant T-lymphoma (MDR), than that in sensitive (PAR) cells in all three series A-C. Advantage of these new-discovered hydantoin selenoethers (red), referring to previous Se-
esters, is the lack of any unpleasant smell and their higher chemical stability. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web
version of this article.)
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the expression of genes related to the regulation of cell cycle and
apoptosis, among which the tumour suppressor gene p53 [40].
Thus, we focused on the regulation of proliferation rate and on
cyclinD1 and p53 expression. We were pleased to observe that the
selenium-containing compound 6 inhibited cell proliferation
through the negative regulation of cyclin D1, while enhanced the
expression of the p53 gene. Furthermore, the co-treatment of
JURKAT cells with doxorubicin and our compound enhances the
chemotherapeutic effect of this drug, suggesting a synergistic ac-
tivity warranting further studies. This effect is evident and statis-
tically significant especially after 72 h of treatment and when
compound 6 is used at the higher dose tested (2 mM). At the present
this data indicate the effectiveness of strategies based on different
compound combinations to enhance the activity of commonly used
antineoplastic drugs.
3. Conclusions
In the present work, we have discussed a new chemical family of
potent selenium-containing compounds as hybrids ofphenylselenoethers with either arylhydantoin or phenylpiperazine
moieties. Comprehensive studies, i.e., design, synthesis and both,
biological and ADMET-screening in vitro, including an insight into
cellular mechanisms of anticancer action and followed by in-depth
SAR analysis, have been performed, yielding promising results.
Among the new hybrids (5e17), the hydantoin derivatives (5, 6,
and 7) were significantlymore effective than the reference inhibitor
verapamil (up to 2.6-fold at a 10-fold lower concentration) in order
to inhibit the crucial tumour MDR mechanism of ABCB1-efflux
pump. The very high stimulation of Pgp efflux pump (>200% of
Pgp basal activity) at the presence of 5e7 confirmed their substrate
potency and the probable competitive actionwith 123 rhodamine to
the binding site in ABCB1-efflux modulating assay. Next, the cyto-
toxic and anti-proliferative action in both, sensitive (PAR) and
resistant (MDR), mouse T-lymphoma cell lines revealed that both
hydantoin- (5e7) and phenylpiperazine-selenoethers (10 and 11)
possessed a good activity profile, being the 5,5-diphenylhydantoin
compound (6) the best one out of the complete series. The prom-
ising antiproliferative action of the hydantoin compounds 6 and 7
were confirmed additionally in non-lymphocytic cancer cells, i.e.
neuroblastoma, suggesting a therapeutically-promising broader
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accent on the longer-linker compound 6. The mechanistic study
results indicate that compound 6 inhibits cell cycle progression
through the reduction of the expression of cyclin D1 and cell pro-
liferation by inducing p53 expression, thus giving a first insight into
themechanismof action. Furthermore, the SAR analysis proved that
the lipophilic properties, together with a longer selenoether spacer,
are the likely factors affecting all, cancer EPI-, antiproliferative- and
cytotoxic effects, in the tested cancer models for the new family of
selenocompounds.
Overall, this study discovered a new chemical space of highly
active selenium-containing anticancer agents, worthy of being
studied more in-depth in order to improve drug-likeness and to
reveal the precise mode of action. In this context, compound 6, as
the most active agent found in this study, will serve as a new lead
structure for further pharmacomodulations and extended mecha-
nistic studies as well as a medicinal chemistry optimization.
4. Experimental
4.1. Chemistry
Reagents were bought from Alfa Aesar (Karlsruhe, Germany) or
Sigma Aldrich (Darmstadt, Germany). Solvents were dried over
calcium hydrochloride (toluene) or calcium oxide (methanol). Re-
action progress was verified using Thin Layer Chromatography
(TLC), which was carried out on 0.2 mm Merck silica gel 60 F254
plates. Spots were visualized by UV light or treatment with Dra-
gendorff reagent. Melting points (mp) were determined using a
MEL-TEMP II apparatus and are uncorrected. The 1H NMR and 13C
NMR spectra were obtained on a Varian Mercury-VX 300 MHz
spectrometer and for the 77Se NMR on a Bruker Variance 500 MHz
spectrometer in DMSO‑d6, CDCl3-d, MeOD-d4, or Acetone-d6.
Chemical shifts in the relative NMR spectra were reported in parts
per million (ppm) on the d scale using the solvent signal as an in-
ternal standard. Data are reported as follows: chemical shift, mul-
tiplicity (s, singlet; br. s, broad singlet; d, doublet; t, triplet; dd,
doublet of doublet, q, quintet, td triplet of doublet, m, multiplet)),
coupling constant J in Hertz (Hz), number of protons, proton’s po-
sition (Ph-phenyl, Flou-Fluorine, Pp-piperazine). LC-MS were car-
ried out on a system consisting of a Waters Acquity UPLC, coupled
to a Waters TQD mass spectrometer. Retention times (tR) are given
in minutes. The UPLC/MS purity of all final compounds was deter-
mined (%). The intermediates 18e20 are described in our previous
works [14,21,22]. While the intermediates 21, 23, 25e30 were ob-
tained according to the procedure described earlier [21] and are
known in the literature [24,26e29,44,45] (for details see Support-
ing Information).
4.1.1. General procedure for the Se-alkylation (5e14)
As part of this general procedure, the appropriate diphenyl
diselenide (9.5 mmol) was dissolved in a 1:1 mixture of water and
THF (50 mL) under protective nitrogen gas. Then, sodium borohy-
dride (47.5 mmol) was added, and the mixture was stirred for
approximately 35 min, with a decolourization of the solution
observed already after 1e3 min. Next, a solution of hydantoin
substitutions or piperazine derivatives (19.37mmol) in THF or DCM
(5 mL) was slowly added, and the reaction mixture was stirred at
room temperature and monitored via TLC until the complete con-
sumption of the starting material which occurred after 24e48 h.
Upon completion, the reaction was quenched with 50 mL of a
saturated aqueous solution of ammonium chloride and extracted
with diethyl ether. The combined organic layers were dried over
sodium sulphate and evaporated under reduced pressure to yield
the desired products 5e14.4.1.1.1. Methyl 2-(2,5-dioxo-4,4-diphenyl-3-(4-(phenylselanyl)butyl)
imidazolidin-1-yl)acetate (5). Compound 18 (10 mmol) was used.
White solid, mp 128 C. Yield 23.59%. LC/MSþ/: purity: 100%,
tR ¼ 8.97, (ESI) m/z [MþH]þ 537.33. C28H28O4N2Se (MW 536.12). 1H
NMR (DMSO) d 7.47e7.43 (m, 5H-Ph), 7.29 (s, 10H-2Ph), 4.34 (s, 2H-
CH2), 3.71 (s, 3H-CH3), 3.33e3.28 (m, 2H-CH2), 2.62 (t, J ¼ 7.3 Hz,
2H-CH2), 1.37e1.17 (m, 2H-CH2), 0.88 (dt, J ¼ 15.3, 7.7 Hz, 2H-CH2).
13C NMR (DMSO) d 172.80, 167.95, 136.69, 131.32, 129.15, 128.93,
128.79, 128.15, 128.07, 126.44, 74.51, 73.31, 52.55, 27.61, 26.47, 26.01.
77Se NMR (CDCL3) d 294.61.
4.1.1.2. Methyl 2-(2,5-dioxo-4,4-diphenyl-3-(6-(phenylselanyl)hexyl)
imidazolidin-1-yl)acetate (6). Compound 19, Cas Number
(1350707-01-5) (10 mmol) was used. Yellowish solid, mp 80 C.
Yield 23.20%. C30H32O4N2Se (MW 564.15). LC/MSþ/: purity: 92.76%,
tR ¼ 9.65, (ESI)m/z [MþH]þ 565.25. 1H NMR (CDCl3) d 7.31e7.27 (m,
2H-Ph), 7.26e7.18 (m, 10H-2Ph), 7.12e7.04 (m, 3H-Ph), 4.17 (s, 2H-
CH2), 3.64 (s, 3H-CH3), 3.20e3.14 (m, 2H-CH2), 2.62 (t, J ¼ 7.5 Hz,
2H-CH2), 1.44 (s, 2H-CH2), 1.36e1.28 (m, 2H-CH2), 0.97 (dt, J ¼ 14.9,
7.5 Hz, 2H-CH2), 0.83 (dt, J¼ 14.6, 7.3 Hz, 2H-CH2), 0.72 (dt, J¼ 15.0,
7.5 Hz, 2H-CH2). 13C NMR (CDCl3) d 173.57, 167.70, 154.88, 136.93,
132.30, 130.56, 128.99, 128.96, 128.79, 128.46, 126.59, 77.26, 77.01,
76.75, 75.25, 52.70, 42.13, 39.84, 33.59, 32.25, 29.69, 28.96, 27.60,
27.57, 26.03. 77Se NMR (CDCL3) d 290.63.
4.1.1.3. 10-Methyl-3’-(4-(phenylselanyl)butyl)spiro[fluorene-9,40-imi-
dazolidine]-20,50-dione (7). Compound 20 (10 mmol) was used.
White solid, mp 132 C. Yield 15.20%. C26H24O2N2Se (MW 476.10).
LC/MSþ/: purity: 95.87%, tR ¼ 8.56, (ESI) m/z [MþH]þ 477.18. 1H
NMR (CDCl3) d 7.72 (d, J ¼ 7.6 Hz, 2H-Flu), 7.45 (td, J ¼ 7.5, 1.1 Hz,
2H- Flu), 7.36e7.31 (m, 2H- Flou), 7.28 (td, J ¼ 7.5, 1.0 Hz, 2H- Flu),
7.21 (d, J ¼ 7.5 Hz, 2H- Ph), 7.20e7.17 (m, 3H-Ph), 3.17 (s, 3H-CH3),
2.96 (t, J¼ 7.4 Hz, 2H-CH2), 2.66e2.55 (m, 2H-CH2), 1.44 (dt, J¼ 15.1,
7.5 Hz, 2H-CH2), 1.20 (dt, J ¼ 15.0, 7.5 Hz, 2H-CH2). 13C NMR (CDCl3)
d 171.89,157.27,141.52,140.17,132.64,130.31,129.85,128.83,128.24,
126.71, 123.57, 120.89, 77.16, 76.91, 76.65, 75.01, 40.63, 28.83, 26.87,
26.83, 25.61. 77Se NMR (CDCL3) d 292.63.
4.1.1.4. 1-Phenyl-4-(3-(phenylselanyl)propyl)piperazine (8).
Compound 21 (10 mmol), CAS Number (10,599-17-4), was used.
White solid, mp 248 C. Yield 20.11%. C19H24N2Se (MW 360.11). LC/
MSþ/: purity: 100%, tR ¼ 4.82, (ESI) m/z [MþH]þ 361.07. 1H NMR
(MeOD) d 7.61e7.58 (m, 2H-Ph), 7.34e7.28 (m, 5H-Ph), 7.05e7.02
(m, 2H-Ph), 6.94 (ddd, J¼ 8.3, 2.0, 1.0 Hz,1H-Ph), 3.79e3.37 (m, 8H-
Pp-2,6-H þ Pp-3,5-H), 3.36 (s, 2H-CH2), 3.05 (t, J ¼ 7.1 Hz, 2H-CH2),
2.24e2.16 (m, 2H-CH2). 13C NMR (DMSO) d 149.57, 131.56, 129.57,
129.32, 129.07, 126.75, 119.88, 115.87, 55.10, 50.65, 45.21, 42.46,
23.74, 23.32. 77Se NMR (DMSO): 283.99.
4.1.1.5. 1-(2-Methoxyphenyl)-4-(3-(phenylselanyl)propyl)piperazine
hydrochloride (9). Commercial 1-(3-chloropropyl)-4-(2-
methoxyphenyl)piperazine (10 mmol), CAS Number (21,279-77-
6), was used. White solid, mp 287 C. Yield 8.6%. Basic form
C20H26ON2Se (MW 390.12), C20H27ClON2Se (MW 426.10). LC/MSþ/:
purity: 100%, tR ¼ 4.97, (ESI) m/z [MþH]þ 391.17. 1H NMR (DMSO)
d 11.36 (s, 1H, NHþ), 7.23e7.15 (m, 6H-Ph), 6.91 (d, J ¼ 8.4 Hz, 2H-
Ph), 6.78 (t, J ¼ 7.3 Hz, 1H-Ph), 3.69 (dd, J ¼ 11.7, 5.3 Hz, 2H-CH2),
3.43 (d, J ¼ 10.3 Hz, 2H-CH2), 3.16e2.96 (m, 8H-Pp-2,6-H þ Pp-3,5-
H), 2.10e2.02 (m, 2H-CH2). 13C NMR (126 MHz, DMSO) d 131.58,
129.59, 129.41, 129.31, 129.08, 126.76, 115.86, 50.58, 45.19, 23.74,
23.31, 0.10. 77Se NMR (DMSO): 481.64.
4.1.1.6. 1-(4-Fluorophenyl)-4-(3-(phenylselanyl)propyl)piperazine
hydrochloride (10). Compound 21 (10 mmol), was used. White
solid, mp 204 C. Yield 37.68%. Basic form C19H23FN2Se (MW
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tR ¼ 4.83, (ESI) m/z [MþH]þ 379.14. 1H NMR (DMSO) d 11.10 (s, 1H,
NHþ), 7.50e7.46 (m, 2H-Ph), 7.31e7.21 (m, 3H-Ph), 7.08e7.02 (m,
2H-Ph), 6.99e6.94 (m, 2H-Ph), 3.65 (d, J¼ 10.3 Hz,2H-CH2), 3.47 (d,
J ¼ 9.8 Hz, 2H-CH2), 3.20e2.96 (m, 8H-Pp-2,6-H þ Pp-3,5-H), 2.08
(dt, J ¼ 15.2, 7.5 Hz,2H-CH2). 13C NMR (DMSO) d 164.50, 157.51,
155.63, 146.41, 131.63, 129.55, 129.34, 126.82, 117.84, 117.78, 115.58,
115.40, 55.17, 50.72, 46.06, 23.85, 23.22. 77Se NMR (DMSO): 285.00.
4.1.1.7. 1-(3,4-Dichlorophenyl)-4-(3-(phenylselanyl)propyl)pipera-
zine hydrochloride (11). Commercial 1-(3-chloropropyl)-4-(3,4-
dichlorophenyl)piperazine (10 mmol), CAS Number (101,364-27-
6), was used. White solid, mp 170 C. Yield 15.09%. Basic form
C19H22Cl2N2Se (MW 428.03), C19H23Cl3N2Se (MW 464.01). LC/MSþ/
: purity: 99.22%, tR ¼ 5.84, (ESI) m/z [MþH]þ 429.12. 1H NMR
(DMSO) d 11.31 (s, 1H, NHþ), 7.55e7.48 (m, 2H, Ph), 7.44 (d,
J ¼ 9.0 Hz, 1H, Ph), 7.35e7.20 (m, 4H, Ph), 6.99 (dd, J ¼ 9.0, 2.9 Hz,
1H, Ph), 3.86 (d, J ¼ 13.2 Hz, 2H, CH2), 3.48 (d, J ¼ 11.7 Hz, 2H, CH2),
3.28e3.16 (m, 4H, Pp-2,6-H), 3.12e2.98 (m, 4H, Pp-3,5-H), 2.11 (p,
J¼ 7.5 Hz, 2H, CH2). 13C NMR (DMSO) d 149.28,131.65,131.61,131.57,
130.63, 129.59, 129.33, 126.79, 120.75, 116.96, 115.79, 55.15, 50.22,
44.65, 23.75, 23.30. 77Se NMR (DMSO): 284.24.
4.1.1.8. 1-Methyl-4-(3-(phenylselanyl)propyl)piperazine hydrochlo-
ride (12). Commercial 1-(3-chloropropyl)-4-methylpiperazine
(10 mmol), CAS Number (104-16-5), was used. White solid, mp
132 C. Basic form C14H22N2Se (MW 298.09), C14H22ClN2Se (MW
333.59). Yield 11.97%. LC/MSþ/: purity: 97.97%, tR ¼ 2.89, (ESI) m/z
[MþH]þ 299.13. 1H NMR (DMSO) d 12.01 (s, 1H, NHþ), 7.52e7.46 (m,
2H, Ph), 7.33e7.22 (m, 3H, Ph), 3.50e3.13 (m, 10H, 8H-Pp-2,6-
H þ Pp-3,5-Hþ 2H-CH2), 3.01 (t, J ¼ 7.4 Hz, 2H, CH2), 2.81 (s, 3H,
CH3), 2.07 (p, J ¼ 7.6 Hz, 2H). 13C NMR (DMSO) d 131.47, 129.59,
129.34, 129.25, 126.74, 55.29, 49.39, 47.99, 23.89, 23.31, 23.05,
22.80. 77Se NMR (DMSO): 284.41.
4.1.1.9. Ethyl 4-(3-(phenylselanyl)propyl)piperazine-1-carboxylate
hydrochloride (13). Synthesis from 10 mmol of ester 26. White
solid, mp 83 C. Yield 23.59%. Basic form C16H24N2O2Se (MW
356.10), C16H24ClN2O2Se (MW 391.60). LC/MSþ/: purity: 98.59%,
tR ¼ 3.82, (ESI) m/z [MþH]þ 357.21. 1H NMR (DMSO) d 11.62 (s, 1H,
NHþ), 7.53e7.48 (br, 2H), 7.33e7.23 (m, 3H, Ph), 4.06 (m, 2H, Ph),
4.00 (d, J ¼ 13.4 Hz, 2H, CH2), 3.39 (d, J ¼ 9.8 Hz, 4H, Pp-2,6-H),
3.18e3.11 (m, 2H, CH2), 3.04e2.91 (m, 4H, Pp-3,5-H), 2.08 (p,
J ¼ 7.5 Hz, 2H), 1.18 (t, J ¼ 7.1 Hz, 3H). 13C NMR (DMSO) d 154.27,
131.65, 131.60, 131.56, 129.57, 129.31, 126.76, 61.31, 55.27, 50.31,
23.66, 23.29, 14.47. 77Se NMR (DMSO) d 283.96.
4.1.2. General procedure of synthesis of 1,3,5-triazines (14e17)
Sodium (10mmol) was dissolved in 10mL of absolutemethanol,
then 4-methylpiperazin-1-yl biguanidine x 2HCl (5 mmol) and the
appropriate carboxylic acid ester (5 mmol) were added. The reac-
tion mixture was refluxed for 15e30 h. After cooling to room
temperature, water (10 mL) was added and the mixture was stirred
for 0.5 h. The precipitated triazine product was separated and
crystallized from methanol.
4.1.2.1. 4-(4-Methylpiperazin-1-yl)-6-((phenylselanyl)methyl)-1,3,5-
triazin-2-amine hydrochloride (14). Synthesis from 10 mmol of
ester 27. White solid. Yield 26%, mp 249 C. Basic form C15H20N6Se
(MW 364.09), C15H20ClN6Se (MW 400.07). LC/MSþ: purity: 100%,
tR ¼ 2.82, (ESI) m/z [MþH]þ 365.12. 1H NMR (DMSO) d 11.50 (s, 1H-
NHþ), 7.87 (br.s. 2H-NH2), 7.61e7.56 (m, 2H Ph), 7.37e7.25 (m, 3H
Ph), 3.96 (d, J ¼ 5.4 Hz, 2H-CH2), 3.50e2.78 (m, 8H, 4H-Pp-2,6-
Hþ4H-Pp-3,5-H), 2.73 (d, J ¼ 4.0 Hz, 3H-CH3). 13C NMR (DMSO)
d 175.48,171.16,167.35,164.82,134.10,131.78,131.40,130.45,129.49,129.25, 127.03, 125.59, 54.77, 46.23, 42.84, 34.62, 33.19.
4.1.2.2. 4-(4-Methylpiperazin-1-yl)-6-(1-(phenylselanyl)ethyl)-1,3,5-
triazin-2-amine hydrochloride (15). Synthesis from 10 mmol of
ester 28. White solid. Yield 12.19%, mp 238 C. Basic form
C16H22N6Se (MW 378.11), C16H23ClN6Se (MW 413.81). LC/MSþ/:
purity: 100%, tR ¼ 3.23, (ESI) m/z [MþH]þ 379.08. 1H NMR (DMSO)
d 11.93 (s, 1H-NHþ), 8.33 (br.s, 2H-NH2), 7.54 (dt, J ¼ 7.0, 1.4 Hz, 2H-
Ph), 7.45e7.29 (m, 3H-Ph), 4.34 (q, J¼ 7.0 Hz,1H-CH), 4.11e2.55 (m,
11H, 4H-Pp-2,6-H þ 4H-Pp-3,5-H þ 3H-Pp-CH3), 1.59 (s, 3H-CH3).
13C NMR (DMSO) d 162.20, 136.14, 131.33, 129.98, 129.64, 129.22,
128.34, 51.62, 42.38, 18.15. 77Se NMR (DMSO) d 492.76.
4.1.2.3. 4-(4-Methylpiperazin-1-yl)-6-(1-(phenylselanyl)propyl)-
1,3,5-triazin-2-amine hydrochloride (16). Synthesis from 10 mmol
of ester 29. White solid. Yield 29.78%, mp 231 C. Basic form
C17H24N6Se (MW 392.12), C17H25ClN6Se (MW 428.10). LC/MSþ/:
purity: 100%, tR ¼ 3.67, (ESI) m/z [MþH]þ 393.17. 1H NMR (DMSO)
d 11.87 (s, 1H, NHþ), 9.02e7.87 (br, 2H, NH2), 7.56e7.50 (m, 2H, Ph),
7.42e7.30 (m, 3H, Ph), 4.07 (t, J¼ 7.6 Hz, 1H, CH), 3.54e2.93 (m, 8H,
Pp-2,6-H þ Pp-3,5-H), 2.75 (s, 3H, CH3), 1.94 (d, J ¼ 76.0 Hz, 2H,
CH2), 0.95 (t, J ¼ 7.2 Hz, 3H, CH3). 13C NMR (DMSO) d 167.12, 164.46,
162.05, 135.95, 131.30, 130.45, 129.97, 129.64, 129.19, 128.32, 51.89,
42.44, 42.37, 28.93, 25.05, 21.87, 13.76, 12.82, 11.32. 77Se NMR
(DMSO) d 454.52.
4.1.2.4. 4-(4-Methylpiperazin-1-yl)-6-(2-(phenylselanyl)propan-2-
yl)-1,3,5-triazin-2-amine hydrochloride (17). Synthesis from
10 mmol of ester 30. Light yellow solid. Yield 12.19%, mp 252 C.
Basic form C17H24N6Se (MW 392.12), C17H25ClN6Se (MW 428.10).
LC/MSþ/: purity: 96.21%, tR ¼ 3.72, (ESI) m/z [MþH]þ 393.10. 1H
NMR (DMSO) d 11.45 (br, 1H, NHþ), 8.83e7.75 (br, 2H, NH2),
7.61e7.41 (m, 3H, Ph), 7.39e7.33 (m, 2H, Ph), 3.36e2.86 (m, 8H, Pp-
2,6-H þ Pp-3,5-H), 2.76 (s, 3H, CH3), 1.69 (s, 6H, 2CH3). 13C NMR
(DMSO) d 174.94, 162.37, 162.09, 157.22, 132.42, 131.30, 130.45,
129.96, 128.31, 71.57, 51.88, 51.54, 42.41, 42.36, 28.81, 27.59, 18.71.
77Se NMR (DMSO) d 447.73.
4.2. Biological assays
4.2.1. Assays in mouse T-lymphoma
4.2.1.1. Cell lines. The L5178Y mouse T-cell lymphoma cells (ECACC
Cat. No. 87111908, obtained from FDA, Silver Spring, MD, USA) were
transfected with pHa MDR1/A retrovirus. The ABCB1-expressing
cell line (MDR) was selected by culturing the infected cells with
colchicine. L5178Y (parental, PAR) mouse T-cell lymphoma cells
and the L5178Y human ABCB1-transfected subline were cultured in
McCoy’s 5A medium supplemented with 10% heat-inactivated
horse serum, 200 mM L-glutamine, and penicillin-streptomycin
mixture in 100 U/l and 10 mg/l concentration, respectively.
4.2.1.2. Assay for cytotoxic effect in mouse lymphoma cells.
Stock solutions of compounds were 10 mM in DMSO. The effects of
increasing concentrations of the drugs alone on cell growth were
tested in 96-well flat-bottomed microtiter plates. The compounds
were diluted in 100 mL of McCoy’s 5Amedium.1 104 mouse T-cell
lymphoma cells (PAR or MDR) in 100 mL of medium were then
added to eachwell, with the exception of themedium control wells.
The culture plates were further incubated at 37 C for 24 h; at the
end of the incubation period, 20 mL of MTT solution (from a 5 mg/
mL stock) was added to each well. After incubation at 37 C for 4 h,
100 mL of SDS solution (10% in 0.01 M HCI) was added to each well,
and the plates were further incubated at 37 C overnight. The cell
growth was determined by measuring the OD at 540 nm (ref. 630
nm) with a Multiscan EX ELISA reader (Thermo Labsystems,
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equation:
4.2.1.3. Assay for antiproliferative effect in mouse lymphoma cells.
The effects of increasing concentrations of the drugs alone on cell
growth were tested in 96-well flat-bottomed microtiter plates. The
compounds were diluted in 100 mL of McCoy’s 5A medium. 6  103
mouse T-cell lymphoma cells (PAR or MDR) in 100 mL of medium
were then added to each well, with the exception of the medium
control wells. The culture plates were further incubated at 37 C for
72 h in a CO2 incubator; at the end of the incubation period, 20 mL of
MTT solution (from a 5 mg/mL stock) was added to each well. After
incubation at 37 C for 4 h, 100 mL of SDS solution (10% in 0.01 M
HCI) was added to each well, and the plates were further incubated
at 37 C overnight. The cell growth was determined by measuring
the OD at 540 nm (ref. 630 nm) with a Multiscan EX ELISA reader
(Thermo Labsystems, Cheshire, WA, USA). IC50 values were calcu-
lated via the following equation:
4.2.1.4. Fluorescence uptake assay. The cell numbers of the L5178Y
PAR and MDR cell lines were adjusted to 2  106 cells/mL, resus-
pended in serum-free McCoy’s 5A medium, and distributed in 0.5
mL aliquots into Eppendorf centrifuge tubes. The tested compounds
were added at a final concentration of 0.2, 2, or 20 mM, and the
samples were incubated for 10 min at room temperature. Verap-
amil was applied as a positive control at 20 mM. DMSOwas added to
the negative control tubes in the same volume as had been used for
the tested compounds. No activity of DMSO was observed. Next, 10
mL (5.2 mM final concentration) of the fluorochrome and ABCB1
substrate rhodamine 123 was added to the samples, and the cells
were incubated for a further 20 min at 37 C, washed twice and re-
suspended in 1 mL PBS for analysis. The fluorescence of the cell
population was measured with a PartecCyFlow®flow cytometer
(Partec, Münster, Germany). The percentage of mean fluorescence
intensity was calculated for the treatedMDR cells as comparedwith
the untreated cells. A fluorescence activity ratio (FAR) was calcu-
lated based on the measured fluorescence values via the following
equation:
FAR¼ MDR treated=MDR control
parental treated= parental control
4.2.2. Assays with JURKAT human T-lymphocytes
4.2.2.1. Cell culture and treatments. JURKAT human T lymphocyte
cells (ATCC, VA, USA) were propagated in RPMI 1640 medium
(Gibco, Monza, Italy) with 10% fetal bovine serum (FBS; Gibco,
Monza, Italy), 2 mM L-glutamine (Euroclone, Pero (MI), Italy), and
antibiotics (100 U/mL penicillin, 100 g/mL streptomycin) (Euro-
clone, Pero (MI), Italy).
For the treatments with compound 6, doxorubicin and DMSO as
a negative control, cells were seeded and treated once with com-
pound 6 at the final concentration of 0,1 mM, 0,5 mMand 2 mM, alone
or in combination with doxorubicin at the final concentration of
50 nM and 250 nM. Cells were collected after 24 and/or 72 h from
the treatment and analysed for proliferation rate and gene
expression.
4.2.2.2. RNA extraction, reverse transcription, and quantitative PCR in
JURKAT cells. RNAs were extracted by ReliaPrep™ RNA Tissue
Miniprep (Promega, Madison, WI, USA) and reverse-transcribed
with PrimeScript RT Master Mix (Takara, Kusatsu, Shiga, Japan).
cDNAs were amplified by a qPCR reaction using GoTaq qPCR Master
Mix (Promega) and analysed with the oligonucleotide pairs specificfor the target genes. Relative amounts, determined with the
2(DCt) method, were normalized with respect to the human
housekeeping gene L32.
The primers used are as follows: L32 (forward: 50-GGAGC-
GACTGCTACGGAAG-30, reverse: 50-GATACTGTCCAAAAGGCTGGAA-
30), CyclinD1 (forward: 50-CCTCTAAGATGAAGGAGACCA-30, reverse:
50-CACTTGAGCTTGTTCACCA-30), and p53 (forward: 50-
GGCCCACTTCACCGTACTAA-30, reverse: 50-GTGGTTTCAAGGCCA-
GATGT-30).
4.2.2.3. Cell proliferation assay. Cell viability was measured using a
CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS)
(Promega) following themanufacturer’s instructions, as reported in
Stazi et al., 2019 [46]. Briefly, JURKAT cells were seeded in 96 well
tissue culture plates. After 24 h or 72 h of treatment with com-
pound 6, doxorubicin, or DMSO as a negative control at the re-
ported concentrations, 20 mL of AQueous One Solution Reagent was
added to each well and absorbance was recorded at 490 nm. Three
independent experiments were performed.
4.2.2.4. Statistical methods. Statistical analysis was performed us-
ing Statistica v10 software (StatSoft, USA). The correlation co-
efficients (r, r2), and the standard errors of the slope, interception,
and estimate (Sa, Sb, Se) were used as the basis for testing the
linearity of regression plots.
Statistical significance for gene expression analysis and prolif-
eration assays was determined with a t-test with GraphPad Prism
version 5.0 (La Jolla, CA, USA). Differences were considered signif-
icant at p < 0.05 (*p < 0.05; **p < 0.01; ***p < 0.001).
4.2.3. Assays with human neuroblastoma cell line SH-SY5Y
4.2.3.1. Cell culture and treatment conditions. Human neuroblas-
toma cell line SH-SY5Y (ATCC® no. CRL-2266™) was grown in Dul-
becco’sModifiedEagle’sMedium/NutrientMixture F-12 (DMEM/F12,
Life Technologies) with 10% (v/v) fetal bovine serum (FBS, South
America, Life Technologies) at 37 C in a humidified atmosphere of 5%
CO2/95% air. Cells were routinely passaged at 70% confluence by
trypsinization (0.05% Trypsin-EDTA, Invitrogen) and re-seeded at
5 103 cells/cm2. Tomake experiments comparable, cells at passages
10e17 were evaluated. In every experiment, cells were seeded in
100 ml (96-well plates) of complete growth medium and initially
cultured for 24 h. Subsequently, themediumwas changed tomedium
containing tested compounds diluted to the desired concentrations.
After 72 h, the given assay was performed as described below. All
tested compoundswere dissolved in DMSO to generate 10mM stock.
Directly before analysis, each stock solution of tested compoundswas
made in DMSO as a 1000-fold stock solution and then diluted in
culture medium to a final desired concentration.
4.2.3.2. Cell viability assay. SH-SY5Y cells (2.5  104 cells/well)
were cultured in transparent 96-well plates (Nunc) in DMEM/F12
supplemented with 10% FBS in the presence of dimethylsulfoxide
(DMSO < 0.1%, vehicle control) or increasing concentration of
compounds 5, 6 and 7 (0.1, 0.5, 2, 10 [mM]). Treatment with com-
pounds was performed for 72 h. After the incubation time, cell
viability was examined using an MTS-based [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2 H tetrazolium] CellTiter96® AQueous One Solution
Cell Proliferation Assay (Promega, Madison, USA) following the
manufacturer’s protocol. Briefly, 20 ml of MTS solutionwas pipetted
into each well containing 100 ml of culture or culture medium
(negative control) and incubated at 37 C for 4 h. After incubation
time, formazan product turnover absorbance was measured at
490 nm using the microplate reader EnSpire (PerkinElmer, Mas-
sachusetts, USA).
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of two independent experiments. Each treatment point was
repeated (six times) in two technical and independent replicates.
All statistical analyses were carried out using GraphPad Prism 7
with significance determined by One-way ANOVA followed by
Bonferroni’s post-hoc comparisons tests as detailed in the figure
legends.
4.2.4. Intrinsic activity towards Pgp in vitro
The luminescent Pgp-Glo™ Assay System used for determina-
tion of 1,3,5-Triazine selenium derivatives influence on P-gp ac-
tivity was purchased from Promega (Madison, WI, USA). The assay
was performed in triplicate, as described previously [33e35].
Compounds 5e7 (100 mM)were incubatedwith Pgpmembranes for
40 min at 37 C. The references: Pgp-stimulator verapamil (VER)
and Pgp-negative compound caffeine (CFN) were incubated at 200
and 100 mM, respectively. For basal P-gp activity calculation, the
membranes were incubated with 100 mM of sodium orthovanadate
(Na3VO4). The luminescence signal was measured by microplate
reader EnSpire PerkinElmer (Waltham, MA, USA). The statistical
significances were calculated using GraphPad Prism 8.0.1 software.
4.3. Lipophilicity study
4.3.1. Thin-Layer Chromatography
The mobile phases were prepared by mixing the respective
amounts of water and organic modifier (methanol) in a range from
40 to 90% (v/v) in 5% increments. TLC was carried out on Silica gel
60 RP-18 F254 plates (7  10 cm) plates (Merck, Darmstadt, Ger-
many). Methanol was used to prepare the solutions of the sub-
stances. Solutions (10 mL) of the analysed compounds were applied
to the plates as 5 mm bands, 10 mm apart, and 10 mm from the
lower edge and sides of the plates, by using a Linomat V applicator
(Camag, Basel, Switzerland). The vertical chamber (SigmaeAldrich,
St. Louis, USA), 20  10  18 cm in size, was saturated with the
mobile phase for 20 min. The development was carried out over
9 cm from the starting line at a temperature of 20 C. Next, the
plates were dried at room temperature, and the spots were
observed in ultraviolet light at 254 and/or 366 nm (UV lamp,
Camag, Basel, Switzerland). In each case, sharp and symmetric
spots without a tendency for tailing were obtained. Each experi-
ment was run in triplicate, and mean RF (retardation factor) values
were calculated.
Starting from the RF values, the RM parameters were computed
as described in the formula:
RM ¼ log(1/RF 1) 1)
Linear correlations between the RM values of the substances and
the concentration of organic modifier in mobile phases were
calculated for each compound with the Soczewinski-Wachtmeister
equation [47].
RM ¼ RM0 þ aC where C is the concentration of the organic
solvent (in %) in the mobile phase, a is the slope, and RM0 is the
concentration of organic modifier extrapolated to zero.
4.4. Metabolic stability assay
The in vitro evaluation of metabolic pathways was performed by
120 min incubation of compounds 5e7 at 37 C with mouse liver
microsomes (MLMs) obtained from Sigma-Aldrich (St. Louis, MO,
USA), according to the described previously protocols [48,49]. The
LC/MS analyses with additional MS ion fragmentation of the
products and substrates were performed to determine the most
probable structures of metabolites.4.5. Drug-drug interaction prediction
The used CYP3A4 P450-Glo™ commercial assay was purchased
from Promega (Madison, WI, USA). The influence of compounds on
CYP3A4 activity was tested according to the manufacturer protocol
and as described previously [48,49]. The bioluminescence signal
was measured with a microplate reader EnSpire (PerkinElmer,
Waltham, MA, USA) in luminescence mode.
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4.1. Synthetic strategies for the designing of novel 5-HT6 Serotonin 
Receptor Ligands 
The project has been focused on introducing two ways of chemical modifications on the 1,3,5-triazine 
motif by involving hydantoin and chalcogens (oxygen, sulfur, and selenium) ether- moieties. This 
study reports the synthesis of the first novel organo-selenium compound to serve as a ligand for 5-
HT6 receptors. From the perspective of drug design, the N-methyl piperazine fragment contains the 
positive ionizable nitrogen PI-feature. The hydantoin (imidazolidine-2,4-dione) moiety has two 
carbonyl functional groups, which serve as hydrogen bond acceptor (HBA-feature). Interestingly, the 
chalcogen atoms also can serve as hydrogen bond acceptor. The heterocyclic 1,3,5-triazine moiety 
provides the central aromatic region (AR) of the pharmacophore. The substituents at the hydantoin 
fragment represent the hydrophobic area (HYD), which were replaced by benzene or benzene 
substituted functional groups in the new chalcogen molecules.  
Thus, the following research tasks have been performed: 
❖ Computer aided-rational design of new derivatives of 1,3,5-triazine. 
❖ The synthesis of the derivatives of the lead structure. 
❖ Studies in vitro on the affinity and selectivity of the compounds for the 5-HT6 receptor. 
Radioligand binding assays have been employed for determining both the affinity and the 
selectivity profile of the synthesized compounds. 
❖ In vitro functional studies on intrinsic mechanisms of action for selected active compounds 
found in the affinity studies in vitro. 
❖ Drug-ability – ADMET studies in vitro for selected active compounds found in the affinity 
studies in vitro 
❖ Structure-activity relationship analysis to review and modify pharmacophore features for the 
ligand-receptor interactions in the case of ligands for the 5-HT6 receptor that belongs to the 
derivatives of 1,3,5-triazine. 





Figure 7: General structures for the 5-HT6 serotonin receptor ligands 
 
Two novel groups of serotonin receptors 5-HT6 ligands have been prepared, i.e., aromatic triazine-
methyl piperazine, coupled with a hydantoin spacer between 1,3,5-triazine (Group 1) and the aromatic 
fragment, and phenoxy alkyl-, phenyl thioether- or phenyl selenoether-1,3,5-triazine derivatives with 
a carbon spacer (Group 2). Figure 7 
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22 new compounds have been synthesized for Group 1, employing four different synthetic pathways 
(107). Nuclear magnetic resonance (NMR), Mass spectra (MS), and chromatographic analytical 
methods confirm the structures and purity of the obtained compounds. Melting point, percentage 
yield, physical state, 1H-NMR, 13C-NMR, molecular weight, and purity have been reported for the 
final compounds. In general, the compounds have been obtained in good yield and purity. No specific 
conditions are needed as the compounds are stable, and no unpleasant smell has been recorded. The 
compounds are prepared following the procedures described in Article 1 and stored at room 
temperature.  
17 new compounds have been synthesized for Group 2 (108). Since all the obtained compounds are 
solid, hence melting point, percentage yield, physical state, 1H-NMR, 13C-NMR, molecular weight, 
and purity have been reported for the final compounds. The compounds have been obtained in good 
yield and have been purified by recrystallization. All the compounds are stable, and no unpleasant 
smell has been recorded. The selenium compounds have been prepared in an inert nitrogen 
atmosphere at room temperature. 
4.2. Biological evaluation of the 5-HT6 ligands  
Considering Lipinski's rule of five, the data obtained show good lipophilicity (3.14-4.49) determined 
with the standard reversed-phase thin-layer chromatography RP-TL. All the hydantoin-triazines 
derivatives (4–26) are predicted as blood-brain-barrier BBB-permeable.  
Because of its unique structure, hydantoin is considered as a versatile motif in medicinal chemistry 
comprising of five potential substituent sites, including two hydrogen bond acceptors and two 
hydrogen bond donors. Moreover, the delocalization of the negative charge at the imidic nitrogen 
atom provides hydantoin a weak acid property, making N-3H more prone to ionization than at N-1H. 








 Computer-aided SAR (structure-activity relationship) analysis reveals a significant influence of 
linker and aromatic moiety to enhance the affinity of the hydantoin ring for the 5-HT6R. Besides, the 
substitution at the hydantoin ring shows that the methylene group at position 3 of hydantoin is 
profitable. In contrast, a significant decrease in the radioligand binding assay activity is noted for 
substitution by the methylene group at position 1 (5). The combination of hydantoin substituted at 
position 5 with the β-naphthyl moiety provides the compound 26 with desired features.  Compound 
26 presents good drug-like features, such as the lipophilicity (3.76) and molecular weight (446.50). 
Compound (26) displays antidepressant-like activity in vivo in forced swim test (FST) and anxiolytic-
like activities employing the Vogel conflict drinking test. Compounds 6 and 26 also exhibit 
antiobesity properties.  
Still, the hydantoin series provides several hints to improve the design of the compounds. As 
observed, the hydantoin ring doesn't prove to be critical for 5-HT6R affinity. The highest affinity is 
obtained with the compound with the largest hydrophobic area 26, which follows Rodríguez et al. 
suggestion for the pharmacophore model (35). Furthermore, a higher affinity for HT6R affinity has 
also been observed for compounds containing more electron-donating functional groups at the phenyl 
ring at para position (compound 6). In general, the most potent 5-HT6R agents (6 and 26) display 
lower toxicity in the HEK-293 eukaryotic cell line. 
These hints provide us with the idea to further modify the structure and replace the hydantoin ring 
with other hydrogen bond acceptor (HBA). For this purpose, we chose to employ the chalcogen 
elements (oxygen, sulfur, and selenium) to produce new compounds with better affinity and 
selectivity.  
The combination of nitrogen heterocycles and chalcogens appears to be unique. And it is still 
following the model pharmacophore suggested by Rodríguez et al. and Łażewska et al. (35, 36).  
Several modifications have been performed to enhance the affinity of compounds for 5-HT6R.  These 
modifications include: (a) the substituents at phenyl ring, including type, number, and position; (b) 
the methyl (un)branched linker; and (c) different chalcogen-ether linker concerning the S-oxidized 
form (SO2), which is an indispensable structural feature of more than 80% 5-HT6R agents (33, 109). 
Interestingly the results obtained confirm our previous findings regarding the substituents at phenyl 
ring, i.e., a higher affinity towards 5-HT6R receptors has been observed for compounds containing 
more electron-donating and hydrophobic substituents at the phenyl ring. In contrast to previous 
results, substitution at ortho-position turns out to be more favorable than substitution at meta- and 
para- positions for the binding of compounds with 5-HT6R. 
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Similarly, mono substitution is more desirable than di-substitution. Replacing oxygen with sulfur and 
selenium, the impact of substituents at the phenyl ring has been less significant. In contrast, the methyl 
branching proves to be more critical and significantly improves the affinity. In general, the biological 
results obtained indicate that this chemical family, consisting of the skeleton of 2-amine-1,3,5-triazine 
core combined with methyl piperazine at position 4 and ether-linked phenyl at position 6, tends to 
target 5-HT6R rather selectively. Besides, the compounds investigated display excellent 
antidepressant-like activity in vivo in forced swim test (FST). 
Regarding the selenium compounds, two "representative" selenoethers (22 and 23) show affinities 
towards 5-HT6R, although they are deprived of any particular substituents at the phenyl moiety. The 
unbranched Se-ether (22) exhibits radioligand binding affinity two-fold higher as compared to the 
corresponding oxygen derivative. This affinity increases with the branched Se-ether (23) and provides 
the maximum 5-HT6R affinity with butyl branched (data is not published yet). The selenium atom 
with a larger atomic radius size and more electron density seems to be important from the perspective 
of affinity towards the receptor. On the other hand, the tellurium analogous is not stable and is not 
possible to obtain.  
As the metabolic test is performed for the most active compounds, it could be essential to investigate 
the redox behavior for different analogous to get a better idea about the role of chalcogens on 5-HT6R 
affinity.  
4.3. Design and synthesis of ABCB1 efflux pump modulating agents 
Three different groups of organoselenium compounds have been employed to evaluate their efficacy 
as ABCB1 efflux pump modulating agents. These groups include 5-arylhydantoin derivatives (Group 
A), piperazine derivatives (Group B), and 1,3,5-triazine derivatives (Group C). As a result, 13 new 
compounds have been synthesized. The biological screening included the evaluation of the efflux 
pump inhibition effect, cytotoxicity, and antiproliferative properties, have been performed. The in 
vitro ADMET (absorption, distribution, metabolism, elimination, and toxicity) studies for selected 





Figure 9: General structures of the ABCB1 efflux pump modulating agents 
 
4.4. Biological evaluation of phenylselenoether-hydantoin hybrids 
As discussed before, the hydantoin ring has a unique structure with two reactive nitrogen centres 
toward electrophiles. N-3H position is more reactive toward electrophiles. After the alkylation of N-
3H, the Se-alkylation on N-1H is possible with high yield and purity. From a biological point of view, 
hydantoin-containing compounds display a spectrum of biological activities, i.e., anticancer (110, 
111), antimicrobial (112), antibiotic (113), androgen receptor modulators(114), P-glycoprotein efflux 
pump inhibitors (102), and 5-HT6 serotonin receptor ligands with anti-depressive-like, anxiolytic and 
antiobesity action in vivo (107).  
Regarding our work, the hydantoin derivatives (Group A) exhibit the highest ABCB1 inhibitory 
activity, which is up to 2.6-fold more than the reference drug verapamil. They also display significant 
ABCB1 substrate potency, which has been significantly higher than that of reference drug verapamil 
in Pgp ATPase assay. Moreover, this group demonstrates significant cytotoxic and antiproliferative 
properties in the MDR cancer cells of T-lymphoma. 
Interestingly, the length of the linker and the substitution at the hydantoin ring is of considerable 
importance. The hydantoin derivatives represent the highest lipophilicity values (3.82-6.05). The data 
has been gained employing the standard RP-TLC method, proving the importance of the lipophilicity 
on the ABCB1 inhibition effect. The highest activity has been observed for 5,5-diphenylhydantoin 
(compound 6) with the most extended carbon linker (C6), log(p)= 6.05.  
Remarkably, Spengler et al. (115) and Żesławska et al. (102) have already reported that both 5,5-
diphenylhydantoin and 5-spirofluorenehydantoin moieties combined with aryl piperazine inhibit 
ABCB1. Nevertheless, this combination did not exhibit any cytotoxic or antiproliferative activity 
against cancer cells (T-lymphoma) pump modulation activity (102, 115, 116). Replacing aryl 
piperazine with phenylselenoether, however, enhanced the cytotoxic and antiproliferative activities.  
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Piperazine is an imperative nitrogen heterocycle which has been found in three families of 
pharmaceuticals: fluoroquinolone family of antibiotics, antihistamine drugs containing cyclizine 
cores, and the homologous blood pressure medications, prazosin, terazosin, and doxazosin.  
In general, piperazine and its derivatives display numerous biological activities, including anticancer 
properties (117), antituberculosis effect (118), serotoninergic receptors affinity (119), and 
antiarrhythmic properties (120). Furthermore, they can be considered as excellent replacements for 
other nucleophiles to improve the overall pharmacological and drug-ability of the molecules. Since 
2010, about 50 patents containing piperazine moiety have been presented. Piperazine core provides 
two secondary nitrogen atoms, which increase their solubility in water and hence bioavailability. As 
a result, the piperazine core can be employed as a subunit in drug design (121, 122). In our work, we 
employed these properties to produce hydrochloride form of the piperazine compounds to increase 
water solubility.  
Piperazine phenylseleno-ethers (Group B) provide less efflux pump inhibition than Group A. The 
structure-activity relationship reveals a variation in both ABCB1-inhibitory and anticancer properties 
correlated to the changing of the substitutions at the N-piperazine. These substitutions include 
aromatic, alkyl, and ester moieties, which in turn influence the hydrophobic properties of the resulting 
compounds, in the following order: 3,4-diCl-Ph (11)> 4-F-Ph (10)> Ph (8)> 2-MeO-Ph (9)> Me (12)> 
EtOCO (13). The most hydrophobic 3,4-dichlorophenyl substituted compound (11) exhibits the 
highest efflux pump modulatory (fluorescence activity ratio FAR = 2.27 at 2 mM), cytotoxic (The 
half-maximal inhibitory concentration IC50= 3.50 mM) and anti-proliferative (IC50= 3.66 mM) 
activities.  
Our results confirm that the aromatic ring, combined with positive ionizable nitrogen of piperazine, 
conforms with the structural requirements of binding pockets found in various protein targets, which 
play essential roles in mammal tissues. Recent evidence indicates their anticancer properties (117). 
More electron-donating substitutions on the aromatic ring provide more cytotoxic and 
antiproliferative effects in sensitive parental (PAR) and resistant (MDR) mouse T-lymphoma cell 
lines. Compound 11 exhibits corresponding or even slightly stronger antiproliferative properties than 
those of hydantoin derivatives 5 and 7. 
Finally, the compounds belonging to the group of triazine phenylseleno-ethers (14-17, group C) are 
inactive. In this group, only dimethyl-branched derivative 17 displays notable antiproliferative 
potential in MDR T-lymphoma (IC50= 8.28 mM). These results show clearly that the triazine ring is 
not a suitable candidate for ABCB1 efflux pump inhibition. It is also confirming the selectivity of 
this moiety for the application for new 5-HT6R ligands, which is proved in Article 2.  
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Overall, the selenoether linker is vital for the cytotoxic and antiproliferative properties of hydantoin 
and piperazine. Furthermore, the length of the carbon linker also plays a significant role in biological 
activities. The activity decreases significantly, moving from the most active hydantoin derivative 6, 
with C6-linker, to the compounds with C4-linker (5 and 7) and C3-linker of phenylpiperazine 
derivatives. The same pattern has also been observed for group C. Yet, the exact role of selenium in 
this activity is still not clear and needs more investigations. Moreover, the role of chalcogens (oxygen, 
sulfur, and selenium) and their related anti- or pro-oxidant activity should be studied to clarify the 





















The present study has described the synthesis and biological evaluation of three families of new potent 
compounds, arylhydantoin derivatives, phenyl piperazine selenoether, and 1,3,5-triazine derivatives. 
Comprehensive studies, i.e., design, synthesis, in vitro ADMET-screening, and biological evaluation, 
including detailed insight into cellular mechanisms of anticancer activity and in-depth SAR analysis, 
have been performed. 
Among the various series of compounds that have been prepared as a part of this study, the hydantoin 
selenoether derivatives represent the most promising group of compounds. Hydantoin selenoether 
significantly inhibited the crucial tumor MDR mechanism of ABCB1-efflux pump in mouse T-
lymphoma cell line transfected with the human MDR1 gene, which codes for the ABC transporter 
ABCB, even better than the reference inhibitor verapamil. Besides, hydantoin and phenylpiperazine-
selenoethers exhibited excellent cytotoxic and antiproliferative activities in both sensitive (PAR) and 
resistant (MDR) mouse T-lymphoma cell lines. The promising antiproliferative activity of the 
hydantoins has also been confirmed in non-lymphocytic cancer cells, i.e., neuroblastoma, suggesting 
a therapeutically promising broader spectrum of anticancer potency for this family.  
On the other hand, the seleniumether- triazine moiety has been employed to synthesize the first novel 
organo-selenium compound for 5-HT6 receptors.  
Considering lines of evidence indicating antidepressive, precognitive, and neuroprotective roles of 
selenides, the organic selenium compounds 22 and 23 (Article 2) represent an excellent starting point 
for new chemical modifications in the search for successful CNS-seleno agents acting via the 5-HT6 
receptor.  
In addition to a wide range of pharmacomodulation possibilities are also possible. These compounds 
can be considered suitable novel lead structures for further chemical modifications in the hunt for 
highly potent and selective 5-HT6R antagonists. Moreover, phenyl chalcogen-nitrogen heterocyclic 
derivatives may serve as new promising alternatives in search of 5-HT6R agents. This unique structure 
differs remarkably from the conventional sulfone and indole motifs. It may form a basis for 
advancement in searching for new therapies of the CNS diseases related to this exceptional serotonin 
GPCR. 
In conclusion, this study describes the synthesis of novel 5-HT6R ligands and ABCB1 efflux pump 
modulating agents. These compounds may serve as new lead structures for further 





1. Guillaume Maroisa ABaWL. Population aging, migration, and productivity in Europe. Proceedings of 
the National Academy of Sciences 2020;117(14):7690–5. 
2. Bonomo SAaRA. Taking stock of infections and antibiotic resistance in the elderly and long-term care 
facilities: a survey of existingand upcoming challenges. European Journal of Microbiology and Immunology 
2011;1(3):190-7. 
3. V.Belikov Aloop. Age-related diseases as vicious cycles. Ageing Research Reviews. 2019;49:11-26. 
4. collaborators NC. NCD Countdown 2030: worldwide trends in noncommunicable disease mortality 
and progress towards Sustainable Development Goal target 3.4. THE LANCET. 2018;392(10152):1072-88. 
5. Noncommunicable diseases country profiles 2018 [database on the Internet]. 2018 [cited September 
2020]. Available from: https://www.who.int/nmh/publications/ncd-profiles-2018/en/. 
6. Barron EJaJ. Age-Related Diseases and Clinical and Public Health implications for the 85 Years Old 
and Over Population. Frontiers in Public Health. 2017;5:1-7. 
7. Jennifer E. DeVoe LSW, and George E. Fryer Jr. Patient Age Influences Perceptions About Health 
Care Communication. Family medicine. 2009;41(2):126-33. 
8. Causes of death by chapters of the ICD-10 and gender. Wiesbaden, Germany: Statistisches Bundesamt 
(Federal Statistical Office); 2020 [updated 18 May 2020; cited 2020 18 May 2020]; Available from: 
https://www.destatis.de/EN/Themes/Society-Environment/Health/Causes-Death/Tables/number-of-
death.html;jsessionid=671FAFF1226AE73156041C767F1C90A8.internet8712. 
9. Orden JLaKAV. Sadness and Worry in Older Adults: Differentiating Psychiatric Illness from 
Normative Distress. The Medical clinics of North America. 2020;104(5):843-54. 
10. Ryan D McMahan DEB, Christine S Ritchie, Chengshi Jin, Ying Shi, Daniel David, Evan J Walker, 
Victoria L Tang and Rebecca L Sudore. Anxious, Depressed, and Planning for the Future: Advance Care 
Planning in Diverse Older Adults. Journal of the American Geriatrics Society. 2020:1-5. 
11. Pshuk OOBaNG. Age and gender features of depressive and anxiety symptomatics of depressive 
disorders. Wiadomości lekarskie 2020;73(7):1476-9. 
12. Judith Dams ER, Regina Steil, Babette Renneberg, Rita Rosner and Hans-Helmut König. Health-
Related Quality of Life and Costs of Posttraumatic Stress Disorder in Adolescents and Young Adults in 
Germany. Frontiers in psychiatry. 2020;11(697):1-8. 
13. Hyung-Mun Yun K-RP, Eun-Cheol Kim, Sanghyeon Kim and Jin Tae Hong. Serotonin 6 receptor 
controls alzheimer’s disease and depression. Oncotarget. 2015;6:26716-28. 
14. Anna Więckowska TW, Justyna Godyń, Adam Bucki, Monika Marcinkowska, Agata Siwek, 
Krzysztof Więckowski, Paula Zaręba, Damijan Knez, Monika Głuch-Lutwin, Grzegorz Kazek, Gniewomir 
Latacz, Kamil Mika, Marcin Kołaczkowski, Jan Korabecny, Ondrej Soukup, Marketa Benkova, Katarzyna 
Kieć-Kononowicz, Stanislav Gobec and Barbara Malawska. Novel Multitarget-Directed Ligands Aiming at 
Symptoms and Causes of Alzheimer’s Disease. ACS Chemical Neuroscience. 2018;9(5):1195-214. 
15. Magdalena Kotańska KL, Adam Bucki, Monika Marcinkowska, Joanna Śniecikowska and Marcin 
Kołaczkowski. Idalopirdine, a selective 5-HT 6 receptor antagonist, reduces food intake and body weight in a 
model of excessive eating. Metabolic brain disease. 2018;33(3):733-40. 
16. Tas DCaD. Cancer in the elderly. North Clin Istanbul 2015;2(1):73-80. 
17. Estapé T. Cancer in the Elderly: Challenges and Barriers. Asia‑Pacific Journal of Oncology Nursing. 
201;5(1):40-2. 
18. Wesam Ali GS, Annamaria Kincses, Marta Nove, Cecilia Battistelli, Gniewomir Latacz, Małgorzata 
Starek, Monika Dabrowska, Ewelina Honkisz-Orzechowska, Annalisa Romanelli, Manuela Monica Rasile, 
Ewa Szymanska, Claus Jacob, Clemens Zwergel and Jadwiga Handzlik. Discovery of phenylselenoether-
hydantoin hybrids as ABCB1 efflux pump modulating agents with cytotoxic and antiproliferative actions in 
resistant T-lymphoma. European Journal of Medicinal Chemistry. 2020;200:1-17. 
19. Nicholas M.Barnes TS. A review of central 5-HT receptors and their function. Neuropharmacology. 
1999;38(8):1083-152. 
20. Sara Fidalgo DKIaSHW. Serotonin: from top to bottom. Biogerontology. 2013;14(1):21-45. 
21. Lorke GAPaDE. The Role of Serotonin in Singultus: A Review. Frontiers in Neuroscience. 
2020;14(629):1-11. 




23. Hyung-Mun Yun HR. The Serotonin-6 Receptor as a Novel Therapeutic Target. Experimental 
Neurobiology. 2011;20(4):159-68. 
24. Ruth Kohen MAM, Naseem Khan, Teresa Druck, Kay Huebner, Jean E. Lachowicz, Herbert Y. 
Meltzer, David R. Sibley, Bryan L. Roth, Mark W. Hamblin. Cloning, Characterization, and Chromosomal 
Localization of a Human 5‐HT6 Serotonin Receptor. Journal of neurochemistry. 1996;66(1):47-56. 
25. Marie L. Woolley CAM, Kevin Fone. 5-ht6 receptors. Current drug targets CNS and neurological 
disorders. 2004;3(1):59-79. 
26. Magdalena Jastrzębska-Więsek AS, Anna Partyka, Marcin Kołaczkowski, Maria Walczak, Magdalena 
Smolik, Gniewomir Latacz, Katarzyna Kieć-Kononowicz, Anna Wesołowska. Study on the effect of 
EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants 
in rats. Naunyn-Schmiedeberg's Arch Pharmacol. 2018;391:37-49. 
27. Lili Hu BW, Yan Zhang. Serotonin 5-HT6 receptors affect cognition in a mouse model of Alzheimer’s 
disease by regulating cilia function. Alzheimer's Research & Therapy. 2017;9(76):1-17. 
28. Marcin Kołaczkowski MM, Adam Bucki, Joanna Sniecikowska, Maciej Pawłowski, Grzegorz Kazek, 
Agata Siwek, Magdalena Jastrzebska-Wiesek, Anna Partyka, Anna Wasik, Anna Wesołowska,, Paweł 
Mierzejewski PB. Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and 
psychological symptoms of dementia. European Journal of Medicinal Chemistry. 2015;92:221-35. 
29. Magdalena Kotańska KL, Adam Bucki, Monika Marcinkowska, Joanna Śniecikowska, Marcin 
Kołaczkowski. Idalopirdine, a selective 5-HT6 receptor antagonist, reduces food intake and body weight in a 
model of excessive eating. Metabolic Brain Disease. 2018:1-8. 
30. Jörg Holenz PJP, Jose´ Luis Dı´az, Ramon Merce, Xavier Codony, Helmut Buschmann. Medicinal 
chemistry strategies to 5-HT6 receptor ligands as potential cognitive enhancers and antiobesity agents. Drug 
Discovery Today. 2006;11(7-8):283-99. 
31. Andrew J Sleight FGB, Michael Bös, Bernard Levet-Trafit, Claus Riemer, Anne Bourson. 
Characterization of Ro 04-6790 and Ro 63-0563: potent and selective antagonists at human and rat 5-HT6 
receptors. British journal of pharmacology. 1998;124(3):556-62. 
32. Charles-Henry Fabritius UP, Josef Messinger, Raymond Horvath, Harri Salo, Michał Gałe˛zowski, 
Mariusz Galek, Klaudia Stefan´ska, Joanna Szeremeta-Spisak, Marta Olszak-Płachta, Anna Buda, Justyna 
Adamczyk, Marcin Król, Peteris Prusis, Magdalena Sieprawska-Lupa, Maciej Mikulski, Katja Kuokkanen, 
Hugh Chapman, Radosław Obuchowicz, Timo Korjamo, Niina Jalava, Mateusz Nowak 1-Sulfonyl-6-
Piperazinyl-7-Azaindoles as potent and pseudoselective 5-HT6 receptor antagonists. Bioorganic & Medicinal 
Chemistry Letters. 2016;26:2610–5. 
33. Annamaria Lubelska GL, Magdalena Jastrzebska-Wiesek, Magdalena Kotanska, Rafał Kurczab, Anna 
Partyka, Małgorzata Anna Mar´c , DariaWilczy ska, Agata Doroz-Płonka, Dorota Ła˙zewsk , Anna 
Wesołowska, Katarzyna Kie´c-Kononowicz, Jadwiga Handzlik. Are the Hydantoin-1,3,5-triazine 5-HT6R 
Ligands a Hope to a Find New Procognitive and Anti-Obesity Drug? Considerations Based on Primary In Vivo 
Assays and ADME-Tox Profile In Vitro. Molecules. 2019;24(4472):1-24. 
34. Ramakrishna Nirogi RA, Vijay Benade, Rajesh Medapati, Pradeep Jayarajan, Gopinadh Bhyrapuneni, 
NageswaraRao Muddana, Venkat Mekala, Ramkumar Subramanian, Anil Shinde, Ramasastry Kambhampati, 
Venkat Jasti. SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, 
behavioral, and neurochemical characterization. Behavioural pharmacology. 2019 30(1):16-35. 
35. María L. López-Rodríguez BB, Tania de la Fuente, Arantxa Sanz, Leonardo Pardo, Mercedes 
Campillo. A Three-Dimensional Pharmacophore Model for 5-Hydroxytryptamine6 (5-HT6) Receptor 
Antagonists. Journal of Medicinal Chemistry. 2005;48(13):4216-9. 
36. Dorota Ła_zewska RK, Małgorzata Wiecek, Katarzyna Kaminska, Grzegorz Satała, Magdalena 
Jastrzebska-Wiesek, Anna Partyka, Andrzej J. Bojarski, Anna Wesołowska, Katarzyna Kiec-Kononowicz, 
Jadwiga Handzlik. The computer-aided discovery of novel family of the 5-HT6 serotonin receptor ligands 
among derivatives of 4-benzyl-1,3,5-triazine. European Journal of Medicinal Chemistry. 2017;135:117-24. 
37. David Benton RC. Selenium supplementation improves mood in a double-blind crossover trial. 
Psychopharmacology. 1990;102:549-50. 
38. Wayne Chris Hawkes LH. Effects of Dietary Selenium on Mood in Healthy Men Living in a Metabolic 
Research Unit. Society of Biological Psychiatry. 1996;39:121-8. 
39. Rayman MP. The importance of selenium to human health. THE LANCET. 2000;356:233-41. 
40. Ulrich Schweizer AUB, Josef Kohrle, Robert Nitsch, Nicolai E. Savaskan. Selenium and brain 
function: a poorly recognized liaison. Brain Research Reviews 45. 2004;45:164- 78. 
87 
 
41. Solovyev ND. Importance of selenium and selenoprotein for brain function: from antioxidant 
protection to neuronal signalling. Journal of Inorganic Biochemistry. 2015;153:1-12. 
42. Eva K. Wirth MC, Jochen Winterer, Christian Wozny, Bradley A. Carlson, Stephan Roth, Dietmar 
Schmitz, Georg W. Bornkamm, Vincenzo Coppola, Lino Tessarollo, Lutz Schomburg, Josef Kohrle, Dolph L. 
Hatfield, Ulrich Schweizer. Neuronal selenoprotein expression is required for interneuron development and 
prevents seizures and neurodegeneration. The FASEB Journal. 2010;24(3):844-52. 
43. Anja Bräuer NS. Molecular Actions of Selenium in the Brain: Neuroprotective Mechanisms of an 
Essential Trace Element. Reviews in the neurosciences. 2004;15(1):19-32. 
44. Carla Elena Sartori Oliveira BMG, Benhur Godoi,Gilson Zenin, Cristina Wayne Nogueira. The 
antidepressant-likeactionofasimpleselenium-containingmolecule, methyl phenylselenide,inmice. European 
Journal of Pharmacology. 2012;690:119-23. 
45. César Augusto Brüning ACGS, Bibiana Mozzaquatro Gai, Gilson Zeni, Cristina Wayne Nogueira. 
Antidepressant-like effect of m-trifluoromethyl-diphenyl diselenide in the mouse forced swimming test 
involves opioid and serotonergic systems. European Journal of Pharmacology. 2011;658:145-9. 
46. Bibiana Mozzaquatro Gai CFB, César Augusto Brüning, Vanessa Angonesi Zborowski, André Luiz 
Stein, Gilson Zeni, Cristina Wayne Nogueira. Depression-related behavior and mechanical allodynia are 
blocked by 3-(4-fluorophenylselenyl)-2,5-diphenylselenophene in a mouse model of neuropathic pain induced 
by partial sciatic nerve ligation. Neuropharmacology. 2014;79:580-9. 
47. Bibiana M. Gay MP, André L. Stein, Cristina W. Nogueira. Antidepressant-like pharmacological 
profile of 3-(4-fluorophenylselenyl)-2,5-diphenylselenophene: Involvement of serotonergic system. 
Neuropharmacology. 2010;59:172-9. 
48. Cristiano R. Jesse EAW, Cristiani F. Bortolatto, Cristina W. Nogueira. Evidence for the involvement 
of the serotonergic 5-HT2A/C and 5-HT3 receptors in the antidepressant-like effect caused by oral 
administration of bis selenide in mice. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 
2010;34:294–302. 
49. Franciele Donato MGdG, André Tiago Rossito Goesa, Natália Seus, Diego Alves, Cristiano Ricardo 
Jesse, Lucielli Savegnagod, more S. Involvement of the dopaminergic and serotonergic systems in the 
antidepressant-like effect caused by 4-phenyl-1-(phenylselanylmethyl)-1,2,3-triazole. Life sciences. 
2013;93((9-11)):393-400. 
50. Lucielli Savegnago CRJ, Larissa G. Pinto, Joao B.T. Rocha, Cristina W. Nogueira. Diphenyl 
diselenide attenuates acute thermal hyperalgesia and persistent inflammatory and neuropathic pain behavior in 
mice. B R A I N  R E S E A R C H. 2007;1175:54-9. 
51. Lucielli Savegnago CRJ, Larissa Garcia Pinto, Joao Batista Teixeira Rocha, Daniela Aline Barancelli, 
Cristina Wayne Nogueira, Gilson Zeni. Diphenyl diselenide exerts antidepressant-like and anxiolytic-like 
effects in mice: Involvement of L-arginine-nitric oxide-soluble guanylate cyclase pathway in its 
antidepressant-like action. Pharmacology, Biochemistry and Behavior. 2008;88:418-26. 
52. Lucielli Savegnago CRJ, Larissa G. Pinto, Joao B.T. Rocha, Cristina W. Nogueira, Gilson Zeni. 
Monoaminergic agents modulate antidepressant-like effect caused by diphenyl diselenide in rats. Progress in 
Neuro-Psychopharmacology & Biological Psychiatry. 2007;31:1261-9. 
53. Viviane Glaser BM, Ariana Schmitz, Alcir Luiz Dafré, Evelise Maria Nazari, Yara Maria Rauh Müller, 
Luciane Feksa, Marcos Raniel Straliottoa, Andreza Fabro de Bem, Marcelo Farina, João Batista Teixeira da 
Rocha, Alexandra Latini. Protective effects of diphenyl diselenide in a mouse model of brain toxicity. 
Chemico-Biological Interactions. 2013;206:18-26. 
54. Hyoung-Chun Kim W-KJ, Dong-Young Choi, Doo-Hyun Im, Eun-Joo Shin, Jeong-Hye Suh, Robert 
A. Floyd, Guoying Bing. Protection of methamphetamine nigrostriatal toxicity by dietary selenium. Brain 
Research. 1999;851:76-86. 
55. Hyoung-Chun Kim W-KJ, Eun-Joo Shin, Guoying Bing. Selenium deficiency potentiates 
methamphetamine-induced nigral neuronal loss; comparison with MPTP model. Brain Research 862. 
2000;862:247-52. 
56. Barbara R. Cardoso BRR, Charles B. Malpas, Lucy Vivash, Sila Genc, Michael M. Saling, Patricia 
Desmond, Christopher Steward, Rodney J. Hicks, Jason Callahan, Amy Brodtmann, Steven Collins, Stephen 
Macfarlana, Niall M Corcoran, Christopher M. Hovens, Dennis Velakoulis, Terence J. O’Brien, Dominic J. 
Hare, Ashley I. Bush. Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central 




57. Ewa Kędzierska JD, Ewa Poleszak, Jolanta H. Kotlińska. Antidepressant and anxiolytic-like activity 
of sodium selenite after acute treatment in mice. Pharmacological reports. 2017;69(2):276-80. 
58. Jamal Rafique SS, Rômulo Faria Santos Canto, Tiago Elias Allievi Frizon, Waseem Hassan, Emily 
Pansera Waczuk, Maryam Jan, Davi Fernando Back, João Batista Teixeira Da Rocha, Antonio Luiz Braga 
Synthesis and Biological Evaluation of 2-Picolylamide-Based Diselenides with Non-Bonded Interactions. 
Molecules. 2015;20(6):10095-109. 
59. Bhaskar J. Bhuyana GM. Synthesis, characterization and antioxidant activity of angiotensin converting 
enzyme inhibitor. Organic & Biomolecular Chemistry. 2011;9(5):1356-65. 
60. Bhaskar J. Bhuyana GM. Antioxidant activity of peptide-based angiotensin converting enzyme 
inhibitors. Organic & Biomolecular Chemistry. 2012;10(11):2237-47. 
61. Liwei Zhao JL, Yiquan Li, Jianwen Liu, Thomas Wirth, Zhong Li. Selenium-containing 
naphthalimides as anticancer agents: design, synthesis and bioactivity. Bioorganic & Medicinal Chemistry. 
2012;20(8):2558-63. 
62. Kim C LJ, Park MS. Synthesis of new diorganodiselenides from organic halides: their antiproliferative 
effects against human breast cancer MCF-7 cells. Archives of Pharmacal Research. 2015 38(5):659-65. 
63. Eduardo H. G. da Cruz MAS, Guilherme A. M. Jardim, Jarbas M. Resende, Bruno C. Cavalcanti, Igor 
S. Bomfim, Claudia Pessoa, Carlos A. de Simone, Giancarlo V. Botteselle, Antonio L. Braga, Divya K. Nair, 
Irishi N. N. Namboothiri, David A. Boothman,  Eufrânio N. da Silva Júnior. Synthesis and antitumor activity 
of selenium-containing quinone-based triazoles possessing two redox centres, and their mechanistic insights. 
European Journal of Medicinal Chemistry. 2016;122:1-16. 
64. Pramod K. Sahu TU, Jinha Yu, Akshata Nayak, Gyudong Kim, Minsoo Noh, Jae-Young Lee, Dae-
Duk Kim, Lak Shin Jeong. Selenoacyclovir and Selenoganciclovir: Discovery of a New Template for Antiviral 
Agents. Journal of Medicinal Chemistry. 2015;58(21):8734-8. 
65. Jozef Salon JJ, Jia Sheng, Oksana O. Gerlits, and Zhen Huang. Derivatization of DNAs with selenium 
at 6-position of guanine for function and crystal structure studies. Nucleic acids research. 2008;36(22):7009–
18. 
66. Huiyan Sun JS, Abdalla E. A. Hassan, Sibo Jiang, Jianhua Gan, Zhen Huang. Novel RNA base pair 
with higher specificity using single selenium atom. Nucleic acids research. 2012;40(11):5171-9. 
67. Stefania Nobili IL, Barbara Giglioni and Enrico Mini. Pharmacological strategies for overcoming 
multidrug resistance. Current Drug Targets. 2006;7(7):861-79. 
68. Baguley BC. Multiple Drug Resistance Mechanisms in Cancer. Molecular Biotechnology. 
2010;43:308–16. 
69. Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc). 
2000;65(1):95-106. 
70. Wanjiru Muriithi LWM, Carlos Pilotto Heming, Juliana Lima Echevarria, Atunga Nyachieo, Paulo 
Niemeyer Filho and Vivaldo Moura Neto. ABC transporters and the hallmarks of cancer: roles in cancer 
aggressiveness beyond multidrug resistance. Cancer biology & medicine. 2020;17(2):253-69. 
71. Karol Bukowski MKaRK. Mechanisms of Multidrug Resistance in Cancer Chemotherapy. 
International Journal of Molecular Sciences. 2020;21(9):1-24. 
72. Christopher F. Higgins IDH, George P. C. Salmond, Deborah R. Gill, J. Allan Downie, Ian J. Evans, 
I. Barry Holland, Lindsay Gray, Scott D. Buckel, Alexander W. Bell, Mark A. Hermodson A family of related 
ATP-binding subunits coupled to many distinct biological processes in bacteria. Nature. 1986;323(6087):448-
50. 
73. Pedersen PL. Transport ATPases into the year 2008: a brief overview related to types, structures, 
functions and roles in health and disease. Journal of bioenergetics and biomembranes. 2007;39(5-6):349-55. 
74. Kentaro Tomii MK. A Comparative Analysis of ABC Transporters in Complete Microbial Genomes. 
Genome research. 1998;8:1048-59. 
75. Wilkens S. Structure and mechanism of ABC transporters. F1000Prime Reports. 2015;7(14):1-9. 
76. NatashaCant NP, Robert C.Ford. CFTR structure and cystic fibrosis. The International Journal of 
Biochemistry & Cell Biology. 2014;52:15-25. 
77. Cédric Orelle FJDA, Michael L. Oldham, Arnaud Orelle, Theodore E. Wiley, Jue Chen, Amy L. 
Davidson. Dynamics of alpha-helical subdomain rotation in the intact maltose ATP-binding cassette 
transporter. Proceedings of the National Academy of Sciences of the United States of America. 2010 
107(47):20293-8. 
78. Frederick R. Blattner GP, Craig A. Bloch, Nicole T. Perna, Valerie Burland, Monica Riley, Julio 
Collado-Vides, Jeremy D. Glasner, Christopher K. Rode, George F. Mayhew, Jason Gregor, Nelson Wayne 
89 
 
Davis, Heather A. Kirkpatrick, Michael A. Goeden, Debra J. Rose, Bob Mau, Ying Shao. The complete 
genome sequence of Escherichia coli K-12. Science. 1997;277(5331):1453-62. 
79. Vasilis Vasiliou KV, Daniel W Neber. Human ATP-binding cassette (ABC) transporter family. 
Human genomics. 2009;3(3):281-90. 
80. I.Barry Holland MB. ABC-ATPases, adaptable energy generators fuelling transmembrane movement 
of a variety of molecules in organisms from bacteria to humans. Journal of Molecular Biology. 
1999;293(2):381-99. 
81. Michael M. Gottesman TF, Susan E. Bates Multidrug resistance in cancer: role of ATP-dependent 
transporters. Nature Reviews Cancer. 2002;2(1):48-58. 
82. Kazuhiro Katayama KN, Yoshikazu Sugimoto. Regulations of P-Glycoprotein/ABCB1/MDR1 in 
Human Cancer Cells. New Journal of Science. 2014:1-10. 
83. Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. 
PHARMACOGENOMICS. 2008;9(1):105-27. 
84. Frank Thévenod JMF, Alice D. Katsen, Ingeborg A. Hause. Up-regulation of multidrug resistance P-
glycoprotein via nuclear factor-kappaB activation protects kidney proximal tubule cells from cadmium- and 
reactive oxygen species-induced apoptosis. The Journal of biological chemistry. 2000;275(3):1887-96. 
85. Lyrialle W. Han CG, Qingcheng Mao. An update on expression and function of p-gp/abcb1 and 
bcrp/abcg2 in the placenta and fetus. Expert Opinion on Drug Metabolism & Toxicology. 2018;14(8):817–29. 
86. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends in pharmacological 
sciences. 2004;25(8):423-9. 
87. Angela Doran RSO, Bill J. Smith, Natilie A. Hosea, Stacey Becker, Ernesto Callegari, Cuiping Chen, 
Xi Chen, Edna Choo, Julie Cianfrogna, Loretta M. Cox, John P. Gibbs, Megan A. Gibbs, Heather Hatch, 
Cornelis E.C.A. Hop, Ilana N. Kasman, Jennifer LaPerle, JianHua Liu, Xingrong Liu, Michael Logman, Debra 
Maclin, Frank M. Nedza, Frederick Nelson, Emily Olson, Sandhya Rahematpura, David Raunig, Sabrinia 
Rogers, Kari Schmidt, Douglas K. Spracklin, Mark Szewc, Matthew Troutman, Elaine Tseng, Meihua Tu, 
Jeffrey W. Van Deusen, Karthik Venkatakrishnan, Gary Walens, Ellen Q. Wang, Diane Wong, Adam S. 
Yasgar, Chenghong Zhang. The impact of P-glycoprotein on the disposition of drugs targeted for indications 
of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug metabolism and 
disposition: the biological fate of chemicals. 2005;33(1):165-74. 
88. Edmund Capparelli NR, Mark Mirochnick. Pharmacotherapy of perinatal HIV. Seminars in fetal & 
neonatal medicine. 2005;10(2):161-75. 
89. Jingwei Zhang FZ, Xiaolan Wu, Xiaoxuan Zhang, Yuancheng Chen, Beth S Zha, Fang Niu, Meng Lu, 
Gang Hao, Yuan Sun, Jianguo Sun, Ying Peng, Guangji Wang. Cellular pharmacokinetic mechanisms of 
adriamycin resistance and its modulation by 20(S)-ginsenoside Rh2 in MCF-7/Adr cells. British journal of 
pharmacology. 2012;165(1):120-34. 
90. Sen Yu YY, Li Liu, Xinting Wang, Shousi Lu, Yan Liang, Xiaodong Liu, Lin Xie, Guangji Wang. 
Increased plasma exposures of five protoberberine alkaloids from Coptidis Rhizoma in streptozotocin-induced 
diabetic rats: is P-GP involved? Planta medica. 2010;76(9):876-81. 
91. Derek Spieler CN, Tamara Namendorf, Manfred Uhr. abcb1ab p-glycoprotein is involved in the uptake 
of the novel antidepressantvortioxetine into the brain of mice. Journal of Psychiatric Research. 2019; 109:48-
51. 
92. Stephan Ruetz PG. Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell. 
1994;77(7):1071-81. 
93. Antonius E. van Herwaarden EW, Gracia Merino, Johan W. Jonker, Hilde Rosing, Jos H. Beijnen, 
Alfred H. Schinke. Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin 
B2) into milk. Molecular and cellular biology. 2007;27(4):1247-53. 
94. Dirk M. Hermann CLB. Implications of ATP-binding cassette transporters for brain 
pharmacotherapies. Trends in pharmacological sciences. 2007;28(3):128-34. 
95. Elaine M.Leslie RGD, Susan P.C.Cole. Multidrug resistance proteins: role of P-glycoprotein, MRP1, 
MRP2, and BCRP (ABCG2) in tissue defense. Toxicology and applied pharmacology. 2005;204(3):216-37. 
96. Jacques Robert CJ. Multidrug Resistance Reversal Agents. Journal of Medicinal Chemistry. 
2003;46(23):4805-17. 
97. Ahcène Boumendjel HB, Cortay  Doriane Trompier,  Thomas Perrotton,  Attilio Di Pietro. Anticancer 
multidrug resistance mediated by MRP1: recent advances in the discovery of reversal agents. Medicinal 
research reviews. 2005;25(4):453-72. 
90 
 
98. Yoshikazu Sugimoto ST, Etsuko Ishikawa,  Junko Mitsuhashi. Breast cancer resistance protein: 
molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics. Cancer science. 
2005;96(8):457-65. 
99. Yilin Fan XL. Alterations in Expression and Function of ABC Family Transporters at Blood-Brain 
Barrier under Liver Failure and Their Clinical Significances. Pharmaceutics. 2018;10(3):1-14. 
100. Edward X She ZH. A novel piperazine derivative potently induces caspase-dependent apoptosis of 
cancer cells via inhibition of multiple cancer signaling pathways. American journal of translational research. 
2013;5(6):622-33. 
101. Bo Wang BZ, Zhe-Sheng Chen, Lu-Ping Pang, Yuan-Di Zhao, Qian Guo, Xin-Hui Zhang, Ying Liu, 
Guang-Yao Liu, Hao-Zhang, Xin-Yuan Zhang, Li-Ying Ma, Hong-Min Liu. Exploration of 1,2,3-triazole-
pyrimidine hybrids as potent reversal agents against ABCB1-mediated multidrug resistance. European Journal 
of Medicinal Chemistry. 2018;143:1535-42. 
102. Ewa Żesławska AK, Gabriella Spengler, Wojciech Nitek, Waldemar Tejchmana, Jadwiga Handzlik. 
Pharmacophoric features for a very potent 5-spirofluorenehydantoin inhibitor of cancer efflux pump ABCB1, 
based on X-ray analysis. Chemical biology & drug design. 2019;93(5):844-53. 
103. Lei Jiao QQ, Baomin Liu, Tianxiao Zhao, Wenlong Huang, Hai Qian. Design, synthesis and evaluation 
of novel triazole core based P-glycoprotein-mediated multidrug resistance reversal agents. Bioorganic & 
Medicinal Chemistry. 2014;22:6857-66. 
104. Ewa Zesławska AK, Gabriella Spengler, Wojciech Nitek, Karolina Wyrzuc, Katarzyna Kiec´-
Kononowicz, Jadwiga Handzlik. The 5-aromatic hydantoin-3-acetate derivatives as inhibitors of the tumour 
multidrug resistance efflux pump P-glycoprotein (ABCB1): Synthesis, crystallographic and biological studies. 
Bioorganic & Medicinal Chemistry. 2016;24:2815-22. 
105. Chao Guo FL, Jie Qi, Jiahui Ma, Shiqi Lin, Caiyun Zhang, Qian Zhang, Hangyu Zhang, Rong Lu, and 
Xia Li. A Novel Synthetic Dihydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1- and ABCG2-
Mediated Multidrug Resistance in Cancer Cells. Molecules. 2018;23(3264):1-14. 
106. Avijeet Chopra AA, and Charles Giardina. Novel piperazine-based compounds inhibit microtubule 
dynamics and sensitize colon cancer cells to tumor necrosis factor-induced apoptosis. The Journal of biological 
chemistry. 2013;289(5):2978-91. 
107. Rafał Kurczab WA, Dorota Łażewska, Magdalena Kotańska, Magdalena Jastrzębska-Więsek, 
Grzegorz Satała, Małgorzata Więcek, Annamaria Lubelska, Gniewomir Latacz, Anna Partyka, Małgorzata 
Starek, Monika Dąbrowska, Anna Wesołowska, Claus Jacob, Katarzyna Kieć-Kononowicz,  Jadwiga 
Handzlik. Computer-Aided Studies for Novel Arylhydantoin 1,3,5-Triazine Derivatives as 5-HT6 Serotonin 
Receptor Ligands with Antidepressive-Like, Anxiolytic and Antiobesity Action In Vivo. Molecules. 
2018;23(10):1-26. 
108. Wesam Ali MW, Dorota Łazewska, Rafał Kurczab, Magdalena Jastrzebska-Wiesek, Grzegorz Satała, 
Katarzyna Kucwaj-Brysz, Annamaria Lubelska, Monika Głuch-Lutwin, Barbara Mordyl, Agata Siwek,, 
Muhammad Jawad Nasim AP, Sylwia Sudoł, Gniewomir Latacz, Anna Wesołowska, Katarzyna Kiec-
Kononowicz, Jadwiga Handzlik. Synthesis and computer-aided SAR studies for derivatives of phenoxyalkyl-
1,3,5-triazine as the new potent ligands for serotonin receptors 5-HT6. European Journal of Medicinal 
Chemistry. 2019;178:740-51. 
109. Yan A Ivanenkov AGM, Mark S Veselov, Nina V Chufarova, Sergey S Baranovsky and Gleb I Filkov. 
Computational Approaches to the Design of Novel 5-HT6 R Ligands. Reviews in the neurosciences. 
2014;25(3):451-67. 
110. Dana E. Rathkopf HIS. Apalutamide for the treatment of prostate cancer. Expert Review of Anticancer 
Therapy. 2018; 18(9):823-36. 
111. MaoZhang Y-R, HuanLiMing-MingLiu, YangWang. Design, synthesis, and biological evaluation of 
hydantoin bridged analogues of combretastatin A-4 as potential anticancer agents. Bioorganic & Medicinal 
Chemistry. 2017;25(24):6623-34. 
112. Shady Farah OA, Natalia Laout, Stanislav Ratner, Abraham J.Domb. Antimicrobial N-brominated 
hydantoin and uracil grafted polystyrene beads. Journal of Controlled Release. 2015;216:18-29. 
113. Ma Su DX, Peng Teng, Alekhya Nimmagadda, Chao Zhang,Timothy Odom, Annie Cao, Yong Hu, 
Jianfeng Cai. Membrane-Active Hydantoin Derivatives as Antibiotic Agents. Journal of Medicinal Chemistry. 
2017;60(20):8456-65. 
114. Xin Wang WH, Jiazhong Li. QSAR Analysis of a Series of Hydantoin-based Androgen Receptor 
Modulators and Corresponding Binding Affinities. Molecular informatics. 2019;38(8-9):1-20. 
91 
 
115. Gabriella Spengler ME, Jadwiga Handzlik, Julianna Serly, Joseph Molnár, Miguel Viveiros, 
Katarzyna Kiéc-Kononowicz and Leonard Amaral. Biological Activity of Hydantoin Derivatives on P-
glycoprotein (ABCB1) of Mouse Lymphoma Cells. Anticancer research. 2010;30(12):4867-71. 
116. Ewa Żesławska AK, Gabriella Spengler, Wojciech Nitek, Karolina Wyrzuc, Katarzyna Kieć-
Kononowicz and Jadwiga Handzlik. The 5-aromatic hydantoin-3-acetate Derivatives as Inhibitors of the 
Tumour Multidrug Resistance Efflux Pump P-glycoprotein (ABCB1): Synthesis, Crystallographic and 
Biological Studies. Bioorganic & medicinal chemistry. 2016;24(12):2815-22. 
117. Lee YB GY, Kim DJ, Ahn CH, Kong JY,  Nam-Sook Kang. Synthesis, anticancer activity and 
pharmacokinetic analysis of 1-[(substituted 2-alkoxyquinoxalin-3-yl)aminocarbonyl]-4-(hetero)arylpiperazine 
derivatives. Bioorganic & Medicinal Chemistry. 2011;20(3):1303-9. 
118. Adrian Blaser BDP, Hamish S. Sutherland, Iveta Kmentova, Scott G. Franzblau, Baojie Wan, 
Yuehong Wang, Zhenkun Ma, Andrew M. Thompson, William A. Denny. Structure-activity relationships for 
amide-, carbamate-, and urea-linked analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-
(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). Journal of Medicinal 
Chemistry. 2011;55(1):312-26. 
119. Jadwiga Handzlik AJB, Grzegorz Satala, Monika Kubacka, Bassem Sadek, Abrar Ashoor, Agata 
Siwek, Magorzata Wiecek, Katarzyna Kucwaj, Barbara Filipek, Katarzyna Kiec-Kononowicz. SAR-studies 
on the importance of aromatic ring topologies in search for selective 5-HT7 receptor ligands among 
phenylpiperazine hydantoin derivatives. European Journal of Medicinal Chemistry. 2014;78:324-39. 
120. Jadwiga Handzlik MB, Małgorzata Zygmunt, Dorota Macia, Małgorzata Dybała, Marek Bednarski, 
Barbara Filipek, Barbara Malawska, Katarzyna Kiec´-Kononowicz. Antiarrhythmic properties of 
phenylpiperazine derivatives of phenytoin with a1-adrenoceptor affinities. Bioorganic & Medicinal Chemistry. 
2012;20:2290-303. 
121. Anuj K. Rathi RS, Han-Seung Shin, Rahul V. Patel. Piperazine derivatives for therapeutic use: a patent 
review (2010-present). Expert Opinion on Therapeutic Patents. 2016;26(7):777-97. 
122. Edon Vitaku DTS, and Jon T. Njardarson. Analysis of the Structural Diversity, Substitution Patterns, 



















7. Supplementary Material 
 
7.1. Supplementary material for Publication 1: Computer-Aided Studies for Novel 
Arylhydantoin 1,3,5-Triazine Derivatives as 5-HT6 Serotonin Receptor Ligands with 



























Computer-aided studies for novel arylhydantoin 1,3,5-triazine derivatives as 5-HT6 serotonin receptor ligands 
with antidepressive-like, anxiolytic and antiobesity action in vivo 
 
 
Rafał Kurczab1†, Wesam Ali2,6†, Dorota Łażewska2, Magdalena Kotańska3, Magdalena Jastrzębska-Więsek4, Grzegorz Satała1, 
Małgorzata Więcek2, Annamaria Lubelska2, Gniewomir Latacz2, Anna Partyka4, Małgorzata Starek5, Monika Dąbrowska5, Anna 
Wesołowska4, Claus Jacob6, Katarzyna Kieć-Kononowicz2, Jadwiga Handzlik2,* 
 
  
Charcteristics of intermediates obtained before27, 29, 50-58, 63, 65 and 68-70 






SAR-studies on the importance of aromatic ring topologies in search for 
selective 5-HT7 receptor ligands among phenylpiperazine hydantoin derivatives. 
By Handzlik, Jadwiga et al 
From European Journal of Medicinal Chemistry, 78, 324-339; 2014 
29 
179409-69-9,  Aldlab Chemicals Building Blocks 
United States 
methyl 2-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)acetate 
Preparation of substituted β-keto esters as intermediates for photographic yellow 
couplers  
Yamakawa, Kazuyoshi; Sato, Tadahisa  






Safari J. and Javadian L., Montmorillonite K-10 as a catalyst in the 
synthesis of 5, 5- disubstituted hydantoins under ultrasound irradiation, J. 




Safari J. and Javadian L., Montmorillonite K-10 as a catalyst in the 
synthesis of 5, 5- disubstituted hydantoins under ultrasound irradiation, J. 




Safari J. and Javadian L., Montmorillonite K-10 as a catalyst in the 
synthesis of 5, 5- disubstituted hydantoins under ultrasound irradiation, J. 




Werbel LM, Elslager EF, Islip PJ and Closier MD, Antischistosomal 
effects of 5-(2,4,5-trichlorophenyl)hydantoin and related compounds, J 




Werbel LM, Elslager EF, Islip PJ and Closier MD, Antischistosomal 
effects of 5-(2,4,5-trichlorophenyl)hydantoin and related compounds, J 
Med Chem. 20 (1977):1569-1572. 
55 no 
(Patent) Preparation of imidazolidinedione compounds containing substituted 
carbinol moiety as LXR modulators for treatment and prevention of 
arteriosclerosis, inflammation, diabetes, etc. 
Matsuda, Takayuki; Okuda, Ayumu; Koura, Minoru; Yamaguchi, Yuki; 
Kurobuchi, Sayaka; Watanabe, Yuuichirou; Shibuya, Kimiyuki 






J. Linol and G. Coquerel, Influence of high energy milling on the kinetics of the 
polymorphic transition from the monoclinic form to the orthorhombic form of 





M. L. KeshtovA. L. RusanovN. M. Belomoina and A. K. Mikitaev, 
Improved synthesis of bis[p-(phenylethynyl)phenyl]hetarylenes, Russ 




M. L. KeshtovA. L. RusanovN. M. Belomoina and A. K. Mikitaev, 
Improved synthesis of bis[p-(phenylethynyl)phenyl]hetarylenes, Russ 
Chem Bull. 46 (1997) 1794-1796 
63 
1372008-89-3, Aurora Building Blocks, United States 
Methyl 2-(4-(2,4-dichlorophenyl)-4-methyl-2,5-
dioxoimidazolidin-1-yl)acetate 
Aurora Building Blocks 
65 
1371767-82-6, Aurora Building Blocks, United States 
Methyl 2-(4-methyl-2,5-dioxo-4-p-tolylimidazolidin-1-
yl)acetate 











23186-92-7, Atomax Chemicals Product List 
China 
5,5-bis(4-chlorophenyl)imidazolidine-2,4-dione 
Electrochemical characterization of phenytoin and its derivatives on bare gold 
electrode. 
Trisovic, Nemanja P.; Bozic, Bojan Dj.; Lovic, Jelena D.; Vitnik, Vesna D.; 
Vitnik, Zeljko J.; Petrovic, Slobodan D.; Ivic, Milka L. Avramov. 
Electrochimica Acta 
Volume 161  
Pages 378-387  









for final products 5-27 
  
DJ24 1H-NMR
2017-10-10 19:24:29Acquisition Time (sec) 1.7064 Date Oct 10 2017 Date Stamp Oct 10 2017
File Name C:\Users\Dorota\Desktop\ANALIZY\NMR\2017\17-10-10_DJ24_dlaz\17-10-10_DJ24_dlaz_PROTON_01.fid\fid Frequency (MHz) 300.08
Nucleus 1H Number of Transients 32 Original Points Count 8192 Points Count 8192
Pulse Sequence s2pul Receiver Gain 34.00 Solvent DMSO-d6 Spectrum Offset (Hz) 1800.4814
Spectrum Type STANDARD Sweep Width (Hz) 4800.77 Temperature (degree C) AMBIENT TEMPERATURE
This report was created by ACD/NMR Processor Academic Edition. For more information go to www.acdlabs.com/nmrproc/



















































































































2017-10-18 11:39:50Acquisition Time (sec) 0.8684 Date Oct 17 2017 Date Stamp Oct 17 2017
File Name C:\Users\Dorota\Desktop\ANALIZY\NMR\2017\17-10-17_DJ24_dlaz\17-10-17_DJ24_dlaz_CARBON_01.fid\fid
Frequency (MHz) 75.46 Nucleus 13C Number of Transients 3000 Original Points Count 16384
Points Count 16384 Pulse Sequence s2pul Receiver Gain 34.00 Solvent DMSO-d6
Spectrum Offset (Hz) 8300.0879 Spectrum Type STANDARD Sweep Width (Hz) 18867.92 Temperature (degree C) 23.000
This report was created by ACD/NMR Processor Academic Edition. For more information go to www.acdlabs.com/nmrproc/






















































































































DJ18 1H-NMR 2017-10-10 18:46:57
Acquisition Time (sec) 1.7064 Date Oct 10 2017 Date Stamp Oct 10 2017
File Name C:\Users\Dorota\Desktop\ANALIZY\NMR\2017\17-10-10_DJ18_dlaz\17-10-10_DJ18_dlaz_PROTON_01.fid\fid Frequency (MHz) 300.08
Nucleus 1H Number of Transients 32 Original Points Count 8192 Points Count 8192
Pulse Sequence s2pul Receiver Gain 38.00 Solvent DMSO-d6 Spectrum Offset (Hz) 1800.4814
Spectrum Type STANDARD Sweep Width (Hz) 4800.77 Temperature (degree C) AMBIENT TEMPERATURE
This report was created by ACD/NMR Processor Academic Edition. For more information go to www.acdlabs.com/nmrproc/







































































Acquisition Time (sec) 1.7064 Date Oct 10 2017 Date Stamp Oct 10 2017
File Name C:\Users\Dorota\Desktop\ANALIZY\NMR\2017\17-10-10_DJ2_dlaz\17-10-10_DJ2_dlaz_PROTON_01.fid\fid Frequency (MHz) 300.08
Nucleus 1H Number of Transients 32 Original Points Count 8192 Points Count 8192
Pulse Sequence s2pul Receiver Gain 38.00 Solvent DMSO-d6 Spectrum Offset (Hz) 1800.4814
Spectrum Type STANDARD Sweep Width (Hz) 4800.77 Temperature (degree C) AMBIENT TEMPERATURE
This report was created by ACD/NMR Processor Academic Edition. For more information go to www.acdlabs.com/nmrproc/




























































































































Acquisition Time (sec) 0.8684 Date Oct 17 2017 Date Stamp Oct 17 2017
File Name C:\Users\Dorota\Desktop\ANALIZY\NMR\2017\17-10-17_DJ2_dlaz\17-10-17_DJ2_dlaz_CARBON_01.fid\fid Frequency (MHz) 75.46
Nucleus 13C Number of Transients 1536 Original Points Count 16384 Points Count 16384
Pulse Sequence s2pul Receiver Gain 34.00 Solvent DMSO-d6 Spectrum Offset (Hz) 8300.0879
Spectrum Type STANDARD Sweep Width (Hz) 18867.92 Temperature (degree C) 23.000
This report was created by ACD/NMR Processor Academic Edition. For more information go to www.acdlabs.com/nmrproc/
















































































































Acquisition Time (sec) 1.7064 Date Oct 10 2017 Date Stamp Oct 10 2017
File Name C:\Users\Dorota\Desktop\ANALIZY\NMR\2017\17-10-10_DJ6_dlaz\17-10-10_DJ6_dlaz_PROTON_01.fid\fid Frequency (MHz) 300.08
Nucleus 1H Number of Transients 32 Original Points Count 8192 Points Count 8192
Pulse Sequence s2pul Receiver Gain 38.00 Solvent DMSO-d6 Spectrum Offset (Hz) 1800.4814
Spectrum Type STANDARD Sweep Width (Hz) 4800.77 Temperature (degree C) AMBIENT TEMPERATURE
This report was created by ACD/NMR Processor Academic Edition. For more information go to www.acdlabs.com/nmrproc/























































































































Acquisition Time (sec) 0.8684 Date Oct 16 2017 Date Stamp Oct 16 2017
File Name C:\Users\Dorota\Desktop\ANALIZY\NMR\2017\17-10-16_DJ6_dlaz\17-10-16_DJ6_dlaz_CARBON_01.fid\fid Frequency (MHz) 75.46
Nucleus 13C Number of Transients 2224 Original Points Count 16384 Points Count 16384
Pulse Sequence s2pul Receiver Gain 34.00 Solvent DMSO-d6 Spectrum Offset (Hz) 8300.0879
Spectrum Type STANDARD Sweep Width (Hz) 18867.92 Temperature (degree C) 23.000
This report was created by ACD/NMR Processor Academic Edition. For more information go to www.acdlabs.com/nmrproc/












































































































































































































7.2. Supplementary material for Publication 2: Synthesis and computer-aided SAR studies 














































































1. Synthesis of intermediates 
2. Spectral analysis for final products  
2 
 
1. Procedures for synthesis of the ester intermediates  
 
1.1.General procedure for the synthesis of aryl(thio)ether esters (32-36)  
 
The mixture of suitable phenol or thiophenol (15 mmol), potassium carbonate (30 mmol) and alkyl 2-bromoacetate (16.5 mmol) in acetonitrile 
(40 ml) was heated at reflux for 24 hours. The resulted mixture was filtered to remove inorganic salt. The filtrate was washed with 40 ml of ethyl 
acetate. The organic phase was collected in a separatory funnel and washed with 40 ml of NaOH 1%, 40 mL of distilled water and 40 ml of brine. 
The organic layer was dried overnight over MgSO4, then filtered and evaporated to provide the crude product which was used without further 
purification for the next step. 
1.1.1. Ethyl 2-(2-chlorophenoxy)acetate (32) 
 
CAS Number (6956-85-0). Brown liquid. Yield 54%, C10H11ClO3 (MW 214.65). 
1
H-NMR: (CDCl3-d) δ [ppm]: 7.38 (dd, J=7.82 Hz, J=1.67 Hz, 
1H, Ph-3H), 7.16-7.22 (m, 1H, Ph), 6.92-6.98 (dt, J=7.63 Hz, J=1.45 Hz, 1H, Ph), 6.84 (dd, J=8.2 Hz, J=1.53 Hz, 1H, Ph), 4.70 (s, 2H, CH2), 
4.23-4.30 (q, J=7.18 Hz, 2H, CH2), 1.29 (t, J=7.18 Hz, 3H, CH3). 
1.1.2. Ethyl 2-(3-chlorophenoxy)acetate (33) 
 
CAS Number (111304-01-9). White solid. Yield 82%, mp 33-35 ˚C, C10H11ClO3 (MW 214.65). 
1
H-NMR: (CDCl3-d) δ [ppm]: 7.18-7.24 (t, 
J=8.21 Hz, 1H, Ph), 6.96-7.00 (m, 1H, Ph), 6.91 (m, 1H, Ph), 6.78-6.82 (m, 1H, Ph), 4.60 (s, 2H, CH2), 4.23-4.31 (q, J=7.18 Hz, 2H, CH2), 1.30 
(t, J=7.05 Hz, 3H, CH3). 




CAS Number (38768-63-7). Colorless liquid. Yield 38%, C10H14O3 (MW 194.23). 
1
H-NMR: (CDCl3-d) δ [ppm]: 7.06-7.10 (m, 2H, Ph), 6.81 
(dd, J=6,41 Hz, J=2,05 Hz, 2H, Ph), 4.59 (s, 2H, CH2), 4.27 (q, J=7,12 Hz, 2H, CH2), 2.29 (s, 3H, CH3), 1.29 (t, J=7,18 Hz, 3H, CH3). 
 
1.1.4. Methyl 2-(phenylthio)acetate (35) 
 
CAS Number (6956-85-0). Yellow liquid. Yield 95%, C9H10O2S (MW= 182.24). 
1
H-NMR (DMSO-d6) δ [ppm]: 7.38–7.32 (m, 4H, Ph), 7.25–
7.21 (m, 1H, Ph), 4.09 (dd, J = 14.3, 7.1 Hz, 2H, CH2), 3.88 (s, 2H, CH2), 1.14 (t, J = 7.1 Hz, 3H, CH3). 
1.1.5.  Methyl 2-((2-chlorophenyl)thio)acetate (36) 
CAS Number (178213-94-0). Yellow liquid. Yield 96%, C9H9ClO2S (MW 216.68). LC/MS
+
: purity: 87.40%, tR=6.49, (ESI) m/z [M+H]
+
 216.99.  
 
1.2. Synthesis of methyl 2-(2-isopropyl-5-methylphenoxy)acetate (37) 
 
2-(2-Isopropyl-5-methylphenoxy)acetic acid (10 mmol) was dissolved in 50 mL of dried methanol, and a few drops of concentrated sulfuric acid 
were added. The mixture was refluxed 8 hours. Next, the solvent was evaporated, and the residue dissolved in 40 mL of ethyl acetate, washed 
with 0.5% NaOH and brine. The organic layer dried over anhydrous Na2SO4 and filtered. The solvent was evaporated to give the product 37.  
CAS Number (111304-01-9). Light yellow liquid. Yield 65%, C13H18O3 (MW 222.28). 
1
H-NMR: (CDCl3-d) δ [ppm]: 7.14 (d, J=7.69 Hz, 1H, 
Ph), 6.80 (d, J=7.95 Hz, 1H, Ph), 6.55 (d, J=0.77 Hz, 1H, Ph), 4.65 (s, 2H, CH2), 3.82 (s, 3H, CH3), 3.38(m, 1H, CH), 2.32 (s, 3H, CH3), 1.24 (d, 
J=6.9 Hz, 6H, 2x-CH3). 




To the solution of 15 mmol of appropriate phenylacetic acid in 45 mL of anhydrous toluene, 15 mmol of DBU was added and the reaction 
mixture was stirred at room temperature for 1 hour. Afterwards, 15 mmol of iodomethane was added and stirring was continued for 2 days. Then, 
the solvent was evaporated under reduced pressure. The resulted residue was dissolved in ethyl acetate and washed with 0.5% NaOH and brine. 
The organic layer was dried over anhydrous Na2SO4, filtered off and evaporated under reduced pressure to provide light yellow liquid. 
1.3.1. Methyl 2-(4-chloro-2-methylphenoxy)acetate (38) 
CAS Number (2436-73-9). Obtained from commercial 2-(4-chloro-2-methylphenoxy) acetic acid with iodomethane in the presence of DBU. 
Light yellow liquid. Yield 56 %, C10H11O3 (MW 214.65). 
1
H-NMR: (CDCl3-d) δ [ppm]: 7.12 (m, 1H, Ph), 7.05-7.09 (dd, J=8.85 Hz, J=3.08 Hz, 
1H, Ph), 6.60 (d, J=8.46 Hz, 1H, Ph), 4.62 (s, 2H, CH2), 3.79 (s, 3H, CH3), 2.25 (s, 3H, CH3). 
1.3.2. Methyl 2-(2,4-dichlorophenoxy)acetate (39) 
 
CAS Number (1928-38-7). Obtained from commercial 2-(2,4-Dichlorophenoxy) acetic acid with iodomethane in the presence of DBU. Light 
yellow liquid. Yield 65 %, C9H8Cl2O3 (MW 235.06). 
1
H-NMR: (CDCl3-d) δ [ppm]: 7.55 (d, J=2.56 Hz, 1H, Ph), 7.30-7.34 (dd, J=8.85 Hz, 
J=2.69 Hz, 1H, Ph), 7.09 (d, J=8.97 Hz, 1H, Ph), 4.93 (s, 2H, CH2), 3.69 (s, 3H, CH3). 
 
1.4. General procedure for the synthesis of methyl 2-(phenylselenyl)acetate (40 and 41) 
 
An appropriate diphenyl diselenide (2.96g, 9.5 mmol) was dissolved in a 1:1 mixture of water and THF (50 mL) under nitrogen gas. NaBH4 
(1.79g, 47.5 mmol) was added. The reaction mixture was stirred until the solution turned colorless (1-3 minutes). The reaction mixture was 
stirred for a further 30 minutes. A solution of a methyl -2-bromoacetate (2.96g, 19.37 mmol) in THF (5 mL) was added through the rubber 
septum without opening the reaction apparatus. The reaction mixture was stirred at room temperature and monitored via TLC (~4 hours). 
5 
 
Subsequently, the solution was stirred for a further 30 minutes on air, then the reaction mixture was diluted with 50 mL of saturated aqueous 
solution of NH4Cl and extracted with diethyl ether. The combined organic phases were dried over Na2SO4, filtered and the solvent was 
evaporated under reduced pressure to get the product.  
1.5.1.Methyl 2-(phenylselenyl)acetate (40) 
 CAS Number (68872-84-4). Colorless liquid. Yield 85%, C9H10O2Se (MW 229.98). LC/MS
+/-




4.1.5.2. Methyl 2-(phenylselanyl)propanoate (41) 
 
CAS Number (65275-66-3). Light yellow liquid. Yield 87%, C10H12O2Se (MW= 243.18). 
1
H-NMR (Acetone-d6) δ [ppm]: 7.62–7.59 (m, 2H-Ph), 












































































































































































C NMR, 125 MHz, DMSO



















































































































































































Compound 15 – 
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C NMR, 125 MHz, DMSO
















































































































































































































































C NMR, 125 MHz, DMSO












































































































 23 - 
13















 24 - 
1























7.3. Supplementary material for Publication 3: Discovery of phenylselenoether-hydantoin 
hybrids as ABCB1 efflux pump modulating agents with cytotoxic and antiproliferative 


























Discovery of phenylselenoether-hydantoin hybrids as ABCB1 efflux pump modulating agents with cytotoxic and antiproliferative actions 





































Procedures for preparation the compounds (21-30) 
The intermediate compounds used in this work were either bought for compounds 22 and 24 or synthesized according to the literature in the case 
of compounds 21, 23 and 25-30. [1-5] Thus, we indicate their references, CAS numbers and 
1
H NMR or their LC/MS
+
 spectra without further 
characterizing them. 
General procedure for the compounds (21, 23, 25-26) 
To a stirred solution of piperazine (10 mmol) in acetone (20 ml) and 20 mmol K2CO3, 1-bromo-3-chloropropane (20 mmol) was added slowly at 
0
o
C. After the addition was completed the reaction mixture was stirred at room temperature for about 48 h. 
The solvent was removed under reduced pressure and water was added to the residue. The resulting mixture was then extracted with CH2Cl2 




CAS Number (10599-17-4). Light yellow liquid. Yield 91.50%.
 1
H NMR (Chloroform-d) δ 7.25–7.22 (m, 2H, Ph), 6.91 (m, 2H, Ph), 6.86–6.82 
(m, 1H, Ph), 3.22–3.19 (m, 4H, Pp-2,6-H), 2.70–2.65 (m, 2H, CH2), 2.64–2.58 (m, 4H, Pp-3,5-H), 2.48–2.43 (m, 2H, CH2), 1.85–1.70 (m, 2H, 
CH2). 
1-(3-chloropropyl)-4-(4-fluorophenyl)piperazine (23)[1]  
CAS Number (81514-10-5). Light yellow liquid. Yield 93.5%, C13H18ClFN2 (MW 256.11). LC/MS
+/-




1-(3-chloropropyl)-4-methylpiperazine (25) [2] 
CAS Number (104-16-5). Colourless liquid. Yield 91.5%, C8H17ClN2 (MW 176.11). LC/MS
+/-




 ethyl 4-(3-chloropropyl)piperazine-1-carboxylate (26) [3] 
CAS Number (74571-66-7). Colourless liquid. Yield 92%, C10H19ClO2N2 (MW 234.11). LC/MS
+/-




General procedure for the Se-alkylation (27-30) 
As part of this general procedure, the appropriate diphenyl diselenide (9.5 mmol) dissolved in a 1:1 mixture of water and THF (50 mL) under 
protective nitrogen gas, sodiumborohydride (47.5 mmol) was added and the mixture was stirred for around 35 minutes while observing a 
decolorization in the first 1-3 minutes. Next, a solution of a methyl -2-bromo-acetate derivatives (19.37 mmol) in THF or DCM (5 mL) was 
added and the reaction was stirred at room temperature and monitored via thin layer chromatography (TLC). Upon consumption of the starting 
material usually occuring after 24-48 hours, the reaction mixture was diluted with 50 mL of a saturated aqueous solution of ammoniumchloride 
and extracted with diethyl ether. The combined organic extracts dried over sodium sulfate, and the solvent was evaporated under reduced 
pressure to obtain the desired intermediate, which was used without further purification. 
.methyl 2-(phenylselanyl)acetate (27) [4] 
 CAS Number (68872-84-4). Colorless liquid. Yield 85%, C9H10O2Se (MW 229.98). LC/MS
+





 methyl 2-(phenylselanyl)propanoate (28) [5] 
CAS Number (65275-66-3). Light yellow liquid. Yield 87%, C10H12O2Se (MW= 243.18). 
1
H-NMR (Acetone) δ: 7.62–7.59 (m, 2H-Ph), 7.40–
7.32 (m, 3H-Ph), 3.88 (q, J = 7.1 Hz, 1H-CH), 3.60 (s, 3H-CH3), 1.50 (d, J = 7.1 Hz, 3H-CH3). 
 
methyl 2-(phenylselanyl)butanoate (29) [6] 
CAS number (946484-90-8). liquid, yellow. C11H14O2Se (MW 258.02). 
  1
H NMR (DMSO) δ 7.55 – 7.51 (m, 2H), 7.37 – 7.30 (m, 3H), 3.71 (dd, 
J = 8.3, 6.7 Hz, 1H), 3.55 (s, 3H), 1.82–1.70 (m, 2H), 1.67 (ddd, J = 13.9, 7.3, 6.8 Hz, 1H), 0.90 (t, J = 7.3 Hz, 3H). 
13
C NMR (DMSO) δ 172.56, 
134.83, 129.18, 128.38, 67.00, 51.79, 44.24, 25.11, 24.72, 12.29. 
 
methyl 2-methyl-2-(phenylselanyl)propanoate (30) [7] 
CAS number (59345-48-1). Dark yellow liquid. C11H14O2Se (MW 258.02). 
  1
H NMR (DMSO-d6) δ 7.56 (d, J = 1.3 Hz, 2H-Ph), 7.47 (s, 1H-Ph), 
7.40–7.35 (m, 2H-Ph), 1.50 (s, 6H-2*CH3), 1.09 (t, J = 7.1 Hz, 3H-CH3). 
13
C NMR (DMSO) δ 173.48, 137.48, 129.38, 129.06, 128.95, 60.56, 
45.15, 30.21, 25.87, 25.11, 13.78. 
 
 
Methyl 2-(2,5-dioxo-4,4-diphenyl-3-(4-(phenylselanyl)butyl)imidazolidin-1-yl)acetate, compound (5), 
1















methyl 2-(2,5-dioxo-4,4-diphenyl-3-(6-(phenylselanyl)hexyl)imidazolidin-1-yl)acetate (6), 
1















 1'-methyl-3'-(4-(phenylselanyl)butyl)spiro[fluorene-9,4'-imidazolidine]-2',5'-dione (7), 
1















































1-(4-fluorophenyl)-4-(3-(phenylselanyl)propyl)piperazine hydrochloride (10),  
1













1-(3,4-dichlorophenyl)-4-(3-(phenylselanyl)propyl)piperazine hydrochloride (11), 
1








Se NMR (DMSO) 
 
Compound 11, LC/MS+ 
 
1-methyl-4-(3-(phenylselanyl)propyl)piperazine hydrochloride (12), 
1








Se NMR (DMSO) 
 
Compound 12, LC/MS+ 
 
ethyl 4-(3-(phenylselanyl)propyl)piperazine-1-carboxylate hydrochloride (13), 
1








Se NMR (DMSO) 
 
Compound 13, LC/MS+ 
 




















4-(4-methylpiperazin-1-yl)-6-(1-(phenylselanyl)propyl)-1,3,5-triazin-2-amine hydrochloride (16), 
1















4-(4-methylpiperazin-1-yl)-6-(2-(phenylselanyl)propan-2-yl)-1,3,5-triazin-2-amine hydrochloride (17), 
1















Lipophilicity of compounds (5-17) was estimated using standard RP-TLC method (Table S1).  
Table S1: Lipophilicity data for the compounds 5- 17 
Compound a Sa b=RM0 Sb r2 Se F 
5 -4,1800 0,3096 4,2540 0,2487 0,9838 0,0490 182,3 
6 -3,2600 0,3105 6,0540 0,2494 0,9927 0,0491 406,5 
7 -3,6767 0,1588 3,8281 0,1088 0,9880 0,0592 578,4 
 8*   -2.3000 0.4254 2.7950 0.3226 0.9360 0.0951 29.23 
 9   -2.1600 0.1433 2,3853 0.1020 0.9701 0.0555 227.22 
10 -2,5309 0,1386 2,5306 0,0927 0,9737 0,0727 333,3 
11 -2,4727 0,0858 2,6218 0,0574 0,9893 0,0450 830,7 
12 -0.7582 0.0337 1,0137 0.0225 0.9825 0.0177 506.31 
13  -0.8660 0.0828 0,7903 0.0537 0.9398 0.9398 109.21 
14  -2.1857 0.4085 2,6821 0.2998 0.8267 0.0017 28.63 
15   -2.4200 0.3245 2,7421 0.2171 0.8607 0.1702 55.62 
16   -1.4455 0.1108 1,7614 0.0741 0.9498 0.0581 170.13 
17   -2.6509 0.2061 2,7467 0.1379 0.9484 0.1081 165.42 
       *Compound 8 tested in basic form, compounds 9-17 tested as hydrochlorides, compounds 5-7 do not have protonable centres 
Retention parameters for the compounds were designated and analysed. Stationary phase RP-18 and mixtures of water/methanol in the variable 
proportions of organic modifier (from 40 to 90%) as a mobile phase were used. In all cases, calculated values of RF corresponding to particular 
substances increased with increases in the percentage of the organic modifier in the mobile phase. The highest RF values were obtained in 
water/methanol mobile phases (1:9, v/v) for all compounds. Substances 5 and 6 (at methanol concentration from 40 to 65%) and substance 7 (at 
methanol up to 45%) were retained at the start line; this could be explained by the highest affinity to the stationary phase and lower solubility in 
water solutions.  
RM values were calculated from the obtained RF data. It was found that the RM parameters decreased linearly with increasing amounts of the 
organic modifier (methanol) in the tested mobile phases. The determined regression coefficients (r
2
) for all compounds were higher than 0.97. On 
the basis of the linear relationship between RM values and the volume fraction of methanol, values of RM0 in the analysed systems corresponding 


























































Figure S3 Ion fragment analyses of compound 7 (A) and its metabolites M1 (B), M2 (C),  M3 (D), M4 (E) and M5 (F) 
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